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You will see yet higher peaks, another landscape beckoning you on; 
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You will still find yourself under the stars.” 
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Abstract 
 
The presence of disease, including infectious disease, has been observed to give rise 
to specific patterns of gene expression in peripheral whole blood, regardless of disease site. 
These gene expression signatures allow for distinction between diseases and have the 
potential to reform diagnostics, particularly in diseases and patient groups for whom 
current diagnostics are unreliable, like Tuberculosis (TB). Although TB is a treatable 
infectious disease, it has high morbidity and mortality, especially in low resource countries 
and HIV infected patients. In this thesis, I propose a bioinformatics toolbox that derives 
minimal transcriptomic signatures from microarray datasets acquired from heterogeneous 
groups regardless of underlying co-infections and geographic locations. The transcripts’ 
expression values are then aggregated into a single value disease risk score (DRS) for every 
patient, that allows for classification between the disease groups in a binary manner. The 
toolbox was employed to analyse an adult and a paediatric TB transcriptomic study, 
comprising HIV infected and uninfected patients from sub-Saharan Africa. In the adult study, 
the DRS based on a 27-transcript signature distinguished culture confirmed TB from latent 
TB infection (LTBI), while 44 transcripts distinguished TB from other diseases phenotypically 
similar to TB (OD), with high sensitivity and specificity. Out-of-sample validation was 
performed using a publicly available dataset. In the paediatric study, a 51-transcript 
signature distinguished TB from OD and a 42-transcript signature from LTBI. The signatures 
were validated out-of-sample using an independent cohort and benchmarked against 
culture-negative TB patients and Xpert® MTB/RIF, currently used for detection of M. 
tuberculosis. This thesis provides proof of principle that minimal host blood transcriptional 
signatures are able to distinguish TB from LTBI and OD regardless of HIV infection. The 
subsequent transformation of the signatures into a score for every patient may facilitate 
disease categorisation and potentially development of diagnostic tools. 
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Chapter 1 
 
Introduction 
 
 
 
 
 
Chapter 1 describes the background regarding the biological aspects of the thesis, focusing 
on how gene expression profiling can help elucidate the host response to external stimuli, 
such as an infection. I discuss how gene expression can further our understanding of the 
mechanisms underlying disease and I present the main laboratory methods to measure 
gene expression, focussing on microarrays and describing how microarrays have been used 
to study disease, and particularly infectious diseases. I then focus on tuberculosis (TB), a 
treatable disease that given its current global burden and lack of reliable diagnostics, is in 
urgent need of better biomarkers that may be used to improve diagnosis. Previous studies 
that have used blood gene expression profiling to identify TB biomarkers are reviewed. 
Finally I describe how the research presented in this thesis might overcome some of 
previous studies’ limitations and lead to improved diagnostics tests for TB. 
  
Chapter 1. Introduction 
2 
 
1.1 Host response to infection 
The human body has a range of external defence barriers to avoid invasion by 
pathogens which are able to cause infection and disease. When these external mechanisms 
fail and the pathogens manage to override them, the immune system - a complex internal 
system of organs, tissues, cells, compounds, molecules and chemical processes - will be 
activated to ensure the survival of the host. The immune system is divided into the innate 
and the adaptive systems, both of which use distinct cells and molecules to fight against 
pathogens but they also interact and complement each other (Figure 1). The innate immune 
system and its components (physical and chemical barriers, phagocytic cells, innate 
leukocytes and plasma proteins) are always present and active in an immunocompetent 
organism. Upon pathogen invasion, the innate immune system identifies the infectious 
agents through pattern recognition receptors (proteins produced in the innate immune 
system cells), which remain either attached to the cell surface, or are soluble in the blood 
and have the ability to recognise microbe-specific molecules. Upon recognition, the 
receptors trigger mechanisms responsible for the direct killing of the microbe (including the 
phagocytic and the natural killer cells) and activate the adaptive immune system as well. 
The receptors are also central for the induction of cytokine synthesis and secretion. 
Cytokines are small proteins that act as mediators, allowing communication between cells. 
The role of cytokines is crucial for containing infections, as they can alter cellular functions 
of the target cells even if they are located at distant sites.  
The activation of the specialised antigen-presenting cells in the innate immune 
system leads to the triggering of the adaptive immune system. The adaptive immune system 
is a network of cells (T-cells, B-cells) that are characterised by high affinity when it comes to 
the recognition and the elimination of microbes and foreign antigens. Different types of T 
cells are activated depending on the type of antigen (cytotoxic T-cells for major 
histocompatibility complex class I (MHCI) antigen presentation, T-helper cells for MHCII). 
The first time that the immune system encounters an infectious agent, the antigen 
presenting cell present its antigens to T-cells which move from the lymph nodes to the site 
of infection to assist with the killing of the invading organism. Helper T-cells play central 
roles in the fight against the microbe. They induce the killing of the microbe by phagocytic 
cells, they trigger the activation of other T-cells, but most importantly they stimulate the 
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activation of B-cells to make antibodies against the new invading pathogen (primary 
response). The antibodies are proteins that consist of constant and variable regions. Their 
variable regions are antigen-binding sites with high-specificity to the antigen and can either 
flag a microbe for other cells to attack it, disrupt the entry of the microbe to cells by 
attaching to it, inactivate its toxins or eradicate it by activating other pathways (i.e. 
complement). The B-cells divide into “clones” and each “clone” produces antibodies with 
the same unique binding site. One of the main characteristics of the adaptive immune 
system is that it exhibits “memory”, so while some of the B-cells (plasma cells) will be 
producing and secreting antibodies against an antigen, a small number of others (memory 
B-cells) will remain in the body in a dormant form for a long time (days to decades). The 
memory cells will allow a much more rapid immune response, in subsequent exposures to 
the same antigen (secondary response) [1]. 
 
Figure 1: The innate and adaptive immune response. Reprinted with permission from 
Nature Reviews|Cancer [2]. 
 
Induction of the immune response and the intracellular signalling of the immune 
cells trigger a biochemical chain of events, leading to production of molecules that are 
needed for defence against infection. In order to undergo activation and release of the 
chemicals and proteins that are responsible for killing invading pathogens, the immune cells 
Chapter 1. Introduction 
4 
 
alter their gene expression and modify their protein synthesising machinery to meet the 
current needs. There are individual genes that govern these responses. Different pathogens 
(i.e. viruses, bacteria) or even different species trigger common as well as different parts of 
the immune system and this trigger drives common as well as unique patterns of gene 
expression. By measuring the gene expression in either particular cells that are involved in 
the immune responses [3] or in complex mixtures of cells (such as blood) researchers can (1) 
understand the immune mechanisms that the body employs to eliminate the infectious 
agents (2) find biomarkers specific for infection/disease that will aid diagnosis, prognosis or 
treatment of disease.  
 
1.2 Gene expression 
DNA (deoxyribonucleic acid) is a macromolecule shared across all the cells of an 
organism that holds information about structure, function, growth and development of the 
cells by coding for functional cellular components [4]. Gene expression is the link between 
the genotype and the phenotype as it uses the information stored in the DNA to produce 
functional products via transcription (ribonucleic acid (RNA) species) and translation 
(proteins) [5]. Even though DNA is the same across the cells of an organism, the particular 
genes that are expressed, their level of expression and their isoforms differ between cells 
and between time points, via gene regulation that defines the state of each cell.  
DNA’s structural unit is the nucleotide and each nucleotide is composed of a 
monosaccharide sugar, a phosphate group and a nitrogenous base (adenine (A), guanine 
(G), thymine (T), cytosine (C)). The sugar of the one nucleotide and the phosphate of the 
next are joined by covalent bonds forming a strand. The bases also bind to each other by 
hydrogen bonds bringing the two strands together and forming a double helix. The specific 
order of the nitrogenous bases (gene) holds the information of the genetic code for the 
creation of the functional products. This encoded information is first transferred to an RNA 
molecule, via transcription. In eukaryotes, the initiation of transcription requires the 
presence of specific proteins, namely transcription factors, which are able to activate or 
suppress the transcription of a gene. Transcription factors can either recruit RNA 
polymerase or block its binding to the promoter area of the gene of interest, to start or 
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cease the transcription process, respectively. RNA polymerase is the enzyme required for 
the synthesis and production of the primary RNA molecule according to the complimentary 
base pairing rule. If the gene that undergoes transcription encodes for a protein, the 
product of transcription is messenger RNA (mRNA) which after processing and editing (in 
eukaryotic cells) will convey the genetic information to the ribosome to produce the protein 
required by the cell (Figure 2). DNA can also be transcribed to different types of RNA, such 
as transfer RNA (tRNA) or ribosomal RNA (rRNA), that have other various functional roles.  
 
Figure 2: An overview of the flow of information from DNA to protein in a eukaryote. 
Reprinted with permission from Nature Education [6]. 
 
Only a fraction of approximately 30,000 genes in human DNA is expressed in a given 
cell at a given time, defining the cell’s state. Cells employ a variety of mechanisms to define 
which genes are transcribed into RNA and which mRNAs are translated into proteins. In 
eukaryotic cells and especially in human cells, the control of gene expression is a very 
complicated process controlled by the regulome which comprises regulatory proteins, 
transcription factors, mRNA and metabolites [7]. The expression levels of a specific gene can 
Chapter 1. Introduction 
6 
 
be quantified by detecting the presence and measuring the abundance of the final product 
(protein or functional RNA species) or its precursor (typically measure mRNA for proteins). 
Measuring the amount of mRNA can act as a “proxy” for the overall cellular activity at the 
molecular level as protein measurements can be more costly and laborious than mRNA 
measurements. However, studies in yeast as well as in mice showed that can be discrepancy 
between the abundance of RNA and proteins [8-10]. Even though protein measurements 
encompass post-transcriptional modifications as well as the action of miRNAs and are closer 
to the phenotype, mRNA analysis is a powerful method for monitoring the gene expression 
of a cell. 
 
1.3 Measuring Gene Expression 
1.3.1 Overview 
Out of the amount of total RNA in a cell, which is usually 10-30 pg, 80% is rRNA, 15% 
is tRNA and the remaining 5% is mRNA along with all the other species [11]. The first step in 
all methods for measuring mRNA abundance is the extraction of RNA and isolation of mRNA 
from the cells, using specific extraction and isolation kits in order to purify it from the rest of 
the RNA. There are various methods to estimate the abundance of mRNA, or complimentary 
DNA (cDNA) synthesized using mRNA as a template, each of which has its own advantages 
and disadvantages. These methods separate into two broad categories: the candidate gene 
approaches (i.e. Northern Blotting, serial analysis of gene expression (SAGE), comparative 
expressed sequence tag (EST), reverse transcriptase followed by polymerase chain reaction 
(RT-PCR)) and the genome-wide profiling methods (i.e. DNA microarrays, RNA-seq) [12]. The 
candidate gene approaches focus on measuring expression of a small number of genes and 
are usually used when the genes of interest are known prior to the experiment for 
hypothesis testing. The genome-wide profiling methods allow for systematic analysis of 
thousands of genes simultaneously and provide a global quantitative profile of the cell or 
tissue of interest. They are more adequate for hypothesis free experiments. Most earlier 
targeted gene approaches (i.e. Northern Blotting, SAGE, EST) are nowadays superseded by 
RT-PCR, while the most popular methods for transcriptional profiling are DNA microarrays 
and RNA-seq, which are discussed in the following section.  
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1.3.2 RT-qPCR  
RT-qPCR is a simple, powerful, widely used method for quantification of mRNA levels 
that consists of two steps: reverse transcription (RT) and real-time quantitative PCR [13, 14]. 
Reverse transcription as a methodological step is shared between most protocols for RNA 
quantification. During this step, the mRNA molecule is used as a template to synthesise a 
cDNA molecule in a reaction catalysed by the enzymes reverse transcriptase and DNA 
polymerase. cDNA is much more biologically stable than its precursor and is the starting 
material for PCR amplification. The PCR part of the RT-qPCR methodology consists of three 
basic discreet stages (denaturation, annealing and elongation). The three different stages 
make up a cycle and at the end of each cycle fluorescent dyes emit fluorescent signal that is 
used for the estimation of the quantity of the starting material [15]. In general, RT-qPCR is a 
sensitive, accurate, highly reproducible method that can detect very small amounts of RNA. 
On the other hand, it is still expensive, prone to contamination and not as high-throughput 
as newer methods (i.e. microarrays and RNA-seq). Nevertheless as the field of gene 
expression analysis has recently started moving from the candidate gene approaches to 
profiling methods, RT-qPCR is still considered as benchmark technology and used as the gold 
standard in many laboratories in the world.  
 
1.3.3 Microarrays 
Microarray technology exploits the principles of specific hybridisation between two 
DNA strands and the emission of fluorescence proportional to the amount of nucleic acid 
that is bound. Amongst other applications (i.e. detection of mutations, single nucleotide 
polymorphisms, comparative genomic hybridisation and identification of genomes), DNA 
microarrays (also referred to as cDNA microarrays / microarray chips) are a rapid, reliable 
and reproducible way to achieve gene expression profiling. They allow for the simultaneous 
genome-wide measurement and analysis of gene expression in a high-throughput manner.  
While array technology in general originates in the 1950s, when the attachment of 
biomolecules to solid surfaces was first used to generate immunoassays for antibody 
binding, further advancements managed to accommodate nucleic acids in a similar way to 
the Southern Blotting technique in the 1980s [16, 17]. Those advancements led to the first 
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microarray fabrication in Stanford University for 45 Arabidopsis genes in 1995 [18]. Since 
then microarrays have started revolutionising the field of life sciences. However, it was the 
completion of the Human Genome Project in 2001 which released an unprecedented 
amount of genomic information that allowed for the assembly of a cDNA library of the 
transcripts of the human organism [19, 20]. 
There are two major types of arrays based on the type of the nucleic acid that is 
bound to the surface, the cDNA microarrays and the oligonucleotide microarrays. In the 
cDNA microarrays, the clones are 500-5000 bp long and products of PCR, while the 
oligonucleotides are 50-70 bp long. Also, oligonucleotides can be synthesised either “a 
priori” or “in situ”, determining further the type of the array. In this thesis, I am going to 
focus on spotted oligonucleotide microarrays [21]. 
Thousands of distinct strands of DNA oligonucleotides, that correspond to segments 
of every known or putative transcript of the genome are immobilised onto a solid surface 
(i.e. a glass slide, silicon) in discrete spots with high density (~500 spots/cm2). Each array 
contains over 30,000 spots, typically around 100-300 μm in size and each spot contains 
multiple identical oligonucleotides [22]. The spots are organised in a grid of rows and 
columns with known location. Due to the micro-scale of the experiment, the fabrication of 
the array involves robotic machinery of high precision and speed, which prints the 
oligonucleotide probes on the surface exploiting material science principles. The arrayed 
probes are complementary to the transcripts of interest and suitable for hybridisation.  
The measurement of the gene expression involves RNA extraction from the sample 
of interest, mRNA isolation and reverse transcription to cDNA. The cDNA is then amplified 
and labelled with a fluorescent dye. Subsequently, the dyed cDNA is hybridised to the array 
in specific and controlled conditions, which permit its binding to particular complementary 
sequences. Then the array is washed in order to eliminate non-specific binding events, 
followed by insertion into a scanner that both excites the fluorescent dyes and records the 
emitted intensity. The more abundant the cDNA for a specific probe, the stronger the 
fluorescence signal it emits. The signals detected by the scanner are processed using 
imaging algorithms which assign intensity measurements to each probe. The measurements 
are then transformed into numerical values that can be related to the abundance of the 
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corresponding RNA transcript in the sample. Prior knowledge of the position of reference 
transcripts allows for relative quantification of the amount of transcripts that is bound to 
the specific probe [23, 24]. The output is a highly dimensional dataset that requires 
bioinformatics analysis to process and understand. The methodology and statistics involved 
are discussed in Chapter 2. 
What is described above is a single-colour array, where the fluorescent dye has one 
colour. However, as the microarrays are often used for comparative analysis between 
different cell types, diseases or populations, mRNA from the two different conditions can be 
made into cDNA with fluorescent dyes of different wavelength emission, usually red (670 
nm) and green (570 nm). This process results into probes emitting shades of red, green and 
yellow fluorescence relative to the amount of starting fluorescent cDNA in each sample. 
While two-colour arrays can control for technical issues by allowing for direct comparisons 
in one hybridisation experiment, single-colour arrays allow for more flexibility in analysis 
[25]. 
Microarray technology enables transcriptional profiling of large cohort sizes in a 
high-throughput way. It utilises cutting-edge advances in material science, automation, 
imaging and data science to quantify gene expression of multiple cells, tissues or organisms 
in a single experiment. Also, as a technique it is now standardised and highly-
commercialised. However, biases in the experimental process due to reverse transcription 
efficiency and dye affinity are often introduced. Also it is still relatively expensive and 
requires more complicated post-experimental bioinformatics data analysis compared to RT-
qPCR, which will be discussed in detail in Chapter 2.  
 
1.3.3 RNA-seq 
Various sequence based approaches have been used to measure gene expression 
since the 70s, however, it was only recently that next generation sequencing (NGS), which 
allows for vast parallelisation of deciphering sequences was introduced [26]. RNA-seq is 
based on the principles of DNA sequencing and allows for mapping and quantifying RNAs 
[27]. Although different sequencing platforms exist, they all share the same core principles. 
Following RNA extraction, rRNA depletion and synthesis of a library of short cDNA 
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fragments, the cDNA fragments are amplified and attached in situ on a solid surface. NGS 
technology is based on detecting and recording light that is emitted when a complimentary 
nucleotide is added to a particular fragment of cDNA. The light detected will determine the 
identity of the nucleotide (“base calling”) and subsequently the sequence of the whole 
“read” in single base-resolution. Millions of short reads are either mapped to a reference 
genome or assembled de novo to produce the transcriptome, a base-resolution expression 
profile [28]. The abundance of each read, along with its alignment coordinates, allows for 
the quantification of specific genomic regions, in an almost digital way, as the output of 
RNA-seq produces discreet counts of transcript abundance. RNA-seq methodology has 
revolutionised the field of transcriptomics allowing for discovery of novel transcripts, as well 
as splice isoforms. RNA-seq also permits for simultaneous sequencing of pools of transcripts 
that may come from different organisms that coexist in the same environment, termed as 
metatranscriptomics [29, 30]. 
 
1.3.5 Value and importance 
All methods used for transcriptome quantification have their own advantages and 
disadvantages. Depending on the nature of the experiment and the actual scientific 
questions posed, one method may be preferable over the other.  
RT-qPCR is the method of preference when a relatively small already identified 
number of transcripts are to be studied. It is still considered the “gold standard” for RNA 
quantification, making it preferable for validation studies. On the other hand, microarrays 
and RNA-seq have made whole transcriptome analysis available, with arrays having limited 
hypothesis space as they examine only the transcripts that are printed a priori on a chip. The 
opportunities for novel transcript discovery and splicing isoform detection along with its 
higher dynamic range are the main biological reasons why RNA-seq has started superseding 
microarrays. Despite its superiority as a method, RNA-seq has not replaced arrays yet, as 
they remain time and cost efficient particularly when it comes to large-cohort studies. On 
the other hand, RNA-seq studies require ample storage space, high level data management, 
as well as powerful computational infrastructure [31]. Comparative analyses between RNA-
seq and microarray techniques have demonstrated that although a larger proportion of 
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genes identified as differentially expressed by RNA-seq than microarrays were subsequently 
validated by RT-PCR, the two methods complement each other in transcriptome profiling 
[32, 33].  
Soon after NGS was established, the third generation sequencing (TGS) methods 
emerged (also known as single molecule sequencing methods and next-next generation 
sequencing). These methods are expected to revolutionise the life science field in an 
unprecedented way as they are expected to reduce the sequencing error rate, the time to 
results from days to hours, and the overall cost per run [34, 35]. As far as the field of 
transcriptomics is concerned the impact is anticipated to be particularly high since TGS allow 
for direct sequencing of RNA molecules whilst omitting the cDNA synthesis and 
amplification steps.  
The aforementioned methods measure gene expression, which is crucial for many 
normal biological cells processes including cells’ response to external stimuli and 
encountering with pathogens. Identifying differentially expressed genes (DEG) between 
cells, tissues, diseases, disease states and treatments can shed light into biological processes 
and detect the key molecules that play crucial roles in the discrimination between the 
different conditions [36]. Even though sequencing methods confer a natural advantage and 
offer a wealth of information and possibility for deeper exploration, gene expression 
microarrays have been addressing the identification of differentially expressed genes 
successfully for many years. They have enabled the elucidation of a patient’s response to 
external stimuli and further our understanding of the molecular regulatory mechanisms that 
underlie disease.  
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1.4 Host gene expression disease biomarkers  
The advent of high-throughput gene expression measuring technologies, such as 
DNA microarrays and RNA-seq, allow for genome-wide level analysis and large cohort sizes. 
This has enhanced gene expression biomarker discovery and subsequent application to the 
clinical diagnostics field. A biomarker is defined as “a characteristic that is objectively 
measured and evaluated as an indicator of a normal biological process, pathogenic process 
or pharmacologic response to a therapeutic intervention” [37]. Biomarkers provide evidence 
for classification of different diseases as well as disease subgroups.  
 
1.4.1 Host gene expression biomarkers for infectious diseases 
During its early days, gene expression analysis for biomarker discovery found 
adoption in cancer research [38, 39]. Several studies since then have focused on a wide 
range of aspects, including classification of tumour types, prediction of metastasis, drug pre-
disposition, patient survival or clinical outcomes in general [40, 41]. Infectious diseases were 
soon to follow, despite the fact that infection by a pathogen and the interaction with the 
host adds certain levels of complexity into host gene expression profiling [42]. Exposure of 
an organism to a pathogen can trigger a consistent biological response, for instance in 
pathways of immune activation. Therefore, disease specific biomarkers that describe the 
host response can be useful for better understanding of well-known as well as emerging 
infectious diseases and their diagnosis.  
Various models are employed to study response to infection, spanning from cell line 
in-vitro experiments and animal models to study of multi-level human responses [43]. In-
vitro host response studies monitor cells after the exposure to the pathogen to unravel cell 
specific mechanisms underlying host response to the pathogen. Cells of preference can 
either be critical components of the immune system (i.e. NK cells, T cells) or pathogen 
specific target cell types and cell lines. Even though in vitro approaches may not be able to 
fully describe the transcriptional response of the host, they offer a controlled environment 
and allow for examining changes in expression over time [44-47]. Furthermore, studies have 
also focused on analysing the transcriptome of human tissue samples from the site of the 
primary pathogen infection [48].  
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The aforementioned approaches can be of high value when the interest is biology 
and identification of disease stages. However in order to study clinical disease and identify 
biomarkers that can be of clinical significance, identification of patterns of gene expression 
in easily accessible bodily fluids such as nasopharyngeal secretions as well as peripheral 
whole blood from human patient samples is crucial. As distinct patterns of gene expression 
have been associated with infectious diseases and disease stages, these patterns allow 
distinction between patients affected by a disease from healthy controls or between 
patients with different diseases [49, 50]. 
 
1.4.2 Host gene expression biomarkers in blood 
Diagnostics for infectious diseases have recently started to shift from identification 
of the causative agents or measuring a specific antibody-mediated response to recognition 
of host response gene expression patterns specific enough to each pathogen to allow for 
accurate disease diagnosis [51]. As the pathogen may be present in undetectable numbers 
or lying in inaccessible sites and as the antibody response is not measurable in the first 
stages of the disease, identification of gene expression patterns in easily accessible samples 
- such as blood - is expected to be beneficial in the field of diagnostics. 
Blood is not only an accessible tissue which permits investigation of candidate 
biomarkers, but it has the potential to convey information about many different organs and 
tissues.  Blood cells interact with all tissues of the body and play a key role in transportation 
of oxygen, nutrients and waste, as well as in immunity, inflammation, signalling and 
defence. Molecular profiling of circulating blood cells reflects physiological and pathological 
events occurring in various different tissues of the body as blood connects the systems of 
the body together and interacts with every organ and tissue. Thus, whole blood expression 
profiling is not only a means for exploring multiple physiological processes, but also a means 
for identification of expression patterns that offer a broad picture of the organism’s health 
state and overall immunity. Microarray studies exploring the variation in whole blood gene 
expression patterns of healthy individuals have shown that differences in gene expression 
between healthy individuals are far less than the variation between healthy  individuals and 
patients with cancers or bacterial infections [52]. Therefore, whole blood expression 
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profiling is not only a means for exploring multiple physiological processes, but also for 
identification of distinct disease signatures, even for diseases that affect different organs 
and tissues of the body. Peripheral blood cells share more than 80% of the transcriptome 
with brain, colon, heart, kidney, liver, lung, prostate, spleen and stomach [53]. Hence, it has 
been feasible to derive distinct host response signatures for a variety of diseases from 
transcriptional profiling of peripheral blood. Gene expression signatures have been reported 
for several diseases including bacterial and viral infections [54, 55] as well as pathogen 
specific diseases including malaria [56], dengue virus infection [57], staphylococcus [58], 
tularemia [59] and TB [60].  
However, the use of whole-blood gene expression patterns to derive diagnostic 
biomarkers capable of distinguishing phenotypically similar diseases remains challenging. 
Differential gene expression (DGE) analysis is used to identify the key genes that undergo 
changes in expression relative to healthy individuals in each disease state as well as to 
identify changes between comparator groups of different diseases. These key genes can act 
as diagnostic, prognostic and predictive markers of disease. Once the gene expression 
“signatures” in the blood are identified, they can potentially be used for diagnosis of 
infectious diseases, where current diagnostics are unreliable or of limited potential.  
 
1.5  Tuberculosis 
Tuberculosis (TB) is among the most important causes of mortality and morbidity 
from infection in the human population. In 2012, it was estimated that 8.6 million people 
developed TB and 1.3 million died, with Africa, South-East Asia and Western Pacific regions 
accounting for 75% of the TB cases worldwide, according to the World Health Organisation 
(WHO) [61].  
The causative agent of TB is Mycobacterium tuberculosis (M.TB), an intracellular acid 
fast bacterium first described in 1882 by Robert Koch, also known as "Koch's bacillus". The 
lungs are the major infection site for M. tuberculosis (pulmonary TB) but it can also affect 
other parts of the body such as the central nervous system, the bones, the lymph nodes and 
the heart (extra-pulmonary TB). TB is an air-borne disease as M. tuberculosis is carried in 
infectious droplets generated by adult patients, who have pulmonary or laryngeal TB 
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disease. Infection by the pathogen can either be eliminated by the host (rare to absent 
event) (i), progress to active disease immediately (ii) or controlled as a latent infection 
(LTBI). Approximately 90% of immunocompetent adults infected with M. tuberculosis will 
contain the disease in a dormant form and will remain persistently infected with a 10% 
lifetime chance of progressing to active disease [62, 63]. However, the probability of 
developing active TB rises with age and is much higher among people infected with human 
immunodeficiency virus (HIV) and in children (Figure 3). 
After inhalation of M. tuberculosis, alveolar macrophages and dendritic cells engulf 
bacteria or their components (Figure 3). Dendritic cells circulate to the draining lymph nodes 
and prime T cells, which then travel to the lungs where they recruit and activate 
macrophages in order to contain the initial phase of bacterial multiplication. Macrophages 
play a crucial role in the infection as they phagocytise M. tuberculosis, which either multiply 
within the infected macrophages, or are contained and/or killed, depending on the state of 
the host immunity. T cells enhance the antibacterial activity of macrophages by releasing 
cytokines, such as interferon gamma (IFN-γ) and tumour necrosis factor alpha (TNF-α), 
which generally results in arrest or clearance of the infection [64].  
. 
Figure 3: Different outcomes of M. tuberculosis infection and underlying immune 
mechanisms. Reprinted with permission from Nature Medicine [65]. 
Chapter 1. Introduction 
16 
 
 
Antigen-specific T cells induce the formation of granulomas around infected 
macrophages to contain bacterial spread [65]. Formation of granulomas prevents 
mycobacteria growth and spread in the body, but does not eliminate the possibility of 
subsequent development of TB in the future.  
Co-infection of TB and HIV increases disease progression, and complicates diagnosis 
and treatment resulting in a dual-epidemic [66]. The lifetime risk of progressing from latent 
to active disease rises from 10% lifetime chance to 10% annually for HIV infected individuals 
[67]. Amongst the 8.6 million TB cases worldwide in 2012, 1.1 million (13%) are estimated to 
be co-infected with HIV but in some countries with high HIV prevalence, such as southern 
Africa, the proportion of patients with dual-infection rises to 80% (Figure 4) [61]. An 
estimated 25% of the 1.3 million deaths from the disease in 2012, approximately 320,000 
deaths, were due to HIV-associated TB. 
Children account for 500,000 to 1,000,000 of the new TB cases per year, while 
estimated deaths from TB amongst the HIV-negative children only were 74,000. The global 
estimated burden varies markedly, while the true global burden of childhood TB is unknown 
due to difficulties in diagnosis and underreporting [63, 68]. Among children infected with M. 
tuberculosis, a higher proportion in comparison to adults will progress to active disease, 
with the majority of them developing disease within a year after infection. Young age, 
severe malnutrition and HIV co-infection are the most important risk factors for developing 
disease. Worldwide, diagnosis and management of childhood TB is mostly based on clinical 
features as the available tests are unreliable in children due to the paucibacillary  nature of 
the disease and high frequency of extra-pulmonary TB presentation [69, 70]. Whereas 
sputum microscopy is the mainstay of adult pulmonary diagnosis and control, sputum is 
difficult to obtain from young children, and is frequently negative on both microscopy and 
culture due to the low numbers of bacteria, absence of cavitatory lesions and frequent 
lympho-haematogenous spread without major pulmonary involvement. 
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Figure 4: Worldwide estimated TB incidence rates from WHO in 2012. 
 
The introduction of the TB vaccine, the bacillus Calmette-Guérin (BCG), in the 1920s 
marked a milestone in the fight against TB. The vaccine consists of an attenuated strain of 
Mycobacterium bovis and has been part of the national childhood immunisation programme 
for neonates and infants in numerous countries [71]. BCG vaccine has a documented 
protective effect against TB meningitis and disseminated TB disease in children but 
unfortunately, it has only moderate efficacy in preventing disease and decreasing mortality 
in children, and it is not able to control chronic infection or to protect from recurrent 
episodes or re-activation of LTBI in adults particularly if co-infected with HIV [72]. 
Although the incidence of new TB cases has been falling worldwide, the rate of 
decline remains slow (2%) [61]. TB is considered a curable disease requiring therapy with 
antibiotics, and most disease remains readily treated with available drugs, apart from multi-
drug resistant TB (MDR-TB) cases that account for an estimated 3.2% of the new cases 
annually. Nevertheless controlling the global TB epidemic has been impeded by the absence 
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of an effective vaccine and the lack of rapid and sensitive diagnostics for both adults and 
children. 
 
1.5.1 Diagnosis of Tuberculosis  
Active TB disease is often diagnosed clinically, based on symptoms and clinical 
examination. Symptoms of the disease include fever, weight loss, night sweats and general 
malaise. Pulmonary tuberculosis usually presents with cough, lung inflammation and 
abnormalities often detectable on chest X-rays [73]. However, these symptoms and physical 
findings are non-specific. The clinical features of the disease are also affected by various 
factors including age, severity of disease, malnutrition, underlying conditions and genetic 
factors [74].  
The gold standard laboratory test for diagnosing pulmonary TB as well as 
extrapulmonary disease is the isolation of M. tuberculosis in culture. Spontaneous or 
induced sputum samples -if produced- or other specimens are cultured for mycobacteria 
using specific growth medium. Due to the slow growth of M. tuberculosis, detection of 
mycobacterial growth usually takes weeks. Sputum smear microscopy to detect acid-fast 
bacilli (AFB) following a staining procedure and an acid wash is a quick method, and 
available even in low resource countries but it is not specific for the species of M. 
tuberculosis. AFB testing requires the presence of 5,000 to 10,000 bacteria per millilitre of 
specimen to allow for detection of bacteria under the microscope, while a positive culture 
requires 10 to 100 bacteria.  
A number of in-vitro and in-vivo immunodiagnostic tests can provide indirect 
evidence of current or past exposure to M. tuberculosis. The Tuberculin Skin Test (also 
known as Mantoux test or purified protein derivative (PPD) skin test) is a method that has 
been used since 1890, and involves a subcutaneous injection of a small amount of M. 
tuberculosis antigens (i.e. PPD). The extent of the subsequent reaction to the antigens, 
measured in millimetres of induration, if present, is an indicator of TB exposure. However, 
the TST cannot discriminate between active and latent TB infection; has poor specificity 
upon prior BCG immunisation and exposure to environmental mycobacteria; can evoke 
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false-positive results and needs a second visit to the clinic 48 - 72 hours later for reaction 
reading [75]. These limitations were overcome by the introduction of Interferon γ–release 
assays (IGRAs). The IGRAs are based on the fact that sensitised host cells, when stimulated 
in vitro with M. tuberculosis specific antigens, will release the cytokine IFN-γ. IGRAs are 
more specific than TST and do not have cross-reactivity due to prior BCG vaccination or non-
tuberculous mycobacterial infections [76, 77]. Currently commercially available tests employ 
similar enzyme-linked immunosorbent assays (ELISAs) to detect production of IFN-γ by 
circulating T cells in response to M. tuberculosis specific antigens (i.e. Early Secretory 
Antigen Target 6 (ESAT-6), Culture Filtrate Protein 10 (CFP-10) and TB7.7). Assays may be 
undertaken in either whole blood, or using separated peripheral blood mononuclear cells 
(PBMCs) that produce IFN-γ in response to ESAT-6 and CFP-10 [78, 79]. 
Sequencing of the M. tuberculosis genome [80] allowed for remarkable progress in 
the field of TB diagnostics by developing nucleic acid amplification tests (NAAT). Research in 
the field of molecular diagnosis for TB using various PCR-based assays has led to 
commercially available kits for both TB diagnosis and the identification of drug resistance-
associated gene mutations. In 2010, WHO recommended the use of the Xpert® MTB/RIF 
assay, a quick, automated, PCR-based assay, which has the capacity to detect M. 
tuberculosis in the samples as well as its resistance to rifampicin [81]. Even for the simplest 
methods though, some experience in PCR methods and availability of laboratory facilities 
are required. 
It is suggested that lab based TB diagnostic tools should be interpreted alongside 
with chest radiography, clinical and laboratory examinations to lead to accurate diagnosis 
and adequate treatment. Currently less than half of all cases of active TB are detected and 
treated, particularly in low resource countries that account for 95% of all TB cases and 98% 
of all TB deaths [61]. This proportion is even higher for children and HIV infected patients. In 
these groups, current technologies to detect TB are ineffective. Smear microscopy, chest 
radiography and TST are unreliable in children, extra-pulmonary cases and BCG vaccinated 
individuals respectively, whilst culture of M. tuberculosis is currently considered as the gold 
standard [20]. Sensitivity of the NAAT tests depends on the DNA abundance in the sample. 
Although molecular diagnosis has improved detection of M. tuberculosis DNA in sputum, the 
sensitivity of this approach is lower in sputum negative, culture positive samples [82], and 
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the method does not detect solely extra-pulmonary disease. IGRAs are not able to 
discriminate TB from LTBI [83] and are of limited utility in African countries where LTBI is 
highly prevalent in the healthy population [84, 85]. 
As a simple, inexpensive point of care test for TB is still not available, there is an 
urgent need for improved diagnostic methods, particularly in African countries where TB 
and HIV persists as a dual epidemic as well as in paediatric populations. Transcriptional 
approaches using blood signatures have mostly been used to gain insight into the host 
response to mycobacteria infection and disease, but can also assist to the discovery of 
diagnostic biomarkers. 
 
1.5.2 Host Gene Expression in Tuberculosis  
The earliest studies using blood transcriptional profiling by microarray analysis in TB 
patients aimed at establishing the feasibility of identification of discriminatory biomarkers 
for a pulmonary disease using PBMCs or whole blood. The initial focus was on distinguishing 
groups of active TB patients, patients with recurrent TB, post-treatment TB patients and M. 
tuberculosis latently infected individuals using gene expression [86, 87]. These studies 
described the first blood transcriptional signatures of TB, detected even from small sample 
sizes, using gene expression microarray technology. Subsequent studies identified 
biomarkers which discriminated between latent TB infected individuals, active TB patients, 
BCG vaccinated individuals as well as healthy controls [88-91]. No differences in gene 
expression have been reported between the LTBI and healthy control groups in vivo, unless 
the samples were stimulated with PPD in vitro prior to microarray analysis [88]. However, 
signatures correlating with extent and progression of the disease, as well as disease 
treatment, have been identified [92-94]. Although these signatures would be very useful in 
discriminating active and latent TB infection, they would be of limited use for diagnostic 
purposes in the clinic, as the early studies did not compare TB with the spectrum of other 
diseases with similar presenting symptoms. 
In order to identify a TB specific signature, a study from the UK and South Africa 
compared transcriptional profiles from adult active TB patients with those from patients 
with other bacterial and inflammatory diseases namely Still’s disease, Staphylococcus, group 
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A Streptococcus and adult & paediatric systemic lupus erythematosus) [60]. A signature of 
86 transcripts dominated by over-representation of interferon-inducible transcripts, able to 
discriminate between TB patients and patient with other diseases was reported. However, 
further studies have observed a significant overlap of this signature with whole blood 
transcriptional signatures for sarcoidosis and melioidosis diseases, highlighting the need for 
appropriate control groups and highly specific biomarker sets [95-97]. A different set of 
studies have used hypothesis driven approaches based on previous microarray experiments 
or biological pathway data and tested the expression of candidate biomarkers in the blood 
of TB infected individuals [98-100].  
Most notably, HIV co-infected patients have been excluded from all the above 
studies. Given the disruptive effect that HIV infection has on the immune system [101] as 
well as the impediments it adds to TB diagnosis and outcome of the disease, HIV patients 
should be considered as a priority group to include in TB biomarker discovery studies. A 
recent study compared the transcriptional profiles of PBMCs of HIV mono-infected patients 
to HIV/TB co-infected patients, and identified a 251-transcript signature able to discriminate 
between the two groups. However, the study excluded any HIV infected patients with other 
underlying diseases or co-infections [102]. In terms of signature identification, these studies 
employ various statistical methods for model fitting, signature identification and patients’ 
classification (i.e. t-test, linear discriminant analysis, support vector machines, decision 
trees, k-nearest neighbor, and random forests). The machine learning methodology is 
discussed extensively in the following chapter. The published literature on host RNA 
expression regarding TB disease and infection available prior to publication of the studies 
described in this thesis is summarised in Table 1 below. 
Due to the different nature of the disease between adults and children and the 
particular challenges involved in diagnosis of paediatric TB, gene expression biomarkers in 
children should be sought for separately. Only one recent study has compared the whole 
blood transcriptional profiling of HIV uninfected native American children with active TB, 
latent TB infection and healthy controls to identify a discriminatory transcriptional signature 
[103]. However, the study excluded HIV infected children as well as children with other 
diseases and infections apart from latent TB infection.  
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Previous studies in TB have suggested that blood transcriptional signatures can be 
used to distinguish TB from healthy controls, latent TB infection, as well as other conditions 
[104]. The major challenge that remains is how to distinguish TB disease from the range of 
other conditions that show similar symptoms to it and represent the “real world” disease 
spectra from which TB must be distinguished in the clinic. This challenge is amplified for 
biomarkers that might be used in settings where TB and HIV are co-endemic, as well as in 
paediatric populations.  
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Study Region Year Sample Groups 
RT-PCR 
Validation 
HIV+ OD OD/HIV+ Paediatric 
Jacobsen et al. [86] Germany 2007 PBMC TB LTBI + - - - - 
Mistry et al. [87] SA 2007 whole blood TB LTBI + - - - - 
Berry et al. [60] UK & SA 2010 whole blood 
TB LTBI HC OD & 
TB treatment 
- - + - - 
Lesho et al. [89] 
USA & 
Brazil 
2011 whole blood TB LTBI HC (TST+) - - - - - 
Lu et al. [88] China 2011 PBMC (PPD) TB LTBI HC - - - - - 
Maertzdorf et al. [90] Gambia 2011 whole blood TB LTBI HC - - - - - 
Maertzdorf et al. [91] SA 2011 whole blood TB LTBI HC - - - - - 
Bloom et al.[92] SA 2012 whole blood TB treatment - - - - - 
Maertzdorf et al. [96] Germany 2012 whole blood TB OD - - + - - 
Ottenhof et al.[93] Indonesia 2012 PBMC 
TB HC & TB 
treatment 
+ - - - - 
Bloom et al. [97] UK 2013 whole blood 
TB & TB 
treatment 
- - + - - 
Cliff et al.[94] SA 2013 whole blood TB treatment - - - - - 
Dawany et al. [102] SA 2014 PBMC 
TB LTBI HC & TB 
treatment 
- limited - - - 
Verhagen et al.[103] Venezuela 2014 whole blood TB LTBI HC + - - - + 
Table 1: Summary of the published literature on RNA expression TB studies available prior to publication of the studies described in this 
thesis in chronological order, indicating the location of cohort, the year, the sample, the patient groups and the RNA quantification method. 
TB: tuberculosis, LTBI: latent tuberculosis, OD: Other Diseases, HC: healthy controls, HIV+/-: HIV infected/uninfected  
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1.6 Pitfalls of employing gene expression for biomarker discovery 
Although measuring transcript abundance in patient cohorts has been used to 
identify genes involved in disease pathways, as well as genes that can act as biomarkers for 
disease, there are limitations that may undermine the power of gene expression profiling if 
not appropriately addressed [105]. 
Firstly, the correct patient groups and relevant tissue samples need to be identified 
and collected to enable a robust approach to the scientific question posed. As the majority 
of gene expression studies are analysed in a comparative way, relevant age-matched 
controls (other diseases or healthy) need to be recruited as well. Before patient recruitment 
starts, accurate and detailed clinical definitions of the groups need to be decided. The 
minimum number of samples required, so that an effect of a certain size is likely to be 
detected, should be calculated (power analysis). Factors such as age, gender and race have a 
strong impact on gene expression and need to be considered, both during the early stages 
of setting up a study as well as during the data analysis stage. As for disease gene expression 
studies, heterogeneity within disease groups may have a strong influence on the results; 
time from onset of symptoms until the sample is taken, different disease subtypes, severity, 
and treatment protocols.  
Sample-related bias can also be introduced during different experimental stages 
from collection and handling (RNA degradation, number of freeze-thaw cycles), to 
processing (RNA extraction) and analysis. Another factor that complicates gene expression 
studies is the large heterogeneity of the tissues. For example in whole blood samples, the 
observed gene expression is a weighted average of the gene expression in all the different 
cell types, reflecting the cell types’ proportions.  
Quality control at various steps of gene expression analysis should be carefully 
assessed. Additionally, alternative technologies and out-of-sample validation should be 
employed to assess the results of analysis and further in vivo and in vitro studies should be 
conducted to address the functional relevance of the findings.  
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1.7  Summary 
This introductory chapter sets the background for the rest of the thesis and 
describes the biological basis and questions which are addressed in the remaining chapters. 
It depicts the importance of host gene expression as a marker of biological processes, and in 
response to particular pathogens or infections. Measuring gene expression can shed light on 
mechanisms underlying complicated biological processes as well as identifying 
transcriptional patterns specific for different diseases and infections. In particular whole 
blood can be used for transcriptional profiling of host response to infection and has been 
shown to be able to distinguish between different diseases and disease types.  
The existing challenges in biomarker discovery using gene expression microarrays 
are then highlighted. Former studies in the field of whole blood transcriptional profiling for 
infectious diseases and in particular tuberculosis disease are also reviewed, presenting their 
advantages and limitations. Previous studies’ findings support that recruitment of 
appropriate control groups is crucial for biomarker discovery and that results should be out-
of-sample validated using independent datasets. In the next section we list the objectives of 
this thesis and how it aims to further the research in the field of identification of whole 
blood RNA biomarkers for Tuberculosis disease.  
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1.8  Objectives of the thesis 
The aims of my thesis are: 
1. To develop an analysis pipeline applicable to whole blood gene expression 
microarray data to derive diagnostic biomarkers capable of distinguishing 
phenotypically similar diseases.  
2. To employ variable selection methods to identify the smallest sets of biomarkers 
that would allow best discrimination between comparator groups. 
3. To develop a risk score for each individual to indicate class of disease and 
evaluate the predictive performance of the score. 
4. To apply the diagnostic pipeline to cohorts of adult and paediatric patients with 
whole blood gene expression measurements, including TB patients as well as 
patients with other diseases that phenotypically mimic TB, while including HIV 
co-infected patients.  
5. To assess the performance of the biomarker sets and validate their classificatory 
power in independent cohorts. 
6. To compare the signatures with published signatures as well as current 
diagnostic methods employed in the clinical setting. 
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In Chapter 2, the statistical pipeline used to analyse gene expression microarrays and 
identify minimal gene expression signatures that can accurately classify patients with 
different diseases is described. High-dimensionality of microarray data, along with the 
particular challenges introduced by gene expression datasets derived from African settings 
was taken into consideration. The driving force behind this analysis was to develop a 
diagnostic test for TB that could be used in clinical practice. For that reason we employed 
parsimonious regression models of transcripts that are biologically interpretable. 
Subsequently, these models are translated into a single value disease score for each patient 
that reflects the risk of the patient having the disease. 
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2.1  Overview 
In terms borrowed from machine learning, the scientific questions that gene 
expression microarray application aims to address fall in three categories: class discovery, 
class comparison and class prediction [106]. The classes represent groupings of samples 
with shared characteristics (for example treated or untreated patients, healthy versus 
disease or differentiation between subtypes of the same disease). In brief, class discovery 
aims at the identification of subgroups of patients that share common gene expression 
patterns in an unsupervised manner. Class comparison aims at the derivation of genes that 
are differentially expressed between conditions in a supervised manner, since the class 
membership is known. Lastly, class prediction seeks for multivariate predictors (i.e. set of 
genes) that would allow for the best classification of samples of unknown class membership. 
The breakthrough for the clinical application of microarrays from a machine learning 
perspective was the molecular classification of different types of leukaemia cancer 
employing both class discovery and class prediction [107]. In this thesis we employ 
techniques that fall in these three categories while analysing gene expression microarrays 
from patients that have TB disease and LTBI as well as other conditions. 
 
2.2  Pre-processing 
The microarray technology allows for simultaneous measuring of thousands of 
transcripts on a dense array in a high-throughput manner that generates high-dimensional 
datasets. These data require dedicated management and statistical analysis in order to 
produce biologically meaningful results. An additional level of complexity arises from the 
experimental process itself, which involves multiple steps that can be prone to error. From 
sample collection to RNA extraction to microarray hybridization and imaging, every step can 
introduce variability and bias and thus affect the end result. 
Microarray analysis can serve as a tool for addressing various biological questions, 
which require distinct experimental design followed by specialised statistical approaches. 
However, the initial pre-processing steps such as quality control, background subtraction 
and normalisation are common across most experiments. In this thesis, we will focus on the 
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analysis of single-colour Human HT-12 V4 Expression BeadChip arrays (Illumina). As 
described in Chapter 1, after scanning the arrays, the image files are converted into a 
numeric table with measures of the intensity for each bead. This automated digitalisation 
procedure employs image processing algorithms that assign a signal intensity value to each 
pixel representing the fluorescence of the corresponding microarray bead [102]. By using 
spatial information for the array, a numerical value for every probe is recovered. 
The raw dataset is initially processed using the Illumina Genome Studio software, 
which provides summary results to assess the quality of the experimental procedures, as 
well as the sample quality. This quality control step measures the fidelity of the 
hybridization of RNA to the array, by assessing non-specific binding and the hybridisation 
stringency and estimates the efficiency of Cy3 binding using biotin tagged probes. In 
addition, the customary inclusion of housekeeping genes in transcriptomic experiments 
allows for a consistency check. This is achieved by comparing the intensities of 
housekeeping genes to background intensity levels and examining the distribution of the 
average housekeeping genes intensity across the samples. 
Following this first inspection, the three main steps of the pre-processing procedure 
are as follows: background adjustment, logarithmic transformation and normalisation. 
Background adjustment eliminates the effects of noise due to image scanning, non-specific 
hybridisation of some probes as well as auto-fluorescence of the chip surface. A specific 
function (forcePositive) adds an offset to all the values of the array, to address any negative 
values.  
The data then undergoes a logarithmic transformation (base 2) in order to reflect 
more intuitively the amplitude of transcriptional change, both the induction and the 
repression of gene expression. Even though ratios are often used as a measure of 
expression change, they are not easily interpretable for under-expression, as this is 
described by numbers between 0 and 1. The logarithmic transformation outputs a 
continuous spectrum of differences of gene expression and treats the up- and down-
regulated expression values in a similar way.  
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Normalisation is used to eliminate the systematic technical variation between arrays 
that is due to non-biological factors. As it has been shown that normalisation processes 
affect the outcome of the analysis, many microarray normalisation methods have been 
developed, having their own advantages and disadvantages. According to a systematic 
comparison, the most appropriate method for normalising Illumina Beadchip microarray 
data is Robust Spline Normalisation (RSN) [108, 109]. RSN combines the advantages of two 
other popular methods, the quantile and loess normalisation [110, 111]. The quantile 
normalisation method is a simple non-parametric normalisation procedure that has low 
computational burden and only uses the assumption that intensities of different arrays are 
derived from the same underlying distribution. It is a quick and efficient way of reducing 
technical variation, while maintaining the ranks of genes. Despite its advantages, quantile 
normalisation has a tendency towards over-correction and may thus reduce existent subtle 
biological differences between the samples. Loess normalisation, on the other hand, is 
based on fitting a smoothing curve to the microarray intensities, in a weighted way which 
penalises the contributions of data points that are far from the curve. It is based on 
principles of multiple localised linear regressions applied to a window of the data each time. 
So, the RSN methodology first employs quantile normalisation to estimate the fold change 
of the probes and then fits a monotonic spline curve on the data.  This information is used 
to down-weight the contribution of probes that are highly differentially expressed 
presumably due to biological factors [109].  
The final stage of the pre-processing is summarisation, which reflects the combining 
of multiple pre-processed probe level intensities that correspond to the same gene into 
gene abundance estimates. This step was skipped in our pipeline, as we analysed the data at 
the transcript level, rather than at the gene level, in order to avoid conflating values from 
transcripts with important biological differences (for instance reflecting alternative splicing 
events).  
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2.2  Microarray Analysis Toolbox  
The output of pre-processing is an expression data matrix of logarithmically 
transformed values, which stands as the base of subsequent statistical analysis. The 
expression matrix is two-dimensional with rows that correspond to transcripts and columns 
that correspond to patient samples. A database file containing the phenotypic 
characteristics of the samples was included in our analysis pipeline.  
 
2.2.1 Quality Control  
Since microarray data are of high dimensionality, as part of the quality control 
process we employed multidimensional scaling. This strategy allows us to summarise and 
visualise the dataset, explore any remaining variance in the expression level even after 
normalisation and to detect outliers. Principal Component Analysis (PCA) is used to perform 
dimensionality reduction (no. of arrays x ~48,000 probes, down to no. arrays x no of 
principal components) [112]. Since the analysis toolbox is designed for gene expression data 
from heterogeneous disease groups, various geographic locations, and different underlying 
endemic infections with samples handled by different laboratories, we needed to detect any 
diagnostically irrelevant subclasses of the data. PCA transforms the data into a new set of 
variables, the principal components, which are linear combinations of the original variables. 
The number of the principal components can be less than or equal to the number of original 
variables in the orthogonal space. The first component accounts for as much of the 
variability in the data as possible and the succeeding components show the highest possible 
variability of the data, while being orthogonal to the previous components. A Hotteling T2 
test statistic, the 2-dimensional equivalent of the t-statistic, was calculated to measure the 
multivariate distance of each observation from the centre of the data set. The Hotelling T2 
distance is a measure that accounts for the covariance structure of a multivariate normal 
distribution. The higher the T2 value, the more distant the observation is from the mean 
[113, 114].  
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2.2.2 Differential Expression  
In this thesis, we set out to identify biological differences and discover biomarkers 
able to discriminate between two predetermined sample classes. For the rest of the thesis 
(unless otherwise stated) we assume that the two classes correspond to accurately 
phenotyped groups of patients. In order to compare the expression of the transcripts 
between classes, the average expression for each examined transcript is summarised by its 
mean value across samples in the class. Differential expression can be assessed by the log 
fold change (logFC) of the transcript expression values, i.e. the difference between the 
means of the log-transformed expression values. However, examining the logFC by itself can 
lead to false positive results. To address this concern, we also employed more rigorous 
statistical tests, such as the Student’s t-test, which evaluates the equality of the means, 
while comparing the effect size with its variance among subjects and is widely used in 
microarray studies. The t-statistic is the difference between two means divided by the 
standard error of the difference between the two means. The null hypothesis of the two 
sample t-test is that the means of the expression values are equal. Thus, the t-test can be 
used to calculate p-values that define the probability of rejecting the equality hypothesis, 
based on a predefined level of significance (α).   
However, within any microarray experiment there is a component of the transcript 
intensity variation that is shared amongst them. Consequently, information from other 
transcripts can be used to aid in estimation of the variance of a single transcript. There are 
many approaches developed that employ Bayesian approaches to leverage information 
across multiple transcripts. In our pipeline,  we assessed differential expression between 
patient groups using LIMMA, a method that combines linear models, moderated t-test 
statistics and an empirical Bayes approach [115]. First, a linear model is fitted to each 
transcript aiming to model any systematic effect on the expression. 
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The response matrix Y for every transcript (j) across the samples (n) is modelled. A 
design matrix X is used for every transcript corresponding to the comparison grouping. It 
establishes the relationship between observations and the parameters of the model. The 
regression coefficient matrix α represents the average difference in expression between the 
classes, with some of the coefficients corresponding to differences of biological interest, 
which are indicated by a contrast matrix C.  
     
      (2.2) 
 
A moderated t-statistic with augmented degrees of freedom (allowing for more than 
two contrasts) is calculated to test the null hypothesis H0 : βjp=0. This statistic employs an 
empirical Bayes approach where the parameters of the prior distribution are estimated from 
the data) permitting estimation and testing of the effects. An assumption underlying the use 
of this statistical model is that there is no interaction of one gene with another. Lastly, the 
moderated t-test statistics are translated into p-values as for the ordinary t-test. 
In microarray expression analysis, where tens of thousands of comparisons are 
conducted simultaneously, the chance of incorrect rejection of the null hypothesis is 
elevated (type I error). However, this type of error can be controlled using methods that 
correct for multiple testing either by adjusting the level of significance or by reducing the 
proportion of false positives transcripts amongst all significant results. Bonferroni correction 
method modifies the significance cut-off (α/n), by dividing the level of significance (α) by the 
number of samples (n), but it is highly conservative, particularly for microarray data [116]. 
Another popular method is the Benjamini-Hochberg False Discovery Rate (FDR) method that 
reduces the false positive results and is less conservative [117]. It is based on assigning ranks 
(i) to the p-values of the transcripts, multiplying them by their number (n) and dividing them 
by their rank (i). In this way the adjusted p-values for transcripts with low ranking are 
deflated.  
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Long lists of transcripts that are significantly differentially expressed between 
conditions of interest are very informative, especially when the aim is biological exploration 
of the data. However, smaller probe lists may achieve better prediction between conditions, 
as noise and redundant information is removed. Also smaller numbers of biomarkers 
enhance the feasibility of diagnostic development based on gene expression. In the pipeline, 
I employ a class comparison step to filter out transcripts that are not adequate candidates 
for biomarker selection (i.e. low log2FC and high p-values). For each comparison of interest, 
only the transcripts with a |log2FC| > 0.5 were taken forward to variable selection. The FC 
threshold was chosen in order to ensure that differential expression for selected variables is 
within the resolution limits of qRT-PCR, in case of subsequent analysis.  
 
2.3 Feature Selection 
There are various methods of implementing feature selection, but regression is an 
intuitive way to identify contribution of gene expression to a particular phenotype [118]. 
Regression is a statistical model that reveals underlying relationships between a dependent 
variable (disease state) and various independent variables (transcripts). The contributions of 
the independent variables are reflected by the regression coefficients. Regression is a 
popular method in systems biology as it constructs models that are simple and easy to 
interpret in a biological context. However, predictor variables are usually highly correlated, 
meaning that multiple variables may explain the same component of the independent 
variable. This holds particularly for gene expression data where many genes can be co-
expressed as part of the same biological process.  
As the aim is to identify the smallest possible transcript set containing key predictive 
variables that will have a good predictive performance, a dimension reduction strategy was 
employed to acquire a parsimonious regression model. There are two broad families of 
model selection in the context of linear models; subset selection methods and shrinkage 
methods.  
Subset selection methods (i.e. forward and backward stepwise selection) have a 
series of limitations amongst which the inability to handle appropriately multicollinearity 
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between the variables and the “large p, small n”. Data derived from microarray experiments 
are typical of the “large p, small n” problem, meaning that the number of features (p) is 
much larger than the number of observations (n). Consequently, in order to address this 
class classification problem we resorted to shrinkage methods.  
Shrinkage methods (also called regularisation methods) shrink the regression 
coefficients -potentially to zero to obtain sparse models- by imposing a penalty on their size, 
and are extensions of the least squares method. That leads to a selection of a small subset 
of variables that exhibits stronger effects on the independent variable than the rest of the 
variables, while maintaining prediction accuracy. It was decided to address this problem 
using elastic net [119], which is an intermediate approach between ridge regression [120] 
and lasso  [121]. 
If we assume a linear model with n observations and p predictors: 
           (2.4) 
where: 
            
  is the response variable 
   is the intercept term 
              
 
 are the predictors 
               is the vector of the coefficients given by the model fitting procedures 
            
  is the vector of the coefficients given by the model fitting procedures 
The most popular method to estimate the coefficients of the model                
is ordinary least squares (OLS). In this method the coefficients are determined by minimising 
a penalised residual sum of squares. 
OLS: 
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In shrinkage methods, a non-negative complexity parameter (λ ≥ 0) is introduced to 
control the amount of shrinkage and the coefficients are determined by minimising the 
penalised residual sum of squares (2.6). The parameter λ determines how important the 
penalty on coefficient weights is.  
Ridge: 
                               
 
   
 
 
 
   
     
 
 
   
  (2.6) 
 
Although ridge regression shrinks the coefficients of the model, it does not produce 
sparse models as it always retains all the predictors. Lasso, on the other hand, uses a 
modified penalty that allows both continuous shrinkage and automatic variable selection 
simultaneously, as well as sparsity exploitation. 
Lasso: 
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Elastic net is a compromise between ridge regression and lasso that selects variables 
like the lasso, but jointly shrinks the coefficients of correlated predictors like ridge 
regression.  
 
Elastic Net: 
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The second term of the elastic net penalty encourages highly correlated variables to 
be averaged while the first one encourages a sparse solution in the coefficients of these 
averaged features. Compared to lasso, elastic net has the ability to result in more than n 
non-zero coefficients, where n is the sample size. This is especially advantageous for 
microarray experiments with small sample sizes, as it overcomes the p>n problem. 
Simulations as well as real data show that the elastic net often outperforms the lasso in 
predictive performance [122]. 
For the above reasons, we selected the elastic net as the shrinkage method used for 
the analysis. In our pipeline, the λ1 and λ2 parameters of elastic net, which indirectly control 
the size of the transcript signature as well, were selected via ten-fold cross-validation (CV) to 
avoid overfitting and promote generalisation. We varied both parameters over a two 
dimensional grid and acquire the full solution path for every combination. Values that 
produced the lowest mean squared error (MSE) determined the final parameterisation of 
the model. 
 
2.4 Disease Risk Score implementation 
The constructed elastic net models based on the microarray data include a specific 
set of transcripts along with their regressors, and they are used to perform class annotation 
of the patient samples. However, the analysis pipeline was created with the ultimate goal of 
developing a simple, affordable TB diagnostic test suited for use in resource poor settings. In 
order for the gene expression signatures information to be routinely utilised for clinical 
diagnosis even in low resource settings, a transformation is required to enable the potential 
development of a suitable for clinical use test that would not rely on sophisticated 
equipment. 
Since a regression model does not hold the potential to be translated into a near 
patient assay test, we therefore developed a general method for converting complex 
weighted multiple transcript RNA signatures into a disease risk score (DRS). The 
simplification technique that we propose enables microarray signatures of disease to be 
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converted into a single value score for every individual. The single value classification could 
aid the development of a simple, low cost, diagnostic test requiring basic laboratory 
facilities and minimal bioinformatics analysis. The calculated DRS is able to classify the 
patients without significant loss of prediction accuracy and could form the basis of a 
diagnostic test (see Results chapter) [123].  
Transcripts from the signatures were separated into up-regulated and down-
regulated based on their in-sample calculated differential expression. The score is 
subsequently derived by adding the total intensity of the up-regulated transcripts and 
subtracting the total intensity of the down-regulated transcripts. The disease risk score for 
an individual i can be calculated using the formula:  
                                
 
 
   
             
          
 
   
 
 
(2.12) 
where: 
n  is the number of up-regulated transcripts in the signature in disease of interest (TB) 
compared to comparator group(s). 
m  is the number of down-regulated transcripts in the signature in disease of interest (TB) 
compared to comparator group(s). 
The threshold for the classification was calculated as the weighted average of the 
risk score within each class (group of patients), with weights given as the inverse of the 
standard deviation of the score within each class. The threshold for the classification 
between group u and v is shown below: 
                
  
  
 
  
  
 
  
 
 
  
 
 
(2.13) 
where: 
μ  is the average of the disease risk score in the group. 
σ  is the standard deviation of the disease risk score in the group. 
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We further explored the effect of adjusting the threshold of the disease risk score for 
assigning individual patients to groups. By accepting a percentage of patients as “not 
classified” by our test and thus requiring further investigation, the majority of patients 
under investigation are accurately assigned. This suggests that the score might be used as 
an initial screening “rule in/rule out” approach to TB diagnosis. We define the indeterminate 
zone, by calculating the lower and upper DRS thresholds as a weighted average given by 
 
  
, 
   
  
  respectively: 
                         
  
  
  
       
  
  
 
  
 
   
  
                (2.14) 
 
For w=1 the formula is equivalent to the main threshold formula (2.13). 
The information that the DRS requires for classification (i.e. the expression values of the 
transcripts in an non-weighted manner) can be derived from the dataset itself, which allows 
its unbiased application using expression data acquired using other array platforms or non-
array technologies. The classification on a single value holds diagnostic potential and could 
be used for the development of rapid diagnostic tests suitable for clinical use for the 
determination of the presence of an infection or disease in a host. It can readily be 
characterised as positive for a disease, disease state or infection. 
 
2.5 Classification metrics  
In order to evaluate the predictive accuracy of the classificatory models derived from 
our variable selection analysis as well as the performance of the DRS, we calculated 
different point and interval metrics typically used for diagnostic tests [124-127]. We 
compared the results obtained using the elastic net model and the DRS to the clinical 
diagnosis of the patients, which is considered the “gold standard” diagnosis. For this 
benchmark, we calculated area under the characteristic curve (AUC), sensitivity, specificity, 
positive predictive value (PPV), negative predictive value (NPV), and likelihood ratios. 
Confidence intervals at 95% were calculated to measure the reliability of our estimates 
(CI95%). 
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Group Definition 
True positive gold standard “positive” individuals that the test classifies them as “positive” 
False positive gold standard “negative” individuals that the test classifies them as “positive” 
True negative gold standard “negative” individuals that the test classifies them as “negative” 
False negative gold standard “positive” individuals that the test classifies them as “negative” 
 
Sensitivity (True Positive Rate): the proportion of true positive correctly identified by the 
classifier. It reflects the probability of being test positive with disease present. 
            
             
                            
 
 
(2.15) 
Specificity (1 - False Positive Rate): the proportion of true negatives correctly identified by 
the classifier. It reflects the probability of being test negative with disease absent. 
            
             
                            
 
 
(2.16) 
Positive predictive value (PPV): the proportion of the outcome positives that are true 
positives. It reflects the probability of a patient having the disease when the test is positive.  
    
             
                            
 
 
(2.17) 
Negative predictive value (NPV): is the proportion of the outcome negatives that are true 
negatives. It reflects the probability of a patient not having the disease when the test is 
negative. 
    
             
                            
 
 
(2.18) 
 
For case-control studies the ratio of gold standard positive and negative individuals 
does not reflect the real prevalence of the disease in a community or hospital setting, as in 
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observational studies. Given the dependency of NPV/PPV on the prevalence of the disease 
in the population, it is important to provide estimates of these values specific to scenarios in 
which such a diagnostic test would be applied. In this case, prevalence can be interpreted as 
“the probability before the test is carried out that the subject has the disease” as suggested 
by D. Altman [128]. The formulas for PPV and NPV can be modified based on Bayes' 
theorem as follows:  
    
                      
                                                     
 (2.19) 
 
    
                          
                                                     
 
 
(2.20) 
 
Positive likelihood ratio (LR+): is the probability that an individual with disease has a 
positive test divided by the probability that an individual without disease has a positive test. 
The ratio indicates the effect of the increase on the probability of disease if the test is 
positive.  
    
           
             
 
 
(2.21) 
Negative likelihood ratio (LR-): is the probability that an individual with the disease has a 
negative test divided by the probability that an individual without the disease has a negative 
test. The ratio indicates the effect of the decrease on the probability of disease if the test is 
negative. 
    
             
           
 
 
(2.22) 
We report positive and negative likelihood ratios along with their confidence intervals 
employing the method described in [129]. 
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Area Under the Receiver Operating Characteristic Curve (AUC): is a global assessment of 
the diagnostic accuracy of the test, summarising both sensitivity and specificity for a varying 
test discrimination threshold (Figure 5). A Receiver Operating Characteristic (ROC) plots the 
true positive rate (sensitivity) of the test against the false positive rate (1-specificity) at 
various thresholds. A random classifier has an AUC of 0.5, while a perfect classifier has an 
AUC of 1. 
 
Figure 5: Characteristics of a ROC curve 
 
The calculation of the confidence intervals at 95% for the aforementioned metrics 
was based on a non-parametric stratified bootstrap resampling. Each replicate contained 
the same number of cases and controls as the original sample and we ran 2000 bootstraps, 
as recommended by Carpenter et al. [130].  
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2.6 The pipeline  
In order to ensure the generalisation of our models, avoid overfitting and estimate 
the accuracy of the classification, we employed the hold-out method as a cross-validation 
technique. The initial microarray dataset was randomly partitioned into two independent 
sets, the training set and the test set, comprising of 80% and 20% of the samples 
respectively. When different prominent subclasses were present, we maintained a balanced 
representation in both sets.  
The training set was used to derive the transcriptional signatures, which were 
subsequently employed to classify the samples in the test set and independent validation 
cohorts. The process begins by identifying the transcripts that exhibit the most substantial 
variation in the training set and selecting them as candidate predictors. An elastic net model 
was then fitted on the subset of the training data defined by the candidate predictors. To 
avoid overfitting, the model’s parameters were tuned using 10-fold cross validation. The 
test set was held out for the accuracy estimation of the elastic net model as well as the DRS. 
The derived signatures were also applied to independent validation cohorts, which can 
comprise either publicly available data or independently collected and processed data 
(Figure 6). 
The pipeline is implemented in the ‘R’ Language and Environment for Statistical 
Computing, version 2.12.1. [131]. R integrates a multitude of packages that are developed 
and contributed by researchers worldwide. In addition there is a specific collection of 
packages named BioConductor, which provides tools for the analysis, visualization and 
comprehension of high-throughput biological data [132]. In Table 2 below the key 
BioConductor packages that were used in the analysis pipeline are summarised:  
 
Task Tool 
pre-processing of microarray data lumi [109] 
differential expression analysis limma [133] 
elastic net model glmnet [134], enet [122] 
ROC curves pROC [135] 
Table 2: BioConductor packages used in the pipeline 
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Clustering tools, such as hierarchical clustering methods (i.e. heatmaps) were used 
to visualise the groups of patients and groups of genes with similar expression profiles 
throughout the pipeline. 
 
Figure 6: Methodological pipeline implemented using R and BioConductor 
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2.7 Summary 
The use of whole-blood gene expression to derive diagnostic biomarkers capable of 
distinguishing phenotypically similar diseases remains challenging. In this chapter I proposed 
a pipeline for discovering biomarker signatures from whole blood transcriptomic data. The 
Disease Risk Score (DRS), which provides a new generalisable approach to reduce the 
dimensionality of multi-transcript signatures, was also introduced.  
The pipeline was created with the particular challenges of acquiring gene expression 
data in an African setting in mind. Those include deriving a signature robust to geographical 
heterogeneity, to the presence of endemic underlying co-infections and to measurement 
variability from different assays. In the following chapters I will describe the application of 
the pipeline to two large gene expression studies from Africa.  
Although the main steps of the bioinformatics pipeline were described in this 
chapter, statistical plug-ins will be introduced in the results chapters, tailored to the needs 
of the particular datasets.  
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Chapter 3 
 
Identification of host gene 
expression biomarkers for 
TB in adults 
 
 
In Chapter 3, I present the analysis of a large, prospective case-control study to identify host 
biomarkers of TB. Patient recruitment and laboratory work was carried out by colleagues in 
the ILULU consortium as stated in the Declaration of Originality. The study compared 
patients with culture proven TB to patients with a wide spectrum of other diseases as well 
as LTBI, including both HIV-infected and -uninfected subjects. After data exploration and 
pre-processing, the bioinformatics pipeline described in Chapter 2 is employed in order to 
identify the minimal transcriptional signatures able to discriminate between diseases and 
disease states. The performance of the signatures is first evaluated using the above cohort 
and then validated in an independent publicly available dataset via the calculation of patient 
disease risk scores. 
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3.1 Cohorts 
To investigate the hypothesis that TB can be distinguished from LTBI and other 
diseases phenotypically similar to TB prevalent in HIV-infected and -uninfected African 
populations, a multicentre international study was set up. In order to enable generalisation 
of the findings to African countries with differing prevalence of malaria and other parasitic 
infections, as well as other environmental exposures that might affect transcription, two 
highly contrasting study sites were chosen (one urban, one rural) in two African countries 
with differing co-endemic diseases: Cape Town, South Africa (SA) and Karonga district, 
Northern Malawi. South Africa has one of the highest TB incidence rates in Africa (860 per 
100,000) [61]. Out of the total number of TB cases, 62% are HIV-positive, while 90% are 
actually tested. In Malawi, the incidence of new TB cases is lower (156 per 100,000) while 
56% of the TB cases are HIV-positive, out of the 90% that are tested. In Malawi, malaria and 
helminth infection are hyperendemic.  
 
3.1.1 Recruitment 
Patients presenting to hospitals in South Africa and Malawi with suspected 
tuberculosis were recruited and biological samples were collected, amongst which 
peripheral blood in Qiagen PAXgene RNA tubes for the microarray study. In addition, 
patients with latent tuberculosis infection (LTBI) were recruited in the community or from 
contact tracing clinics. Overall, 311 patients from South Africa and 273 from Malawi were 
recruited. All patients underwent examination adequate for suspected TB cases: chest 
radiographs and serological testing for HIV, along with cultures of blood, cerebrospinal fluid 
and urine, and biopsies for histological examination including TB culture. Two sputum 
samples obtained after induction or coughing were examined by standard microscopy for 
acid fast bacilli (AFB) and cultured for TB.  
Healthy LTBI controls were recruited by random community selection (Malawi) and 
from HIV screening clinics (South Africa) from the same areas as patients with TB. TST 
and/or in vitro IGRAs was undertaken to validate LTBI categorisation. Individuals were 
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assigned into diagnostic groups based on examination results at enrolment and follow-up, 
as well as HIV status.  
 
3.1.2 Diagnostic Process and data generation 
Following the diagnostic work-up, patients were assigned to groups using the 
following definitions shown in Table 3 below. 
Group Definition 
Definite TB case  
(TB) 
Clinical condition consistent with TB and microbiological evidence 
(M.tuberculosis was cultured from sputum or tissue samples) 
Latent TB infection 
(LTBI) 
Clinically assessed as healthy without any clinical syndrome in which 
tuberculosis is likely. TST positive (>10mm or more if HIV-uninfected, or 
>5mm or more if HIV-infected) and/or a positive IGRA and negative 
sputum culture (if cough was productive) 
Other disease case  
(OD) 
Disease syndrome that on presentation included tuberculosis in the 
differential diagnosis, but following clinical investigation and 
management, tuberculosis was excluded and a firm alternative 
diagnosis was established 
Table 3: Definitions for “gold standard” classification of patient samples of the adult study 
from South Africa and Malawi. 
 
Individuals were either assigned to one of the diagnostic groups above or excluded 
once the results of investigations and follow-up were available (Figure 7). After 
investigation, any case with an established alternative diagnosis to TB, no microbiological 
evidence of TB and an absence of TB symptoms at the time of follow-up, or with an 
observed improvement of clinical symptoms on follow-up without TB treatment, was 
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recruited as an OD case. If TB could not be reliably ruled out of the differential, the patient 
was excluded. 
 
Figure 7: Diagnostic algorithm for patient classification into LTBI, active TB and other 
diseases groups. 
 
In the RNA expression study 96 TB patients, 117 patients with OD and 98 LTBI 
individuals were included from Cape Town. From Malawi, the first 119 patients with TB, 77 
patients with OD and 77 LTBI individuals were included (Figure 8).  
Amongst the culture confirmed TB cases, there were some patients with negative 
smear results. In Cape Town, 36.7% (18/49) HIV-infected patients with TB were smear-
negative and 8.5% (4/47) HIV-uninfected patients were smear-negative. In Malawi, 13.3% 
(8/60) HIV-infected patients with TB were smear-negative and 10.2% (6/59) HIV-uninfected 
patients were smear-negative. The Other Diseases (OD) group reflected the range of 
conditions with similar clinical manifestations to TB at each site. Patients were followed up 
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26 weeks post diagnosis to confirm that those with other diseases remained TB-free. The 
spectrum of infectious and malignant diseases in the OD cohort is shown in Table 4. 
Disease Groupings HIV infected HIV uninfected  
 SA Malawi SA Malawi Total 
Pneumonia/LRTI/PJP 24 (35%) 19 (50%) 5 (10%) 13 (33%) 61 (31%) 
Malignancy & other neoplasia* 
(other than Kaposi's sarcoma) 
2 (3%) 4 (11%) 17 (35%) 5 (13%) 28 (14%) 
Pelvic inflammatory disease / 
UTI 
4 (6%) 1 (3%) 15 (31%) 5 (13%) 25 (13%) 
Bacterial, viral meningitis or 
meningitis of uncertain origin 
4 (6%) 4 (11%) 0 (0%) 6 (15%) 14 (7%) 
Hepatobiliary disease 6 (9%) 0 (0%) 7 (14%) 0 (0%) 13 (7%) 
Febrile syndromes of uncertain 
origin 
1 (1%) 3 (8%) 1 (2%) 6 (15%) 11 (6)% 
Kaposi's sarcoma 9 (13%) 1 (3%) 0 (0%) 0 (0%) 10 (5%) 
Cryptococcal meningitis 6 (9%) 4 (11%) 0 (0%) 0 (0%) 10 (5%) 
Non TB pleural effusion / 
Empyema 
5 (7%) 0 (0%) 2 (4%) 0 (0%) 7 (4%) 
Gastroenteritis 5 (7%) 0 (0%) 0 (0%) 0 (0%) 5 (3%) 
Peritonitis 0 (0%) 1 (3%) 0 (0%) 3 (8%) 4 (2%) 
Other* 0 (0%) 1 (3)% 2 (4%) 1 (3%) 4 (2%) 
Gastric ulcer or gastritis 2 (3%) 0 (0%) 0 (0%) 0 (0%) 2 (1%) 
Total 68 38 49 39 194 
Table 4: Major clinical diagnoses of the patients in the other diseases (OD) group. 
* (14) Bronchial carcinoma, (4) Lymphoma, (1) Cervical carcinoma, (1) Ovarian carcinoma, 
(1) mesothelioma, (1) gastric carcinoma, (4) metastatic carcinoma of unknown origin, (1) 
benign salivary tumour, (1) Dermatological tumour 
** (1) HIV-related lymphadenopathy, (1) Crohn's, (1) Orchitis, (1) Pyomyositis 
LRTI: Lower Respiratory Tract Infection, UTI: Urinary tract infection, PJP: Pneumocystis 
jirovecii pneumonia 
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Uniform protocols for sample collection, separation, recovery of RNA and storage 
were utilised in both sites. Whole blood was collected in PAXgene RNA tubes, frozen at -
20oC within 3 hours, and then stored at -80oC. RNA was extracted using PAXgene blood RNA 
kits at one site (Cape Town) to minimise any sample handling bias. The integrity and yield of 
the total RNA was assessed using an Agilent 2100 Bioanalyser and a NanoDrop 1000 
spectrophotometer respectively. Total RNA was then shipped to the Genome Institute of 
Singapore (GIS). After quantification and quality control, biotin-labeled cRNA was prepared 
using Illumina TotalPrep RNA Amplification kits (Applied Biosystems) from 500ng RNA. 
Labelled cRNA was hybridised overnight to Human HT-12 V4 Expression BeadChip arrays 
(Illumina). After washing, blocking and staining, the arrays were scanned using an Illumina 
BeadArray Reader. Using Genome Studio software the microarray images were inspected 
for artefacts and QC parameters were assessed (Appendix). During sample handling for RNA 
expression analysis 48 samples were excluded: 45 due to low RNA concentration prior to 
amplification, 2 failed amplification and 1 was excluded during the data QC. A total of 536 
microarrays were used for gene expression analysis (Figure 8). The expression data has been 
submitted to Gene Expression Omnibus (record GSE37250). 
 
Figure 8: South Africa/Malawi Patient cohorts and microarrays 
Prospective cohorts of patients undergoing investigation for TB were established in two sub-
Saharan African countries (South Africa, Malawi) with differing patterns of endemic 
diseases. TB uncertain: patients for whom TB diagnosis could not be excluded were not 
included in the study. 
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3.2 Dataset exploration 
First we pre-processed the microarray data as described in Chapter 2. Then, after 
background adjustment and normalisation, quality control was performed in order to 
examine the effect of disease state on transcript expression and to check for possible 
assignment errors. PCA analysis was employed and the first three principal components 
were examined, based on all transcripts on all samples (Figure 9). Inspection revealed that 
the primary clustering was based on disease state (TB, LTBI or OD) rather than geographical 
location or HIV status. The sample highlighted (categorised as active TB HIV+ from Malawi) 
was removed from the analysis. The elliptic rings represent levels of confidence (0.9 inner 
circle; 0.9999 outer circle). 
         
Figure 9: Principal components analysis (PCA) plot of the microarray samples.  
The PCA plot is based on all transcripts and all samples after background adjustment and 
normalisation. On the left PCA1 & PCA2 are plotted and on the right PCA1 & PCA3. The 
sample highlighted was removed from the analysis. Rings are levels of confidence (0.9 inner 
circle; 0.9999 outer circle). 
 
The six first principal components were examined further. The ratio of variance that 
can be predicted independently by the PCs (R2 values) shows the importance of each 
component. In this analysis the R2 values for the principal components are: R2 (PC1) = 0.128; 
R2 (PC2) = 0.108; R2 (PC3) = 0.049; R2 (PC4) = 0.045; R2 (PC5) = 0.036; R2 (PC6) = 0.031. In 
order to interpret the principal components, a correlation analysis was used to identify 
which variables are strongly correlated with each component. A threshold of 0.5 for 
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correlation was used to indicate strong correlation. As for disease status, only the LTBI 
samples had a correlation with PC2 over 0.5 (0.52), indicating that PC2 is probably capturing 
a “healthy” component of gene expression (Figure 9). Location (South Africa) was correlated 
with PC5 (-0.57) and HIV status was correlated with PC6 (0.55) (Figure 10). 
                
Figure 10: Principal components correlated with location and HIV status.  
Principal components 5 and 6 are shown. On the left plot colour coding depicts the location 
(South Africa or Malawi), and on the right plot colour coding depicts the HIV status (negative 
or positive).  
 
As previous gene expression TB studies have not considered different locations and 
HIV prevalence, we explored if there was evidence of a robust underlying signature of TB, 
independent of HIV status and geographical location. Two pairwise comparisons were of 
particular interest as they reflect the real world diagnostic questions: TB vs. LTBI and TB vs. 
OD. In contact screening, the aim is to distinguish active TB from latent infection, whereas 
distinguishing TB from other phenotypically similar diseases is the challenge in the clinical 
context of a sick patient.  
Separate linear models were fitted to the data for the different HIV groups and the 
different locations using the suitable design matrices: TB vs. LTBI in HIV-uninfected patients 
from South Africa, TB vs. LTBI in HIV-uninfected patients from Malawi, TB vs. LTBI in HIV-
infected patients from South Africa, TB vs. LTBI in HIV-infected patients from Malawi. The 
same comparisons were performed for TB vs. OD. The outputs were lists of transcripts with 
adjusted p-values reflecting the level of confidence for evidence of differential expression. 
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The negative logarithm of the corrected p-values was plotted and their Pearson 
correlation coefficient was calculated to assess how location and HIV status affect the 
signatures. Substantial correlation was observed for TB vs. LTBI differential expression 
across different geographic locations regardless of HIV co-infection (Figure 11, Table 5). Less 
correlation was observed for TB vs. OD between the different locations which may reflect 
the different spectra of conditions that TB has to be differentiated from in the two different 
sub-Saharan regions (Figure 11, Table 5). 
 
 
Figure 11: Concordance of differential expression across sites for the TB vs. LTBI 
comparison (top) and TB vs. OD comparison (bottom), by HIV status (uninfected: left, 
infected: right).  
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Each circle corresponds to a transcript and the negative logarithm of the corrected p-values 
is plotted for each comparison. 
 
Comparison Correlation Coefficient for Locations 
TB vs. LTBI HIV negative 0.56 (0.55-0.56) p-value < 2.2e-16 
TB vs. LTBI HIV positive 0.70 (0.69-0.71) p-value < 2.2e-16 
TB vs. OD HIV negative 0.11 (0.10-0.12) p-value < 2.2e-16 
TB vs. OD HIV positive 0.26 (0.25-0.27) p-value < 2.2e-16 
Table 5: Pearson correlation coefficient for the negative logarithm of the corrected p-
values for the different pairwise comparisons. 
 
Regarding the different HIV groups, the correlations for all the comparisons were 
positive (Figure 12, Table 6). However, the correlations for TB vs. OD HIV-infected and -
uninfected individuals were less strong than for TB vs. LTBI, reflecting the different spectrum 
of conditions among the HIV-infected individuals that mimic the symptoms of TB disease. 
 
Comparison Correlation Coefficient for HIV status 
South Africa TB vs. LTBI  0.66 (0.65-0.67) p-value < 2.2e-16 
South Africa TB vs. OD  0.55 (0.54-0.56) p-value < 2.2e-16 
Malawi TB vs. LTBI  0.78 (0.77-0.79) p-value < 2.2e-16 
Malawi TB vs. OD  0.34 (0.33-0.36) p-value < 2.2e-16 
Table 6: Pearson correlation coefficient for the negative logarithm of the corrected p-
values for the different pairwise comparisons. 
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Figure 12: Concordance of differential expression for HIV status for the TB vs. LTBI 
comparison (left) and TB vs. OD comparison (right), by location (SA: top, Malawi: bottom).  
Each circle corresponds to a transcript and the negative logarithm of the corrected p-values 
is plotted for each comparison is plotted. 
 
This analysis provides evidence that a substantial number of transcripts are 
significantly differentially expressed irrespective of location and HIV status, with the same 
direction of expression. However, HIV status and location should be accounted for in the 
linear models, and in any partitioning of the dataset, to ensure the identification of robust 
TB signatures independent of HIV status or geographical location.  
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3.3 Power calculation  
In order to evaluate the suitability of the sample cohorts to detect effects that would 
be appropriate for biomarker use in this study, a power calculation was used. As the study 
has two diagnostic arms (TB vs. LTBI and TB vs. OD) different calculations were implemented 
for each comparison. 
For an anticipated sensitivity of 90% and a specificity of 90% for the TB vs. LTBI 
comparison in adults, a sample size of 194 TB patients and 167 LTBI patients will provide 
95% confidence intervals (CI) spanning 4.2% from the point estimate of sensitivity and 4.7% 
from the point estimate of specificity. In an 80-20 split of the cohort, the 95% CI will span 
10.3% for sensitivity and 10.9% for specificity for the test set.  
For an anticipated sensitivity of 90% and a specificity of 90% for the TB vs. OD 
comparison in adults, a sample size of 194 TB patients and 175 OD patients will provide 95% 
CI spanning 4.2% from the point estimate of sensitivity and 4.5% from the point estimate of 
specificity. In an 80-20 split of the cohort the 95% CI will span 10.4% for sensitivity and 
10.4% for specificity for the test set. The adjusted Wald method was used for the 
calculations.  
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3.4 Results 
3.4.1 Overview 
To identify transcript signatures applicable across geographic locations and in 
patients with differing HIV status, we combined HIV-infected and -uninfected patient 
cohorts from South Africa and Malawi. The recruited participants were randomly assigned 
into a training set (80% of the participants) and a test set (20%) with no overlap, using the 
“sample()” function without replacement in R which obtains a subset of a given set [136]. 
We used the training set to determine the transcript signatures (80% of the samples to train 
elastic net and 20% to test elastic net and the disease risk score) and an independent 
published cohort to validate the findings [60]. 
 
3.4.2 Signatures Discovery 
To find minimal transcript sets required to discriminate TB from other patient 
groups, we applied the pipeline described in Chapter 2 to the training cohort, for the two 
comparisons of interest: TB vs. LTBI and TB vs. OD (Figure 13).  
 
Figure 13: Microarray analysis plan for the adult dataset from South Africa and Malawi. 
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3.4.2.1 TB vs. LTBI signature 
The training set for the TB vs. LTBI comparison comprised of 285 individuals while 
the test set comprised of 76 individuals. After fitting a linear model using the geographical 
location and HIV status as factors, 2054 transcripts passed the |log2FC|>0.5 criterion for the 
TB vs. LTBI comparison and were used as candidate predictors for elastic net modelling. The 
tuning parameters of the model was cross-validated in the two dimensional space. For every 
combination of the lasso (λ1) and ridge regression penalty parameters (λ2), the entire 
solution path is calculated and the 10-fold cross-validated mean squared prediction error 
was computed. The different values of lasso parameter are reflected by the s parameter, 
which corresponds to λ1 standardised by the full solution obtained via Ordinary Least 
Squares (0 to 1). For the minimum square error (MSE) λ2=0.5 and s=0.6 (Figure 14).  
 
Figure 14: Mean Squared Prediction Error (MSE) plot and trace plot of the standardised 
coefficients for the TB vs. LTBI comparison (s=0.6). 
 
For these parameters the model was fitted to the training data to estimate the 
weights (the standardised coefficients). The plot shows the number of zero and non-zero 
coefficients across the solution path. The vertical line represents the value with minimum 
mean squared error (acquired from the CV), which was obtained through model training. A 
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27 transcript model was identified for discriminating TB from LTBI which was subsequently 
used for discrimination of the samples of the training, as well as the test set.  
The elastic net model had very good classification accuracy in the training as well as 
the test set, with sensitivity and specificity of 89% CI95%(78-97) and 90% CI95%(80-97) 
respectively (Table 7). The accuracy of the classifier was also assessed separately for the 
HIV-infected and -uninfected groups, with the classifier performing better on the HIV-
uninfected individuals, AUC 100% CI95%(100-100) vs. AUC 96% CI95%(91-100). This might be 
explained by the lower cell counts that HIV infected patients have and/or the alteration in 
gene expression caused by the presence of the underlying HIV infection.  
 
  HIV+/- HIV- HIV+ 
  
Training Test Training Test Training Test 
(95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) 
AUC 97% 97% 99% 100% 95% 96% 
(95% CI) (95-98%) (94-99%) (98-100%) (100-100%) (91-98%) (91-100%) 
Sensitivity 87% 89% 84% 84% 89% 94% 
(95% CI) (81-92%) (78-97%) (75-92) (68-100%) (81-96%) (83-100%) 
Specificity 91% 90% 99% 100% 84% 80% 
(95% CI) (86-96%) (80-97%) (96-100%) (100-100%) (75-91%) (60-95%) 
Table 7: Classification of the South Africa/Malawi training and test sets using the 27 
TB/LTBI transcript signature elastic net model.  
The elastic net model was applied to the South Africa/Malawi training and test set. Metrics 
were calculated for the HIV-infected and -uninfected patients combined, as well as 
separately. 
 
In addition, unsupervised clustering analysis was performed on the data using the 27 
TB/LTBI transcript signature identified by the elastic net. We calculated the Euclidean 
distance measure for the expression values of the transcripts of the samples in the test set 
to create a heatmap. In the hierarchical clustering we observed two distinct clusters 
corresponding to TB and LTBI individuals, regardless of HIV co-infection (Figure 15). The 
rows correspond to transcripts; the red colour scheme indicates up-regulation, and green 
down-regulation. Columns correspond to patients regardless of HIV status; purple colour 
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indicates patients with TB and green indicates individuals with LTBI. Dendrograms are added 
for both the transcripts and the patients to indicate the level of similarity in the groupings. 
Good clustering of the groups based on the signature reflects its classificatory potential. 
 
Figure 15: Heatmap showing clustering of the South African/Malawi test set using the 27 
TB/LTBI signature. 
The rows correspond to transcripts (red colour indicates up-regulation; green colour 
indicates down-regulation). Columns correspond to patients regardless of HIV status 
(purple=TB; green=LTBI).  
 
The disease risk score based on the 27 transcript signature was calculated using 
equation 2.12 for the patients of the training and the test set. In the combined HIV-infected 
and -uninfected test set, the 27 transcript disease risk score discriminated TB from LTBI with 
sensitivity and specificity of 95% CI95%(87-100) and 90% CI95%(80-97) respectively (Figure 16, 
Table 8). Its classificatory power was also assessed for the HIV-infected and uninfected 
individuals separately (Figure 17). It achieved perfect classification in the HIV-uninfected 
group (AUC=100%, CI95%(100-100)) while it had a slightly reduced accuracy in the HIV-
infected group (AUC=97%, CI95%(95-100)) (Table 8).  
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Figure 16: Classification of the South African/Malawi test set using the Disease Risk Score 
based on the 27 TB/LTBI transcript signature. 
Disease risk score (left) and receiver operating characteristic curve (right) based on the 
TB/LTBI 27 transcript signature applied to the combined HIV infected and uninfected South 
African/Malawi test cohort. Sensitivity, specificity and AUC are reported in Table 8.  
 
  HIV+/- HIV- HIV+ 
  
Training Test Training Test Training Test 
(95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) 
AUC 95% 98% 98% 100% 92% 97% 
(95% CI) (93-97%) (95-100%) (97-100%) (100-100%) (88-96%) (95-100%) 
Sensitivity 87% 95% 91% 100% 81% 94% 
(95% CI) (81-92%) (87-100%) (85-97) (100-100%) (72-90%) (83-100%) 
Specificity 87% 90% 89% 100% 86% 90% 
(95% CI) (81-92%) (80-97%) (81-95%) (100-100%) (77-94%) (75-100%) 
Table 8: Classification of the South Africa/Malawi training and test sets using the Disease 
Risk Score based on the 27 TB/LTBI transcript signature.  
The DRS based on the 27 TB/LTBI transcript signature was applied to the South 
African/Malawi training and test sets. Metrics were calculated for the HIV-infected and -
uninfected patients combined, as well as separately. 
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Figure 17: Classification of the South African/Malawi test set by HIV status using the 
Disease Risk Score based on the 27 TB/LTBI transcript signature. 
Disease risk score (top panels) and receiver operating characteristic curves (bottom panels) 
based on the 27 TB/LTBI transcript signature applied to the HIV-uninfected and -infected 
patients of the South African/Malawi test set separately. Sensitivity, specificity and AUC are 
reported in Table 8.  
 
Overall, the disease risk score has a very similar classificatory performance to the elastic net 
classifier both in the training and the test set, even though it is not using any weighting for 
the expression values of the transcripts, apart from their direction of regulation. 
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3.4.2.2 TB vs. OD signature 
In the TB vs. OD comparison 379 transcripts were used as candidate predictors for 
elastic net modelling. The training set comprised of 293 patients, while the test set 
comprised of 76 patients. Cross-validation of the elastic net tuning parameters in the 
training set resulted in a model with 44 variables for λ2=0.5 and s=0.013 (Figure 18).  
The predictive performance of the 44 transcript elastic net model on the test set was 
estimated. The elastic net model had a sensitivity and specificity of 83% CI95%(71-93) and 
97% CI95%(91-100) respectively, when applied to the test set (Table 9). The accuracy of the 
classifier was also assessed separately for the HIV-infected and -uninfected groups, with its 
performance being 1% better for the HIV-uninfected individuals (AUC=95%, CI95%(88-100) in 
the HIV-uninfected vs. AUC=94%, CI95%(84-100) in the HIV-infected group). 
 
Figure 18: Mean Squared Prediction Error (MSE) plot and trace plot of the standardised 
coefficients for the TB vs. LTBI comparison (s=0.013). 
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HIV+/- HIV- HIV+ 
  
Training Test Training Test Training Test 
(95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) 
AUC 97% 94% 97% 95% 97% 94% 
(95% CI) (95-98%) (88-99%) (94-100%) (88-100%) (94-99%) (84-100%) 
Sensitivity 93% 83% 95% 82% 92% 85% 
(95% CI) (90-97%) (71-93%) (89-99) (64-96%) (86-97%) (70-100%) 
Specificity 89% 97% 90% 100% 88% 95% 
(95% CI) (83-94%) (91-100%) (82-96%) (100-100%) (80-95%) (84-100%) 
Table 9: Classification of the South Africa/Malawi training and test sets using the 44 
TB/OD transcript signature elastic net model. 
The elastic net model was applied to the South Africa/Malawi training and test set. Metrics 
were calculated for the HIV infected and uninfected patients combined, as well as 
separately. 
 
Unsupervised cluster analysis on the data using the identified 44 TB/OD transcript 
signature was performed. Based on the Euclidean distance measure, two distinct clusters 
were observed corresponding to TB and OD patients regardless of HIV co-infection (Figure 
19). The rows correspond to transcripts; red colour scheme indicates them being up-
regulated, and green down-regulated. Columns correspond to patients regardless of HIV 
status; purple colour indicates patients with TB while blue indicates patients with other 
diseases. 
Chapter 3. Identification of host gene expression biomarkers for TB in adults 
 
67 
 
 
Figure 19: Heatmap showing clustering of the test set using the 44 TB/OD signature. 
The rows correspond to transcripts (red colour indicates up-regulation; green colour 
indicates down-regulation). Columns correspond to patients regardless of HIV status 
(purple=TB; blue=OD).  
 
The disease risk score based on the 44 transcript signature for every patient on the 
training and the test set was then calculated. In the test set, DRS had sensitivity and 
specificity of 93% CI95%(83-100) and 88% CI95%(74-97) respectively (Figure 20, Table 10). Its 
accuracy remained consistent in the HIV-infected and -uninfected test cohorts, with AUC 
96% CI95%(89-100) and 94% CI95%(83-100) respectively (Figure 21, Table 10). Similar metrics 
were obtained when the DRS was evaluated in the training dataset, demonstrating its 
robustness. 
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Figure 20: Classification of the South African/Malawi test set using the Disease Risk Score 
based on the 44 TB/OD transcript signature. 
Disease risk score (left) and receiver operating characteristic curve (right) based on the 
TB/OD 44 transcript signature applied to the combined HIV-infected and -uninfected South 
African/Malawi test cohort. Sensitivity, specificity and AUC are reported in Table 10.  
 
  HIV+/- HIV- HIV+ 
  
Training Test Training Test Training Test 
(95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) 
AUC 96% 95% 97% 96% 95% 94% 
(95% CI) (94-98%) (89-99%) (94-99%) (89-100%) (92-98%) (83-100%) 
Sensitivity 88% 93% 89% 91% 86% 95% 
(95% CI) (82-93%) (83-100%) (83-96) (77-100%) (78-92%) (85-100%) 
Specificity 87% 88% 88% 93% 86% 84% 
(95% CI) (82-92%) (74-97%) (79-96%) (80-100%) (78-95%) (68-100%) 
Table 10: Classification of the South Africa/Malawi training and test sets using the Disease 
Risk Score based on the 44 TB/OD transcript signature. 
The DRS based on the 44 TB/OD transcript signature was applied to the South 
African/Malawi training and test sets. Metrics were calculated for the HIV-infected and -
uninfected patients combined, as well as separately. 
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Figure 21: Classification of the South African/Malawi test cohort by HIV status using the 
Disease Risk Score based on the 44 TB/OD transcript signature. 
Disease risk score (top panels) and receiver operating characteristic curves (bottom panels) 
based on the 44 TB/OD transcript signature applied to the HIV-uninfected and -infected 
patients of the South African/Malawi test set separately. Sensitivity, specificity and AUC are 
reported in Table 10.  
 
The test set (20% of the samples) was used to evaluate the performance of the 
signatures and the DRS and the good accuracy of the classification showed that we did not 
over fit on the training data. However, further benchmarking of both the signatures and the 
DRS technique using an independent validation cohort, as well as estimating their 
performance on subgroups of interest of the data was crucial.  
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3.5 Benchmarking  
3.5.1 Performance of the DRS on the Berry et al. dataset 
In order to further assess the performance of the disease risk score based on the 
TB/LTBI 27 transcript signature and TB/OD 44 transcript signature, we employed a publicly 
available microarray dataset: the whole blood expression dataset of Berry et al. [60]. The 
dataset was generated using Illumina HT12 V3 arrays comparing TB with LTBI and other 
infections. The dataset comprised HIV-uninfected TB, LTBI and OD individuals, as no TB HIV-
infected adult cohort was publically available. For each testing dataset (accession series SA 
TB GSE19491 SA GSE19442, OD GSE22098), both quantile and robust spline normalisation 
were applied separately to the arrays and the data was base 2 log transformed. However 
the results were the same regardless of normalisation method. 
We evaluated the performance of the TB/LTBI 27 transcript signature, using the TB 
and LTBI patients in the South African testing set (TB n=20, LTBI n=31). Out of the 27 
transcripts of the signature, one had no corresponding transcript on the HT12 V3 array 
(ILMN_3247506 - FCGR1C). For the evaluation of the performance of the 44 TB/OD 
transcript signature, we used TB patients from the South African testing set (TB n=20) and 
OD patients that did not include patients with systemic lupus erythematosus as they were 
judged to be a rare disease in an African setting (n=82). Three of the transcripts in the 
TB/OD signature had no corresponding transcripts on the HT12 V3 array:  ILMN_3287952 
(LOC100133800), ILMN_3215715 (LOC389386) and ILMN_3308961 (MIR1974). 
First we employed hierarchical clustering on the validation dataset using the 
transcripts present in the signatures. Distinct clusters of the samples were observed from 
the dendrograms for both TB vs. LTBI and TB vs. OD comparisons (Figure 22).  
Subsequently we calculated the DRS and assessed its classificatory performance on 
the validation cohort (Figure 23). For the TB vs. LTBI comparison the DRS achieved a 
sensitivity of 95% CI95%(85-100) and a specificity of 94% CI95%(84-100). Regarding the 
discrimination between TB and OD, the 44 transcript DRS’s sensitivity and specificity in the 
validation dataset were 100% CI95% (100-100) and 96% CI95%(93-100) respectively (Table 11). 
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Figure 22: Heatmap showing clustering of the validation cohort.  
The 27 TB/LTBI and the 44 TB/OD transcript signatures were used. The rows correspond to 
transcripts (red colour indicates up-regulation; green colour indicates down-regulation). 
Columns correspond to patients (red=TB; green=LTBI; blue=OD) 
 
 
  Validation Dataset 
  TB vs. LTBI TB vs. OD 
AUC 99% 100%* 
(95% CI) (97-100%) (100-100%) 
Sensitivity 95% 100% 
(95% CI) (85-100%) (100-100%) 
Specificity 94% 96% 
(95% CI) (84-100%) (93-97%) 
Table 11: Classification of the Berry et al. validation set using the Disease Risk Score based 
on the 27 TB/LTBI and the 44 TB/OD transcript signatures 
The DRS based on the 27 TB/LTBI and 44 TB/OD transcript signatures was applied to the 
validation set from Berry et al. [60]. *99.94 
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Figure 23: Classification of the Berry et al. validation set using the Disease Risk Score 
based on the 27 TB/LTBI and the 44 TB/OD transcript signatures.  
Disease risk score (top panels) and receiver operating characteristic curves (bottom panels) 
based on the 27 TB/LTBI and the 44 TB/OD transcript signatures applied to the dataset from 
Berry et al. [60]. Sensitivity, specificity and AUC are reported in Table 11.  
 
For a comparison between the performance of the DRS on our test set and the 
independent validation dataset, we present a summary statistics table (Table 12). The test 
set is separated by HIV status to provide a direct comparison of the performance with the 
validation dataset which included only HIV –uninfected individuals. We also calculated the 
positive and negative likelihood ratios to reflect the effect of the increase/decrease on the 
probability of disease if the test is positive/negative. The actual numbers of patients per 
group and the calls of DRS classification are also presented in Table 13. 
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South Africa/Malawi test cohort Validation dataset 
HIV+/-  HIV-  HIV+  HIV-  
TB vs. LTBI     
Number of patients n=76 n=38 n=38 n=51 
AUC 
(95% CI) 
98%  100%  97%  99% 
(95-100%) (100-100%) (95-100%) (97-100%) 
Sensitivity 
(95% CI) 
95%  100%  94%  95% 
(87-100%) (100-100%) (83-100%) (85-100%) 
Specificity 
(95% CI) 
90% 100%  90%  94% 
(80-97%) (100-100%) (75-100%) (84-100%) 
Likelihood ratio+ 
(95% CI) 
9.23  NA  9.44  14.73 
(3.63-23.4)  (2.52-5.34) (3.84-56.47) 
Likelihood ratio- 
(95% CI) 
0.06  0 0.06  0.05 
(0.02-0.23)  (0.01-0.42) (0.01-0.36) 
TB vs. OD  
Number of 
patients 
n=76 n=37 n=39 n=102 
AUC 
(95% CI) 
95%  96%  94%  100*% 
(89-99%) (89-100%) (83-100%) (100-100%) 
Sensitivity 
(95% CI) 
93%  91%  95%  100% 
(83-100%) (77-100%) (85-100%) (100-100%) 
Specificity 
(95% CI) 
88% 93%  84%  96% 
(74-97%) (80-100%) (68-100%) (93-100%) 
Likelihood ratio+ 
(95% CI) 
7.89 14.3   6.02 27.67 
(3.13-19.89) (2.15-95.12) (2.1-17.08) (9.11-84.03) 
Likelihood ratio- 
(95% CI) 
0.08 0.05 0.06 0 
(0.03-0.24) (0.01-0.35) (0.01-0.41)  
Table 12: Classification of the South African/Malawi test set and the Berry et al. validation 
set using the Disease Risk Score based on the 27 TB/LTBI and the 44 TB/OD transcript 
signatures. 
The DRS based on the 27 TB/LTBI and 44 TB/OD transcript signatures was applied to the 
South African/Malawi test and the validation set from Berry et al. [60].Metrics were calculated 
for the HIV-infected and -uninfected patients combined, as well as separately. *99.94 
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South Africa/Malawi test cohort Validation dataset 
HIV+/-  HIV-  HIV+  HIV-  
TB vs. LTBI     
Number of patients 
nALL=76; 
nTB=37; 
nLTBI=39 
nALL=38; 
nTB=19; 
nLTBI=19 
nALL=38; 
nTB=18; 
nLTBI=20 
nALL=51; 
nTB=20;  
nLTBI=31 
DRS positive calls/gold 
standard positive  
[35/37] [19/19] [17/18] [19/20] 
DRS negative calls/gold 
standard negative 
[35/39] [19/19] [18/20] [29/31] 
TB vs. OD  
Number of patients 
nALL=76; 
nTB=42; 
nOD=34 
nALL=37; 
nTB=22; 
nOD=15 
nALL=39; 
nTB=20; 
nOD=19 
nALL=102;  
nTB=20;  
nOD=83 
DRS positive calls/gold 
standard positive  
[39/42] [20/22] [19/20] [20/20] 
DRS negative calls/gold 
standard negative 
[30/34] [14/15] [16/19] [80/83] 
Table 13: Number of patients per group and calls for the classification using Disease Risk 
Score per group. 
 
In order to assess the potential predictive value of DRS in a cohort of patients 
undergoing investigation for persistent symptoms such as cough, fever and weight loss i.e. 
where TB was included in the differential diagnosis, we calculated the Positive and Negative 
Predictive Values (PPV, NPV). As the recruitment in Malawi was conducted in a prospective 
manner, we used the prevalence of TB in the Malawi cohort for the calculations. Out of the 
437 patients with suspected TB, 254 ended up with a confirmed TB diagnosis, giving a 
prevalence of 58%. The DRS for TB vs. OD had a PPV of 92% CI95%(84-99) and a NPV of 90% 
CI95%(80-100) (Table 14). We also employed a scenario of 20% prevalence which may be 
more reflective of a general primary care setting in a high-burden African country [61]. NPV 
for TB vs. OD was higher: 98% CI95%(96-100), but PPV decreased: 66% CI95%(46-87). These 
metrics suggest that the DRS could be used as a rule-out test, with patients with positive 
DRS selected for further investigation. 
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South Africa/Malawi test cohort Validation dataset 
HIV+/-  HIV-  HIV+  HIV-  
 PPV NPV PPV NPV PPV NPV PPV NPV 
TB vs. LTBI     
20% prevalence 
(95% CI) 
70%  99%  100%  100%  70%  98%  79%  99%  
(50-89%) (97-100%) (100-100%) 100-100%) (42-99%) (96-100%) (56-100%) (96-100%) 
58% prevalence 
(95% CI) 
93%  92%  100%  100%  93%  92%  95%  93%  
(86-99%) (83-100%) (100-100%) (100-100%) (84-100%) (78-100%) (89-100%) (81-100%) 
TB vs. OD     
20% prevalence 
(95% CI) 
66% 98% 77% 98% 60% 99% 87% 100%  
(46-87%) (96-100%) (44-100%) (94-100%) (35-85%) (96-100%) (75-100%) (100-100%) 
58% prevalence 
(95% CI) 
92%  90%  95%  88%  89%  92%  97%  100%  
(84-99%) (80-100%) (86-100%) (74-100%) (79-99%) (79-100%) (95-100%) (100-100%) 
Table 14: Positive and negative predictive values for the classification of the South African/Malawi test set and the Berry et al. 
validation set using Disease Risk Score based on the 27 TB/LTBI and the 44 TB/OD transcript signatures. 
The DRS based on the 27 TB/LTBI and 44 TB/OD transcript signatures was applied to the South African/Malawi test set and the validation 
set from Berry et al. [60]. PPV and NPV were calculated for the HIV-infected and -uninfected patients combined, as well as separately 
for different scenarios of prevalence of the disease. *99.94 
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3.5.2 Performance of Berry et al. signatures on the SA/Malawi dataset 
In contrast to the South African/Malawi TB cohort, recruitment in previous studies 
for TB host transcriptomics research has excluded HIV-infected patients, while other disease 
controls have not been recruited concurrently with TB cases or from the same population of 
patients undergoing investigation for TB. We wanted to estimate how these differences in 
biomarker study design may affect the discovery and performance of transcriptomic 
signatures, with potential for TB diagnostics. We compared the performance of the 27 
transcript TB/LTBI signature and the 44 probe TB/OD signature with the performance of the 
signatures reported in Berry et al. [60]. The authors reported a 393-transcript signature for 
TB vs. LTBI and a 86-transcript signature for TB vs. OD that were derived using a Kruskal–
Wallis test for the transcript comparisons across all study groups, with α=0.01 and after 
Benjamini–Hochberg adjustment for multiple testing (1%). These signatures were tested on 
the South African/Malawi cohort (Figure 24, Figure 25).  
 
Figure 24: Classification of the combined South Africa and Malawi cohort using the 
transcript signature for TB vs. LTBI from Berry et al. [60].  
DRS (top panels) & ROC curves (bottom panels) based on the TB/LTBI transcript signature 
from Berry et al. [60] applied to the combined training & test South African and Malawi 
cohort, calculated for the HIV-infected and -uninfected patients combined, as well as 
separately. Sensitivity, specificity and AUC are reported in Table 15. 
Chapter 3. Identification of host gene expression biomarkers for TB in adults 
 
77 
 
 
 
Figure 25: Classification of the combined South Africa and Malawi cohort using the 
transcript signature for TB vs. OD from Berry et al. [60].  
DRS (top panels) & ROC curves (bottom panels) based on the TB/OD transcript signature 
from Berry et al. [60] applied to the combined training & test South African and Malawi 
cohort, calculated for the HIV infected and uninfected patients combined, as well as 
separately. Sensitivity, specificity and AUC are reported in Table 15. 
 
For testing the performance of the reported 393 TB vs. LTBI signature and the 86 TB 
vs. OD signature on the African dataset, the disease risk score was calculated with these 
signatures as previously described, although 7 transcripts in the reported signatures were 
not present on the HT-12 V4 array (TB vs. LTBI 6 transcript, TB vs. OD 1 transcript). 
The 393 TB/LTBI signature achieved a sensitivity of 82% CI95%(76-87) and a specificity 
of 81% CI95%(75-87) on the entire South Africa/Malawi TB/LTBI cohort regardless of HIV. In 
the HIV-uninfected individuals the 393 TB/LTBI signature achieved a sensitivity of 88% 
CI95%(80-94) and a specificity of 84% CI95%(76-92) while the performance on the HIV-infected 
group was lower with a sensitivity of 74% CI95%(65-82) and a specificity of 80% CI95%(71-87) 
respectively (Table 15). Furthermore, the Berry et al. TB/OD 86 transcript signature had a 
sensitivity of 68% CI95%(61-73) and a specificity of 70% CI95%(62-76) on the entire South 
Africa/Malawi TB/OD cohort regardless of HIV. In the HIV-uninfected group it achieved 71% 
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CI95%(62-80) sensitivity and 76% CI95%(67-84) specificity, while its classificatory performance 
dropped in the HIV-infected group (sensitivity 67% CI95%(58-75), specificity 69% CI95%(59-78)) 
(Table 15). 
 
South Africa/Malawi cohort (test & training) 
HIV+/-  HIV-  HIV+  
TB vs. LTBI signatures Berry et al.    
Number of patients n=361 n=180 n=181 
AUC 
(95% CI) 
89%  94%  88%  
(86-92%) (91-97%) (82-92%) 
Sensitivity 
(95% CI) 
82%  88%  74%  
(76-87%) (80-94%) (65-82%) 
Specificity 
(95% CI) 
81% 84%  80%  
(75-87%) (76-92%) (71-87%) 
TB vs. OD signatures Berry et al.    
Number of patients n=369 n=180 n=189 
AUC 
(95% CI) 
76%  78%  75%  
(70-80 (70-84%) (68-82%) 
Sensitivity 
(95% CI) 
68%  71%  67%  
(61-73%) (62-80%) (58-75%) 
Specificity 
(95% CI) 
70% 76%  69%  
(62-76%) (67-84%) (59-78%) 
Table 15: Classification of the combined South African/Malawi training and test sets using 
the Berry et al. published signatures. 
The DRS based on the TB/LTBI and TB/OD Berry et al. transcript signatures was applied to 
the South African/Malawi training and test sets. Metrics were calculated for the HIV-
infected and -uninfected patients combined, as well as separately. 
 
Thus the minimal transcript signatures and the DRS method show better 
classificatory performance in distinguishing TB from LTBI and OD (especially in the HIV-
infected cohorts), than the much larger number of probes identified by Berry et al. [60]. 
In order to compare directly the differences of the performance of our signatures to 
the signatures presented by Berry et al. [60], we calculated the subtraction of the means of 
the measures of classification (namely the AUC, the sensitivity and the specificity) on our 
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test set along with their 95% confidence intervals using the following mathematical 
formulas:  
                    (3.1) 
 
    
        
  
 
        
  
 (3.2) 
 
Where: 
  ,    are the lower and upper confidence bounds 
   ,     are the sample proportions of successes in population 1 and 2. 
   ,    are the sizes of each sample. 
SE is the standard error 
z = 1.96 for a 95% CI 
 
The predictive performance of the 27 TB/LTBI transcript signature on the test set 
was higher in comparison to the 393 transcript (minus 6 transcripts) TB/LTBI Berry et al. 
signature (Table 16). Comparison of the statistical measures of performance of disease 
classification using the 44 TB/OD transcript signature and the Berry et al. 86 transcript 
(minus one transcript) signature suggested a better performance of the 44 TB/OD signature 
on the test set as well. The difference was actually larger for the TB vs. OD comparison, 
reflecting the need for real world control sets when deriving diagnostic signatures. 
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South Africa/Malawi test cohort 
 
HIV+/- (95% CI) HIV- (95% CI) HIV+ (95% CI) 
 
Our 
signatures 
Berry et al. 
signatures Difference* 
Our 
signatures 
Berry et al. 
signatures Difference* 
Our 
signatures 
Berry et al. 
signatures Difference* 
TB vs. LTBI comparison 
AUC 98% 88% 10% 100% 91% 9% 97% 89% 9% 
(95% CI) (95-100%) (85-97%) (2-18%) (100-100%) (88-100%) (0-18%) (92-100%) (83-98%) (-3-20%) 
Sensitivity 95% 84% 11% 100% 90% 11% 94% 78% 17% 
(95% CI) (87-100%) (73-95%) (1-21%) (100-100%) (74-100%) (1-20%) (83-100%) (61-94%) (2-32%) 
Specificity 90% 87% 3% 100% 79% 21% 90% 85% 5% 
(95% CI) (80-97%) (77-97%) (-8-13%) (100-100%) (58-95%) (8-34%) (75-100%) (65-100%) (-10-20%) 
TB vs. Other Diseases comparison 
AUC 95% 73% 22% 96% 76% 20% 94% 72% 21% 
(95% CI) (89-99%) (63-86%) (10-33%) (89-100%) (62-91%) (5-35%) (82-100%) (57-89%) (5-37%) 
Sensitivity 93% 74% 19% 91% 77% 14% 95% 70% 25% 
(95% CI) (83-100%) (60-86%) (8-31%) (77-100%) (59-96%) (-3-30%) (85-100%) (50-90%) (9-41%) 
Specificity 88% 74% 15% 93% 67% 27% 84% 74% 11% 
(95% CI) (74-97%) (59-88%) (2-27%) (80-100%) (40-87%) (9-44%) (68-100%) (53-90%) (-7-28%) 
Table 16: Classification of the South African/Malawi test set using the 27 TB/LTBI, 44 TB/OD and Berry et al. transcript signatures. 
The DRS based on the 27 TB/LTBI and 44 TB/OD transcript signatures identified by elastic net and the TB/LTBI and TB/OD Berry et al. 
transcript signatures was applied to the South African/Malawi training and test sets. Metrics were calculated for the HIV-infected and -
uninfected patients combined, as well as separately, and the differences along with their CIs are reported. 
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3.5.3 Performance of the DRS on the smear negative TB patients 
A small proportion of the TB culture positive patients in the study were smear-
negative; 31 TB patients had a definite negative smear status. The performance of the 
signatures by smear-status is important for estimating the potential utility of the signature 
in the clinical arena. We evaluated the performance of the signatures in the smear-negative 
sub-group of patients with TB, the majority of whom were HIV-infected (7 TB HIV-
uninfected and 24 TB HIV-infected). In these patients, the DRS showed a sensitivity for 
detecting TB of 68%, CI95% (52–84), when using the TB versus LTBI signature and a sensitivity 
of 90%, CI95%(81–100), with the TB/OD signature (Table 17). The results for the performance 
of the signatures are comparable to the results obtained in the larger HIV-infected cohort of 
smear-positive and -negative patients. As we used the same LTBI and OD patients from the 
test set, the specificity was unchanged (90%, CI95% (80–97), for TB versus LTBI and 88%, CI95% 
(74–97), for TB versus OD).  
 
  
South Africa/Malawi smear negative TB  
and controls from the test set 
  Sensitivity Specificity 
TB vs. LTBI comparison 
nALL=70; nTB smear neg=31; nLTBI=39 
Calls by DRS [21/31] [35/39] 
Measures 68% (52-84) 90% (80-97) 
TB vs. OD comparison 
nALL=65; nTB smear neg=31; nOD=34 
Calls by DRS [28/31] [30/34] 
Measures 90% (81-100) 88% (74-97) 
Table 17: Classification of the South Africa/Malawi smear negative TB patients and 
controls from the test set using Disease Risk Score based on the 27 TB/LTBI and the 44 
TB/OD transcript signatures. 
The DRS based on the 27 TB/LTBI and 44 TB/OD transcript signatures was applied to the 
smear negative TB cases from South Africa and Malawi as well as the respective controls 
from test set.  
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3.5.4 Smaller Signatures 
Although elastic net suggested the smallest possible model able to achieve the best 
classification, we also explored whether a smaller number of transcripts could be used to 
distinguish TB from LTBI and from OD. 
Instead of optimising the parameters of elastic net (which control the size of the 
selected model) via ten-fold cross-validation (CV), we used penalty settings that run the 
lasso method. Lasso constructs more parsimonious models than elastic net, by setting more 
β coefficients to zero. Then, within the cross-validation step of choosing s, we forced the 
penalty to be such that the error would remain within one standard deviation of the 
minimum error. This analysis resulted in a 21 transcript signature for the TB versus LTBI 
comparison (12 overlapping with the 27 transcript signature) and a 29 transcript signature 
for the TB versus OD comparison (14 overlapping with the 44 transcript signature). The 
sensitivity of the smaller models was 6% - 10% lower than the original models, while 
retaining almost the same specificity (Table 18).  
After calculation of the DRS for every patient using the TB/LTBI signature, sensitivity 
and specificity were 89%, CI95% (78-97) and 89%, CI95%(79-97) respectively. As for the TB 
versus OD comparison, DRS had a sensitivity of 83% CI95% (69-93) and a specificity of 88% 
CI95%(75-97) respectively. In conclusion, smaller models have reduced sensitivity in 
comparison to the elastic net models. 
  South Africa/Malawi test set 
  Sensitivity Specificity 
TB vs. LTBI comparison 
27 transcript signature 95% (87-100%) 90% (80-97%) 
21 transcript signature 89% (78-97%) 89% (79-97%) 
TB vs. OD comparison 
44 transcript signature 93% (83-100%) 88% (74-97%) 
29 transcript signature 83% (69-93%) 88% (75-97%) 
Table 18: Classification of the South African/Malawi test set using Disease Risk Score 
based on the elastic net and lasso transcript signatures. 
The DRS based on the 27 TB/LTBI and 44 TB/OD transcript signatures identified by elastic 
net, as well as the 21 TB/LTBI and 29 TB/OD transcript signatures identified by lasso was 
applied to the South African/Malawi test set.   
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3.5.5 Missing Rate 
We also explored the option of allowing the test to classify some patients as having 
“inconclusive diagnosis” with the thought that any patients falling into this category can be 
sent for further testing, as the result is not considered definitive. As expected, the 
introduction of a missing rate impacts on the error rate of the classification as well.  
This was achieved by studying the effect of adjusting the threshold for the DRS in 
assigning individual patients to TB or LTBI/OD. By accepting a percentage of patients as 
“non-classifiable”, the majority of patients under investigation were accurately assigned. 
These “non-classifiable” patients could then be selected for more detailed investigation or 
could be followed-up a later (Figure 26). This strategy seems to be better applicable to TB 
vs. LTBI patients. 
 
 
Figure 26: The error rate of classification in relation to the percentage of unclassified 
samples (missing rate).  
The solid lines correspond to the training set while the dotted lines correspond to the test 
set. Black colour depicts the HIV-infected and -uninfected patients combined; blue colour 
the HIV-uninfected only and red colour the HIV-infected only.  
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3.5.6 TB vs. LTBI and OD simultaneously 
As it would be advantageous from a clinical perspective to have a single signature 
that can distinguish patients with active TB from individuals with latent TB infection as well 
as patients with diseases other than TB, we assessed the performance of a signature in 
distinguishing TB from both LTBI and OD. A 53 transcript signature was identified by elastic 
net (Figure 27). The DRS based on the 53 transcript signature distinguished TB from both 
LTBI and OD with sensitivity of 91% and specificity of 82%, a lower performance than 
TB/LTBI and TB/OD signatures alone (Figure 28).  
 
Figure 27: Mean Squared Prediction Error (MSE) plot and trace plot of the standardised 
coefficients for the TB vs. LTBI+OD comparison. 
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Figure 28: Classification of the TB vs. LTBI+OD test set using the Disease Risk Score based 
on the 53 TB/LTBI+OD transcript signature. 
Disease risk score (left) and receiver operating characteristic curve (right) based on the 53 
TB/LTBI+OD transcript signature applied to the combined HIV-infected and -uninfected 
South African/Malawi test cohort. 
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3.6 Adult TB Signatures 
In this section we present the transcripts that comprise the transcriptomic 
signatures. We also present the direction of expression as well as the signatures’ overlap 
and the overlap with the previously published signatures [60] (Table 19, Table 20). 
Additionally the biological role that the genes may play in the host response to TB is 
discussed. 
Only three transcripts overlap between the TB/LTBI and TB/OD signatures, 
corresponding to genes: DUSP3, GBP6 and LHFPL2. The TB/OD signature could be used to 
differentiate TB from OD in the clinical context of a sick patient, whereas the TB/LTBI 
signature may be used in contact screening where the problem is to distinguish active TB 
from latent infection. The combined TB vs. OD+LTBI signature which performed less 
favourably than the separate TB/OD signatures is also presented (Table 21). 
 
Array ID Gene Symbol Probe ID Direction* 
Overlap with 
393-transcript 
signature 
130181 ANKRD22 ILMN_1799848 Up √ 
5910019 C1QB ILMN_1796409 Up √ 
1440341 C1QC ILMN_1785902 Up  
2650605 C4ORF18 ILMN_1672124 Up  
1340241 C5 ILMN_1746819 Up √ 
5890470 CCR6 ILMN_1690907 Down √ 
1780440 CD79A ILMN_1659227 Down  
6450594 CD79B ILMN_1710017 Down  
3890400 CXCR5 ILMN_2337928 Down  
6560156 DUSP3 ILMN_1797522 Up √ 
2810373 FAM20A ILMN_1812091 Up  
520086 FCGR1A ILMN_2176063 Up √ 
2710709 FCGR1B ILMN_2261600 Up √ 
6620209 FCGR1B ILMN_2391051 Up √ 
5570398 FCGR1C ILMN_3247506 Up  
1510026 FLVCR2 ILMN_2204876 Up √ 
70730 GAS6 ILMN_1779558 Up √ 
4280632 GAS6 ILMN_1784749 Up √ 
3780047 GBP6 ILMN_1756953 Up √ 
1300139 GNG7 ILMN_1728107 Down  
360132 LHFPL2 ILMN_1747744 Up √ 
5570039 LOC728744 ILMN_1654389 Up √ 
3520601 MPO ILMN_1705183 Up  
6060468 S100A8 ILMN_1729801 Up  
5910632 SMARCD3 ILMN_2309180 Up √ 
2630195 VAMP5 ILMN_1809467 Up √ 
2970397 ZNF296 ILMN_1693242 Down  
Table 19: The 27 transcript signature for distinguishing TB from latent TB infection 
* in TB patients in relation to patients with latent TB infection.  
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Array ID Gene Symbol Probe ID Direction* 
Overlap with 86-
transcript 
signature 
1170332 AAK1 ILMN_1688755 Up  
1070477 ALDH1A1 ILMN_2096372 Up  
6510754 ALDH1A1 ILMN_1709348 Up  
5270753 ARG1 ILMN_1812281 Down  
3130600 BTN3A1 ILMN_1802708 Up  
6380681 C19ORF12 ILMN_1664920 Up  
1030433 CALML4 ILMN_1815707 Up  
540041 CASC1 ILMN_1708983 Up  
4560047 CD74 ILMN_1761464 Up √ 
4070524 CERKL ILMN_1801091 Up  
4290619 CREB5 ILMN_1728677 Up  
130086 CYB561 ILMN_1771179 Up  
840446 CYB561 ILMN_2378376 Up  
6560156 DUSP3 ILMN_1797522 Up  
1110592 EBF1 ILMN_1778681 Down  
3780047 GBP6 ILMN_1756953 Up  
2350114 GJA9 ILMN_1710161 Up  
1050360 HLA-DPB1 ILMN_1749070 Up  
270039 HM13 ILMN_1766269 Up  
7210110 HM13 ILMN_2236655 Up  
2000682 HS.131087 ILMN_1916292 Down  
5260161 HS.162734 ILMN_1893697 Down  
2340241 IMPA2 ILMN_2094061 Down  
360132 LHFPL2 ILMN_1747744 Up  
6760056 LOC100133800 ILMN_3287952 Up  
150224 LOC196752 ILMN_1803743 Up  
4570164 LOC389386 ILMN_3215715 Up  
5290100 MAK ILMN_1803984 Down  
3120475 MAP7 ILMN_2216815 Down  
5820491 MAP7 ILMN_1712719 Down  
2260349 MIR1974 ILMN_3308961 Up  
2850315 ORM1 ILMN_1696584 Down  
3310504 PDK4 ILMN_1684982 Down  
1580437 PGA5 ILMN_1717572 Down  
380541 PPPDE2 ILMN_1737580 Up  
450379 PRDM1 ILMN_2294784 Up  
450132 RBM12B ILMN_1805778 Up  
1690184 RNF19A ILMN_1812327 Up  
3360553 RP5-1022P6.2 ILMN_1701111 Down  
4670458 SEPT4 ILMN_1776157 Up  
2030309 SERPING1 ILMN_1670305 Up  
6760471 TMCC1 ILMN_1677963 Down  
3840053 UGP2 ILMN_1671969 Up  
4640768 VPREB3 ILMN_1700147 Down  
Table 20: The 44 transcript signature for distinguishing TB from other diseases. 
* in TB patients in relation to patients with OD 
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Array ID Gene Symbol Probe ID Direction* 
1070477 ALDH1A1 ILMN_2096372 Up 
6510754 ALDH1A1 ILMN_1709348 Up 
130181 ANKRD22 ILMN_1799848 Up 
6330471 BLK ILMN_1668277 Down 
3130600 BTN3A1 ILMN_1802708 Up 
1030433 CALML4 ILMN_1815707 Up 
540041 CASC1 ILMN_1708983 Up 
4560047 CD74 ILMN_1761464 Up 
6380040 COL9A2 ILMN_1685122 Down 
4290619 CREB5 ILMN_1728677 Up 
1090497 CREG1 ILMN_1680624 Up 
3890400 CXCR5 ILMN_2337928 Down 
130086 CYB561 ILMN_1771179 Up 
840446 CYB561 ILMN_2378376 Up 
4540239 DEFA1 ILMN_2193213 Up 
4860128 DEFA1B ILMN_1725661 Up 
7150170 DEFA1B ILMN_2102721 Up 
2970747 DEFA3 ILMN_2165289 Up 
6560156 DUSP3 ILMN_1797522 Up 
1110592 EBF1 ILMN_1778681 Down 
6590646 FAM26F ILMN_2066849 Up 
520086 FCGR1A ILMN_2176063 Up 
6620209 FCGR1B ILMN_2391051 Up 
5570398 FCGR1C ILMN_3247506 Up 
5720180 FZD2 ILMN_1653711 Up 
70730 GAS6 ILMN_1779558 Up 
1510364 GBP5 ILMN_2114568 Up 
3780047 GBP6 ILMN_1756953 Up 
1300139 GNG7 ILMN_1728107 Down 
3840753 HEY1 ILMN_1788203 Down 
1940274 IFI27L2 ILMN_1740319 Up 
870408 IL15 ILMN_1724181 Up 
5260161 ILMN_1893697 ILMN_1893697 Down 
2000682 ILMN_1916292 ILMN_1916292 Down 
360132 LHFPL2 ILMN_1747744 Up 
4570164 LOC389386 ILMN_3215715 Up 
6400414 LOC650546 ILMN_1814812 Up 
4670113 LOC90925 ILMN_1794927 Down 
5820491 MAP7 ILMN_1712719 Down 
3420259 MIR21 ILMN_3310840 Up 
6760593 OSBPL10 ILMN_1669497 Down 
1580437 PGA5 ILMN_1717572 Down 
6380338 POLB ILMN_1767894 Up 
380541 PPPDE2 ILMN_1737580 Up 
1660021 RNU4ATAC ILMN_3240594 Up 
4670458 SEPT4 ILMN_1776157 Up 
2680136 SIGLEC11 ILMN_1674593 Up 
6620161 SPIB ILMN_2143314 Down 
6760471 TMCC1 ILMN_1677963 Down 
3840053 UGP2 ILMN_1671969 Up 
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2340682 UHMK1 ILMN_2096012 Up 
4640768 VPREB3 ILMN_1700147 Down 
3190113 VPS13B ILMN_2268409 Up 
Table 21: The 53 transcript signature for distinguishing TB from both latent TB and other 
diseases 
* in TB patients in relation to patients with OD+LTBI 
 
In the signatures, there are multiple transcripts for the same gene. This is a result of 
the “grouping effect” of the variables by elastic net. The inclusion of the transcripts from the 
same gene minimises further the MSE. However, lasso could be used as an alternative 
method that does not promote clusters of highly correlated variables in the final model. 
The 27 transcripts for distinguishing active TB from latent TB infection correspond to 
24 unique genes (18 up-regulated and 6 down-regulated in TB disease). Three of the up-
regulated genes map to the complement pathway (complement component 1, q 
subcomponent B chain, C1QB; complement component 1, q subcomponent C chain C1QC; 
and complement component 5, C5) and have been reported elevated in the peripheral 
blood of active TB patients in comparison to LTBI and healthy controls [91, 137, 138]. The 
three FCGR1 (Fc-gamma receptor 1) genes (that produce six different RNA transcripts by 
alternative splicing) encode for Fc receptors (FcR) that bind to immunoglobulin G (IgG) 
antibodies with high affinity. The FcRs are expressed by different immune effector cells and 
upon recognition of IgG, they trigger and regulate indicated inflammatory and cytotoxic cell 
responses, including phagocytosis, antigen presentation and T-cell activation that aid the 
elimination of pathogens [139]. FCGR1s are induced by interferon-γ and are mainly 
expressed by monocytes and macrophages. FCGR1 genes have been previously identified as 
being among the most differentially expressed between patients with active TB and latently 
infected individuals in previous whole blood microarray studies. [60, 91] It has also been 
shown that FCGR1A has significantly higher levels of expression in participants with active 
TB than in those with LTBI regardless of HIV infection and ethnicity, using a dual-colour 
reverse transcriptase multiplex ligation-dependent probe amplification (RT-MLPA) assay 
[98]. MPO (myeloperoxidase) encodes for a protein abundantly expressed in neutrophils 
that is central to their microbicidal activity during the oxidative burst [140]. GBP6 
(guanylate-binding proteins 6) encodes for a member of a family of proteins that are 
involved in protection against intracellular pathogens and are induced by IFN-γ. Guanylate-
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binding proteins contribute to interferon responses in a variety of organisms, including 
humans [141] and particularly in the IFNγ-mediated killing of intracellular pathogens. While 
it is known that GBP6 has a role in IFNγ-mediated killing of intracellular bacteria, such as 
Mycobacterium bovis BCG, its mechanisms of action have not been fully determined [142]. 
DUSP3 (dual specificity phosphatase 3) has been associated with murine susceptibility to 
bacterial infection and human sepsis [143]. 
As for the genes that are more highly expressed in LTBI than in active TB, CCR6 
(chemokine (C-C motif) receptor 6) is preferentially expressed by immature dendritic cells 
and memory T cells. It may also regulate the migration and recruitment of dendritic cells 
and T cells during inflammatory and immunological responses [144]. TB-specific CD4+ T cells 
with a characteristic chemokine expression signature (CCR6+ CXCR3+ CCR4-), are important 
for controlling TB infections [145] [146]. CXCR5 (chemokine (C-X-C motif) receptor 5) has 
been identified as significantly differentially up-regulated in whole blood from individuals 
with LTBI in comparison to individuals with active TB regardless of HIV [98]. Also, CXCR5+ T 
helper cells play a protective role in the immune response against TB [147]. CD79A and 
CD79B encode for proteins that are required in co-operation for initiation of the signal 
transduction cascade activated by binding of antigen to the B-cell antigen receptor (BCR) 
complex which leads to internalisation of the complex and antigen presentation [144]. Out 
of the 24 unique genes, 15 were reported as being IFN-inducible (either type I or type II) in 
the Interferome database [148]. In order to explore the biological pathways associated with 
the signature genes, the signatures were analysed with QIAGEN’s Ingenuity Pathway 
Analysis (IPA, QIAGEN Redwood City, www.qiagen.com/ingenuity). The top disease/function 
annotation reported was infectious disease, particularly bacterial infection, which included 
C1QB, C5, CCR6, FCGR1A, FCGR1B, MPO, CD79. As for canonical pathways analysis, the role 
of nuclear factor of activated T-cells (NFAT) in regulation of the immune response, the 
complement system, the B-cell development pathway and the role of pattern recognition 
receptors in recognition of bacteria and viruses pathway were among the top 5.  
The 44 transcripts for distinguishing active TB from other diseases correspond to 36 
unique genes (25 up-regulated and 11 down-regulated in TB disease). CYB561 (cytochrome 
B561) that is up-regulated in active TB disease, encodes for a ferric reductase protein, 
harmonising with existing evidence that there is competition between the MTB and the host 
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for iron during infection [149, 150]. HLA-DPB1 (HLA Class II Histocompatibility Antigen, DP 
Beta 1 Chain) is a protein coding gene that belongs to the HLA class II beta chain paralogues. 
The protein product binds to the HLA-DPA1 protein, forming a functional antigen-binding 
protein complex, the DPαβ heterodimer, that is expressed in antigen presenting cells (APCs: 
B lymphocytes, dendritic cells, macrophages). HLA plays a central role in the immune system 
by presenting foreign antigens to T-cells. Particularly, during M.TB infection APCs present 
M.TB antigens in association with MHC class II molecules to stimulate CD4+ T cells [151]. 
ORM (orosomucoid 1) gene encodes for an immune-related protein that has been identified 
as differentially expressed in human urine of patients with active TB disease [152]. Out of 
the 36 unique genes, 24 were reported as being IFN-inducible (either type I or type II) in the 
Interferome database [148]. In IPA, the top canonical pathway was antigen presentation, 
and the top diseases and function for the largest network containing 12 molecules, was cell-
to-cell signalling and interaction and inflammatory response.  
The 53 transcript signature for distinguishing TB from both latent TB and other 
diseases consists of 45 unique genes (33 up-regulated and 12 down-regulated in TB disease). 
It largely includes genes from the TB vs. LTBI signature and the TB vs. OD signature. It also 
includes a cluster of genes (DEFA1 - defensin alpha 1, DEFA1B - defensin alpha 1B, DEFA3 - 
defensin alpha 3) that encode for proteins that belong to the α-defensin family of 
antimicrobial peptides. Defensins are abundant in the granules of neutrophils and also 
found in the epithelia of mucosal surfaces and are involved in phagocyte-mediated host 
defence [144]. Out of the 45 unique genes, 25 were reported as being IFN-inducible (either 
type I or type II) in the Interferome database [148]. In IPA, the top canonical pathways were 
dendritic cell maturation, the role of macrophages, fibroblasts and endothelial cell in 
arthritis, and the role of nuclear factor of activated T-cells (NFAT) in regulation of the 
immune response. The top disease/function annotation was infectious disease where 
DEFA1, DUSP3, FCGR1A, FCGR1B and IL15 were mapped, along with 6 other genes. The top 
upstream regulator of the genes in the signature was IFNγ, highlighting its central role in 
immune response during active TB disease [60].  
In general, the blood transcriptional signatures are consistent with previous findings 
in the literature for pathway analysis of host TB signatures, showing up-regulation of IFN-
inducible genes (both type I and type II) and inflammatory genes, and down-regulation of B 
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and T-cell genes [153]. The identification of TB specific genes and their good classificatory 
performance regardless of HIV infection suggests that they are not HIV status dependent.  
 
3.7 Summary 
The bioinformatics toolbox described in Chapter 2 was applied to a large prospective 
study to identify host biomarkers of TB from host transcriptional data. The study includes 
patients with active culture proven TB, latent TB infection and a broad range of infectious 
and malignant conditions that have similar clinical symptoms and findings with TB, 
regardless of HIV co-infection. Patients were recruited in South Africa and Malawi.  
We investigated the hypothesis that host peripheral blood RNA expression would 
distinguish TB from other conditions prevalent in African populations and explored the use 
of a transcriptional signature as the basis for a diagnostic test. After pre-processing of the 
microarray data, the analysis identified a 27 transcript signature for discriminating TB from 
LTBI and a 44 transcript signature for discriminating TB from OD. The signatures were used 
to calculate a patient risk score able to classify the patients in the training and test sets with 
good performance. The signatures were also applied to a published dataset from South 
Africa which, unlike the discovery cohort, included only HIV-uninfected participants. The 
performance of the signature was further benchmarked in sub-groups of patients of 
particular interest and compared with the performance of signatures of smaller size. 
The analysis highlights the ability of the signatures to discriminate active TB from 
latent TB infection and other diseases phenotypically similar to TB in adults regardless of 
HIV, location and smear status. Most previous attempts to identify biomarkers of TB have 
excluded HIV-infected individuals, have generally used control diseases from different 
populations, or have compared TB to other diseases not representative of the spectrum of 
diseases from which TB needs to be distinguished in African hospitals. In addition, the size of 
the signatures that had been reported would not allow potential translation into a test.  
Although the signatures identified and DRS distinguished the majority of patients 
with TB from those with LTBI or OD, a proportion of patients were not correctly classified. 
Some false assignment by the test currently used as ‘gold standard’ is to be expected as 
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noted by post-mortem studies at which undiagnosed TB is confirmed. In addition, as all 
patients in the OD group presented in the clinics with symptoms similar to TB, it is possible 
that TB may have been misdiagnosed in a small proportion of OD patients despite the 
extensive clinical investigation used to assign each patient to each diagnostic group. 
The 27/44 transcript signatures are derived and tested on an adult dataset. 
However, TB differs substantially in the pathophysiology, progression and clinical 
presentation in children which complicates the understanding as well as the diagnosis of the 
disease. In the next Chapter we aim to extend the findings of Chapter 3 by looking for 
biomarkers specific to paediatric TB disease.  
  
Chapter 3. Identification of host gene expression biomarkers for TB in adults 
 
94 
 
 
Chapter 4. Identification of host gene expression biomarkers for TB in children 
 
95 
 
Chapter 4 
 
Identification of host gene 
expression biomarkers for 
TB in children 
 
 
 
In Chapter 4 we present the analysis of a large, prospective study to identify host gene 
expression biomarkers of TB disease in children. The study included both HIV-infected and -
uninfected children with LTBI, active TB and a wide spectrum of other diseases 
phenotypically similar to TB. The analysis was based on the pipeline described on Chapter 2. 
Minimal transcriptional signatures were identified and the patients’ disease risk score was 
calculated. The performance of the signatures in the form of disease score were evaluated 
in an independent paediatric dataset. The accuracy of the disease risk score was also 
compared to a molecular diagnostic tool now establishing itself in clinical use: the Xpert® 
MTB/RIF. .
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4.1 Paediatric Tuberculosis 
Tuberculosis in children differs from adult disease in several aspects including clinical 
presentation, degree of infectiousness, diagnostic difficulty, progression of the disease, risk 
of disseminated disease and response to treatment. The majority of these can be attributed 
to the different immune responses in children compared to adults, and particularly to the 
immaturity of their immune system [154].  
While most adult TB cases can be diagnosed by detection of AFB on sputum 
microscopy or culture, the majority of childhood TB cases are both smear and culture-
negative. As children do not produce sputum or produce only small amounts, sample 
acquisition requires complex invasive procedures (i.e. hospital admission to obtain early 
morning gastric lavage fluids, or saline-induced sputum aspirates) [155]. Even then, 
microbiological confirmation is the exception rather than the rule due to the paucibacillary 
nature of the disease and frequent extra-pulmonary presentations [69, 70, 156]. Only 10-
15% of children that are commenced on TB treatment are actually smear positive and 30% 
are culture positive [63]. Therefore, diagnosis and treatment initiation are often based 
solely on clinical suspicion. 
The most common presentations of TB in symptomatic children are fever, 
respiratory symptoms, weight loss and anorexia. However, as these symptoms are common 
to a range of other conditions, such as pneumonia, viral and bacterial infections, 
malnutrition and HIV, clinical diagnosis is unreliable [138]. Clinical scoring systems that use 
evidence of exposure to an infectious adult, chest x-rays, TST and IGRA positivity are 
employed to aid the diagnostic procedure. However, chest x-rays findings are not specific 
and TST and IGRA cannot differentiate active disease from latent infection, which poses an 
impediment in high burden settings [157, 158]. Furthermore, children with TB, particularly if 
HIV-infected or malnourished, may be both TST and IGRA negative [159-162]. In addition to 
the above, NAAT have low sensitivity in diagnosing TB in smear negative samples [163]. 
The difficulty in microbiological and immunological diagnosis of childhood TB results 
in a high proportion of children with TB being diagnosed late, and in some cases the 
diagnosis is only made post-mortem [164]. Conversely, as definitions of latent infection and 
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disease for children are less definitive than for adults, many patients are treated 
unnecessarily due to the difficulty of excluding TB from the diagnosis.  
Due to the lack of reliable diagnostics and underreporting, the true global burden of 
childhood TB remains unknown. Improved methods to diagnose childhood TB are therefore 
urgently needed, particularly in countries of sub-Saharan Africa where the burden of TB and 
HIV co-infection is highest [69, 156, 165-167]. Thus, we investigated the possibility that RNA 
expression signatures in whole blood might distinguish TB from latent TB infection and from 
other diseases, and explored the potential role of RNA expression signatures as a diagnostic 
tool. 
 
4.2 Cohorts 
A three site paediatric recruitment process was undertaken in Kenya, South Africa 
and Malawi. The study was conducted in these three sub-Saharan African countries as they 
have high burden of tuberculosis as well as HIV co-infection (Figure 29), while also having 
different patterns of malaria and other endemic diseases. The samples from children 
evaluated for suspected tuberculosis in hospitals in South Africa and Malawi were grouped 
together to form a discovery cohort. The performance of the signatures was assessed on the 
third cohort, comprising children evaluated for suspected tuberculosis in Kenya. 
The incidence of new TB cases in Kenya is 268 per 100,000, higher than Malawi (156 
per 100,000) but lower than South Africa (860 per 100,000). Out of the total number of TB 
cases, 38% tested positive for HIV [61]. Despite >98% infant BCG vaccination coverage in 
South Africa, 90%.5 in Malawi and 96%.7 in Kenya, there is a high incidence of TB in children 
in all three countries [168, 169]. In the areas where children were recruited for this study 
(Kilifi District and Mombasa in Coast Province), a mixed rural and urban population is based, 
malaria and malnutrition are endemic, while invasive bacterial and helminth infections are 
also common. Epidemiological data for TB in South Africa and Malawi were presented in 
Chapter 3. 
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Figure 29: The incidence rate of TB in Africa and recruitment sites for the paediatric study. 
The map was plotted using WHO estimates of TB incidence by country imported in the R 
package rworldmap [170]. 
 
 4.2.1 Recruitment 
In South Africa and Malawi, children were referred to the study team for 
investigation if the clinician looking after the child suspected a diagnosis of TB. In Kenya, all 
children admitted to hospital were formally screened for features of TB disease (fever, 
weight loss and cough for more than two weeks). Children with one or more of these 
features plus those referred for outpatient investigation for TB and children <5 years old 
who were identified as household TB contacts of smear positive pulmonary TB, were eligible 
for inclusion in the study.  
Chapter 4. Identification of host gene expression biomarkers for TB in children 
 
99 
The investigations included chest radiography, measurement of the CRP levels, a 
serologic test or polymerase-chain-reaction (PCR) assay for HIV, and a TST, with or without 
an IGRA. Two spontaneous or induced sputum samples and a specimen of tissue or 
cerebrospinal fluid (if clinically indicated) were examined for AFB and cultured for 
mycobacteria. The Xpert® MTB/RIF real-time PCR assay (a test for presence of M. 
tuberculosis and resistance to the antibiotic rifampicin) was performed on respiratory 
samples in the Kenyan cohort. Bacterial cultures, histological examination of tissue-biopsy 
specimens, and analysis of blood films for the presence of malaria were performed as 
clinically indicated. Clinical follow-up was undertaken at 3 months to confirm that children 
with LTBI remained free of TB and other diseases and to determine whether there had been 
a response to treatment in children with confirmed or suspected tuberculosis. 
After screening and evaluating 1356 children in South Africa and Malawi for 
symptoms of TB, 157 patients from South Africa and 189 patients from Malawi were 
included in the study. In Kenya, a total of 1599 children presenting to clinics in Kenya met 
the inclusion criteria for the study, and 1471 were evaluated for TB. Patients were assigned 
into study diagnostic groups based on examination results at enrolment and follow-up, as 
well as their HIV status. 
 
 
  
Chapter 4. Identification of host gene expression biomarkers for TB in children 
 
100 
4.2.2 Diagnostic Process 
Following the diagnostic work-up, patients were assigned to groups (Figure 30),using 
the following definitions shown in Table 22 : 
Group Definition 
Culture-confirmed TB Clinical condition consistent with TB and microbiological evidence (M. 
tuberculosis was cultured from sputum or tissue samples). 
Culture-negative TB Negative mycobacterial culture in a child with clinical and radiologic 
features that prompted empirical treatment for tuberculosis. Culture-
negative tuberculosis was further categorised as a case in which 
tuberculosis was highly probable, probable, or possible. (Figure 30) 
Latent TB case (LTBI) Clinically assessed as healthy on presentation and follow-up, contact 
with a person who had a positive smear for TB and had positive results 
on both the TST and the IGRA (discovery cohort) and had positive results 
on either the TST or the IGRA (validation cohort).  
Other disease case (OD) Children were classified as having diseases other than TB if they received 
a definitive alternative diagnosis or had no clinical deterioration on 
follow-up in the absence of TB therapy. 
Table 22: Definitions for “gold standard” classification of patient samples. 
 
Since a positive result on an IGRA in the group of patients with diseases other than 
TB might indicate either LTBI or primary tuberculosis that had resolved without treatment, 
we excluded patients in the discovery cohort who had a positive result on an IGRA. In the 
Kenyan validation cohort, patients who had diseases other than TB were included regardless 
of whether an IGRA result was positive or negative. Also, TST positivity was defined as 
≥10mm in HIV-uninfected and ≥5mm in HIV-infected children.  
Chapter 4. Identification of host gene expression biomarkers for TB in children 
 
101 
 
 
Figure 30: Diagnostic algorithm for patient classification into the culture confirmed TB, 
culture negative TB, other diseases and LTBI groups. 
IGRA positive OD patients were excluded from Cape Town and Malawi but were included in 
the Kenyan cohort. IS: induced sputum, CXR: chest X-ray 
 
Of the 346 children included in the study from South Africa and Malawi, 114 had 
culture-confirmed tuberculosis, 175 had diseases other than TB, and 57 had LTBI. The 
discovery cohort included only those children with TB that was confirmed using culture; 
children for whom the diagnosis of TB could not be confidently established or ruled out 
were excluded (Figure 31). 
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Figure 31: Samples randomly selected for microarrays from South Africa and Malawi. 
Out of the 1356 participants recruited in the study from South Africa and Malawi, 144 
patients with cultured confirmed TB (72 HIV-; 42 HIV+), 175 patients with OD (105 HIV-; 70 
HIV+) and 57 LTBI individuals (all HIV-) were selected for array analysis.  
 
From Kenya, 157 children were included in a nested case–control RNA expression 
study that contained the culture-confirmed TB cases and all subgroups in the group with 
culture-negative TB: children in whom TB was highly probable, probable, or possible. 
Microarray analysis was conducted for 35 patients with culture-confirmed TB and 14 
patients with LTBI, 44 patients with culture-negative TB (8 patients in whom TB was highly 
probable, 19 in whom it was probable, and 17 in whom it was possible) and 64 randomly 
selected patients from the group with diseases other than TB (55 with negative IGRA results 
and 9 with positive IGRA results) (Figure 32). 
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Figure 32: Samples selected for microarrays from the Kenyan cohort. 
Out of the 1487 participants recruited in the study from Kenya, 35 patients with cultured 
confirmed TB (25 HIV-; 10 HIV+), 44 patients with cultured negative TB (27 HIV-; 17 HIV+), 54 
patients with OD (37 HIV-; 27 HIV+) and 14 LTBI individuals (all HIV-) were selected for array 
analysis. 
 
 
 
 
In order to assess if arrayed samples were representative of the population, clinical 
features of the patients included in the microarray study were compared to the features of 
patients who were not included, using Fisher’s exact 2-sided test. The groups were very 
similar with two exceptions: in the group with probable tuberculosis, a history of close 
contact with a person who had tuberculosis was more common among patients included in 
the microarray study (Table 23), and in the group with diseases other than tuberculosis, 
weight loss and pleural effusion were more common among patients who were included 
(Table 24). 
Chapter 4. Identification of host gene expression biomarkers for TB in children 
 
104 
 
Highly probable TB Probable TB Possible TB 
Included 
(n=8) 
Excluded 
(n=7) 
p value 
Included 
(n=19) 
Excluded 
(n=45) 
p value 
Included 
(n=17) 
Excluded 
(n=49) 
p value 
Tuberculosis exposure                
Close TB contact history 5 (63%) 2 (29%) 0.31 11 (58%) 10 (22%) 0.009 5 (29%) 8 (16%) 0.29 
TST positive 8 (100%) 6 (86%) 0.47 6 (39%) 13 (29%) 1 1 (6%) 1 (2%) 0.45 
Tuberculosis exposure 8 (100%) 6 (86%) 0.47 13 (68%) 20 (44%) 0.10 5 (29%) 8 (16%) 0.29 
Clinical symptoms/signs of TB                
Persistent cough >2 weeks 5 (63%) 5 (71%) 1 11 (58%) 30 (67%) 0.57 12 (71%) 30 (61%) 0.57 
Persistent fever >2 weeks 4 (50%) 4 (57%) 1 6 (32%) 27 (60%) 0.06 8 (47%) 33 (67%) 0.16 
Night sweats >2 weeks 3 (38%) 3 (43%) 1 6 (32%) 7 (16%) 0.18 3 (18%) 10 (20%) 1 
Weight loss/failure to thrive 7 (88%) 6 (86%) 1 12 (63%) 28 (62%) 1 12 (71%) 34 (69%) 1 
CXR features of TB                
Airway compression 1 (13%) 0 (0%) 1 1 (5%) 0 (5%) 0.30 0 (0%) 0 (0%) - 
Lymphadenopathy 6 (75%) 6 (86%) 1 7 (37%) 19 (42%) 0.78 1 (6%) 4 (8%) 1 
Airspace shadowing 3 (38%) 2 (29%) 1 9 (47%) 18 (40%) 0.59 3 (18%) 15 (31%) 0.36 
Miliary/nodular shadowing 0 (0%) 0 (0%) - 1 (5%) 1 (2%) 0.51 1 (6%) 1 (2%) 0.45 
Pleural effusion 0 (0%) 1 (14%) 0.47 2 (11%) 2 (4%) 0.58 0 (0%) 1 (2%) 1 
Cavities 0 (0%) 0 (0%) - 2 (11%) 3 (7%) 0.63 0 (0%) 1 (2%) 1 
Calcified Ghon focus 0 (0%) 0 (0%) - 0 (0%) 0 (0%) - 0 (0%) 0 (0%) - 
Vertebral spondylitis 0 (0%) 0 (0%) - 0 (0%) 0 (0%) - 0 (0%) 0 (0%) - 
Table 23: Comparison of culture negative TB cases included in & excluded from the microarray analysis of the cohort from Kenya. 
 
Chapter 4. Identification of host gene expression biomarkers for TB in children 
 
105 
 Included 
(n=64) 
Excluded 
(n=935) 
p value 
Tuberculosis exposure 
Close TB contact history 6 (9%) 143 (15%) 0.28 
TST positive 4 (6%) 118 (13%) 0.17 
Tuberculosis exposure 16 (25%) 297 (32%) 0.27 
Clinical symptoms/signs of TB 
Persistent cough >2 weeks 23 (36%) 433 (47%) 0.12 
Persistent fever >2 weeks 21 (33%) 379 (41%) 0.24 
Night sweats >2 weeks 10 (16%) 143 (15%) 1 
Weight loss or failure to thrive 50 (78%) 514 (56%) <0.001 
CXR features of TB 
Airway compression 0 (0%) 2 (0.2%) 1 
Lymphadenopathy 5 (8%) 67 (7%) 0.80 
Airspace shadowing 17 (27%) 156 (17%) 0.06 
Miliary/nodular shadowing 0 (0%) 0 (0%) - 
Pleural effusion 4 (6%) 17 (2%) 0.04 
Cavities 0 (0%) 1 (0.1%) 1 
Calcified Ghon focus 0 (0%) 0 (0%) - 
Vertebral spondylitis 0 (0%) 0 (0%) - 
Table 24: Comparison of OD cases included in & excluded from the microarray analysis of 
the cohort from Kenya. 
 
Amongst the 175 patients of the group with diseases other than TB from South 
Africa and Malawi and the 64 patients from Kenya, pneumonia was the most common 
definite diagnosis. As shown in Table 25, some diseases were more prevalent in some 
locations or amongst HIV-infected individuals than others, therefore the groupings were 
taken into account in the partitioning of the discovery cohort (South Africa & Malawi) into 
the training and test set for the signatures identification, in order to control for overfitting.  
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Group HIV-infected HIV-uninfected  
Location SA Malawi Kenya SA Malawi Kenya Total 
Pneumonia 24 15 15 30 17 18 119 
Bronchiectasis/chronic lung disease 2 7 - - 1 - 10 
Lymphocytic Interstitial Pneumonitis - 2 - - - - 2 
Upper respiratory tract infection  - - - 11 - - 11 
Inflammatory bone&joint diseases - 1 - - 8 2 11 
Bacterial soft tissue infection - 5 - - 16 - 21 
Gastroenteritis 2 - - 5 - - 7 
Infection at ≥2 sites 2 - - 3 - - 5 
Sepsis without a focus - - 4 - - 1 5 
Kaposi Sarcoma - 7 - - - - 7 
Other malignancy - - - - 5 1 6 
Malaria + severe malnutrition - - - - 1 3 4 
Primary diagnosis: sev. malnutritiona - 1 4 - 1 3 9 
Otherb - 2 3 1 6 1 13 
Table 25: Major clinical diagnoses in the ‘Other Diseases’ groups from each study site. 
a These are children who had a primary diagnosis of severe malnutrition; many other 
children in the OD group also had severe malnutrition in addition to the diagnoses listed. 
b Includes cryptococcal meningitis (2); empyema (3); septicaemia (2); congenital spinal 
abnormalities (2); abscess + bacteremia (1); bacterial meningitis (1); severe anemia (1); and 
one child with severe malnutrition and a febrile illness of uncertain aetiology which resolved 
without TB treatment. 
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4.3 Power calculation  
In order to evaluate the suitability of the sample cohorts to detect effects that would 
be appropriate for biomarker use in this study, a power calculation was used. As the study 
has two diagnostic arms (TB vs. LTBI and TB vs. OD) and two datasets (discovery and 
validation), different calculations were implemented. For an anticipated sensitivity of 90% 
and a specificity of 90% in the discovery set for the TB vs. LTBI comparison, a sample size of 
72 TB patients and 57 LTBI patients will provide 95% confidence intervals spanning 7.2% 
from the point estimate of sensitivity and 8.5% from the point estimate of specificity. In an 
80-20 split of the cohort, the 95% confidence intervals will span 17% for sensitivity and 20% 
for specificity for the test set. In the validation set, for the TB vs. LTBI comparison, a sample 
size of 35 TB patients and 14 LTBI patients will provide 95% confidence intervals spanning 
10% from the point estimate of sensitivity and 17% from the point estimate of specificity. 
For the TB vs. OD comparison, for an anticipated sensitivity of 90% and a specificity 
of 90% in the discovery set, a sample size of 72 TB patients and 175 OD patients will provide 
95% confidence intervals spanning 7.2% from the point estimate of sensitivity and 4.5% 
from the point estimate of specificity. In an 80-20 split of the cohort the 95% confidence 
intervals will span 17% for sensitivity and 10% for specificity for the test set. In the validation 
set, a sample size of 35 TB patients and 64 LTBI patients will provide 95% confidence 
intervals spanning 10% from the point estimate of sensitivity and 7.6% from the point 
estimate of specificity. As for the sensitivity for the culture negative TB patients, a sample 
size of 44 patients will provide 95% confidence intervals spanning 9.3% from the point 
estimate of sensitivity. The adjusted Wald method was used for the calculations.  
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4.4 Results 
 4.4.1 Pre-processing 
First we pre-processed and performed quality control analysis on the dataset from 
South Africa and Malawi by following the steps of the pipeline described in Chapter 2. First, 
the data underwent background adjustment and normalisation, and then quality control 
was performed in order to inspect for irrelevant groupings and to check for possible 
assignment errors. PCA analysis was employed and the first principal components were 
examined, based on all transcripts on all samples (Figure 33). Inspection revealed that the 
primary clustering was based on disease state (TB, LTBI, and OD) rather than geographical 
location or HIV status. Two samples indicated by the arrows (a TB/HIV+ and an OD/HIV+ 
case from Malawi) were removed from the analysis. Confidence ellipses calculated for the 
population mean are shown below (0.999 inner circle, 0.9999 outer circle). 
 
 
Figure 33: Principal components analysis (PCA) plot of the microarray samples from South 
Africa and Malawi. 
The plot depicts PCA1 & PCA2 and is based on all transcripts and all samples after 
background adjustment and normalisation. The samples highlighted were removed from the 
analysis. Rings represent levels of confidence (0.9 inner circle; 0.9999 outer circle). 
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The R2 values for the principal components, which reflect the importance of each 
component, are: R2 (PC1) = 0.132; R2 (PC2) = 0.103; R2 (PC3) = 0.063; R2 (PC4) = 0.041; R2 
(PC5) = 0.032; R2 (PC6) = 0.024. Correlation analysis indicated that none of the variables is 
correlated with the components, with a correlation coefficient over 0.5. However, there is 
evidence of correlation for TB disease and TB infection with PC1 (-0.32 and 0.30) (Figure 33). 
Also, HIV status (positive) was correlated with PC4 (0.39) and location (South Africa) was 
correlated with PC5 (-0.48). 
                 
Figure 34: Principal components correlated with location and HIV status.  
Principal components 3, 4 and 5, 6 are shown. On the left plot colour coding depicts the 
location (South Africa or Malawi), and on the right plot colour coding depicts the HIV status 
(negative or positive).  
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4.4.2 Application of Adult Signatures  
As in Chapter 3 where we described the derivation of gene expression signatures for 
TB in adults from South Africa and Malawi, we first wanted to assess the performance of 
these signatures in the paediatric South African and Malawi cohort. We calculated the 
disease risk score of the patients in the paediatric cohort recruited at the same sites as the 
adults and calculated the classification metrics based on the 27 transcript signature for TB 
vs. LTBI (Table 26, Figure 35) and the 44 transcript signature for TB vs. OD (Table 26, Figure 
36). 
 
  Paediatric Dataset 
  
TB vs. LTBI adult 
signature 
TB vs. OD adult 
signature 
AUC 
(95% CI) 
89% 81% 
(85-94%) (76-86%) 
Sensitivity 
(95% CI) 
80% 75% 
(72-87%) (66-83%) 
Specificity 
(95% CI) 
80% 74% 
(69-89%) (67-81%) 
Table 26: Classification of the South Africa/Malawi paediatric dataset using the Disease 
Risk Score based on the 27 TB/LTBI and 44 TB/OD transcript signatures. 
The DRS based on the 27 TB/LTBI and 44 TB/OD transcript signatures was applied to the 
South African/Malawi paediatric dataset.  
 
The adult TB vs. LTBI signature when applied to the paediatric cohort achieved a 
sensitivity and a specificity of 80% CI95%(72-87) and 80% CI95%(69-89) respectively. For the TB 
vs. OD comparison the DRS classified the paediatric samples with sensitivity of 75% CI95%(66-
83) and specificity of 74% CI95%(67-81) (Table 26). 
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Figure 35: Classification of the South African/Malawi paediatric dataset using the Disease 
Risk Score based on the 27 TB/LTBI adult transcript signature. 
Disease risk score (left) and receiver operating characteristic curve (right) based on the 27 
TB/LTBI adult transcript signature applied to the patients of the South African/Malawi 
paediatric dataset. Sensitivity, specificity and AUC are reported in Table 26. 
 
 
Figure 36: Classification of the South African/Malawi paediatric dataset using the Disease 
Risk Score based on the 44 TB/OD adult transcript signature. 
Disease risk score (left) and receiver operating characteristic curve (right) based on the 44 
TB/OD adult transcript signature applied to the patients of the South African/Malawi 
paediatric dataset. Sensitivity, specificity and AUC are reported in Table 26. 
 
The classification achieved using the adult signatures has reduced performance in 
comparison to the performance in the adult test and validation datasets. This fact, in 
addition to the differences of the TB disease and infection between children and adults and 
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the effect that they are expected to have on gene expression in whole blood, led us to 
follow an analysis plan that would use the paediatric dataset to discover paediatric specific 
signatures and to validate them as well. 
 
4.4.3 Discovery of Paediatric Signatures 
In order to detect TB specific transcriptional signatures, accounting for the 
differences of the TB epidemic in the two countries, the microarray datasets from South 
Africa and Malawi were combined, pre-processed and analysed together. The Kenyan 
cohort was not included in the initial analysis and derivation of the signatures, but was 
subsequently used to benchmark the signatures (Figure 37).  
The analysis was performed as previously described in Chapter 2. The combined 
dataset from South Africa and Malawi, the discovery dataset, was partitioned into training 
and test sets, comprising 80% and 20% of the samples respectively. As different prominent 
subclasses of different diseases were present in the other diseases group, we maintained a 
balanced representation in both sets. For the two comparisons of interest, TB vs. LTBI and 
TB vs. OD, we performed differential expression analysis for the transcripts on the training 
set. Then, the elastic net was run using the preselected sets of transcripts that were 
differentially expressed between the comparator groups.  
Once the transcripts were selected, we calculated the disease risk score using the 
expression values of the transcripts selected by elastic net of the microarray samples from 
the Kenyan validation cohort. 
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Figure 37: Microarray analysis plan for the paediatric microarray dataset. 
The combined dataset from South Africa and Malawi was partitioned into training and test 
sets employed for signature discovery and in-sample testing. The signatures and Disease 
Risk Score were then validated using the microarray samples from the Kenyan cohort. 
 
 
4.4.3.1 TB vs. LTBI 
The training set for the TB vs. LTBI comparison included 86 culture confirmed TB 
cases and 43 LTBI individuals, comprising 80% of samples from the discovery cohort. After 
fitting a linear model accounting for HIV status and location we identified 3434 transcripts 
that were differentially expressed between TB and LTBI. These transcripts were used as 
input variables to run the elastic net. The 10-fold cross-validation for the elastic net 
parameters indicated that a model with λ2=0.6 and s=0.27 would produce the minimum 
mean squared error, corresponding to a 42-transcript model (Figure 38). 
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Figure 38: Mean Squared Prediction Error (MSE) plot and trace plot of the standardised 
coefficients for the TB vs. LTBI paediatric comparison (s=0.27). 
 
After the signature identification by elastic net, the disease risk score using the 42 
TB/LTBI transcript signature was calculated for the patients of the test (Figure 39), as well as 
the training set (Figure 40).  
The test set included 23 culture confirmed TB cases (14 HIV-uninfected and 9 HIV-
infected) and 11 LTBI individuals, while the training set included 86 culture confirmed TB 
cases (56 HIV-uninfected and 30 HIV-infected) and 43 LTBI individuals. As progression from 
latency to active disease in children is usually very quick, particularly for HIV infected 
children, no LTBI HIV-infected child was included in the study. AUC, sensitivity and specificity 
of the classifier were calculated to assess the DRS’s classificatory performance (Table 27). 
The DRS based on the 42-transcript signature distinguished TB from LTBI in the patients of 
the test set with sensitivity and specificity of 96% CI95% (87-100) and 91% CI95% (73-100) 
respectively. Similar metrics were obtained for the classification of the training set samples.  
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Figure 39: Classification of the South African/Malawi paediatric test set (20%) using the 
Disease Risk Score based on the 42 TB/LTBI transcript signature. 
Disease risk score (left) and receiver operating characteristic curve (right) based on the 42 
TB/LTBI transcript signature applied to the patients of the South African/Malawi paediatric 
test set (20%). Sensitivity, specificity and AUC are reported in Table 27 below. 
 
 
Figure 40: Classification of the South African/Malawi paediatric training set (80%) using 
the Disease Risk Score based on the 42 TB/LTBI transcript signature. 
Disease risk score (left) and receiver operating characteristic curve (right) based on the 42 
TB/LTBI transcript signature applied to the patients of the South African/Malawi paediatric 
training set (80%). Sensitivity, specificity and AUC are reported in Table 27 below. 
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South Africa/Malawi cohort 
Training set Test set 
AUC 
(95% CI) 
98.4% 98.4% 
(96.3 - 99.8%) (94.5 - 100.0%) 
Sensitivity 
(95% CI) 
95.4% 95.7% 
(90.8 - 98.9%) (87.0 - 100.0%) 
Specificity 
(95% CI) 
97.7% 90.9% 
(93.0- 100.0%) (72.7 - 100.0%) 
Table 27: Classification of the South Africa/Malawi paediatric training and test sets using 
the Disease Risk Score based on the 42 TB/LTBI transcript signature. 
The DRS based on the 42 TB/LTBI transcript signature was applied to the South 
African/Malawi training and test sets.  
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4.4.3.2 TB vs. OD 
In the training set, for the comparison of TB against other diseases, 86 culture-
confirmed TB cases and 133 patients with other diseases were included, comprising 80% of 
samples from the discovery cohort. After fitting a linear model accounting for HIV status and 
location, we identified 409 transcripts that were differentially expressed and met the 
criterion for being candidate biomarkers. These transcripts were used as input variables to 
elastic net. The 10-fold cross-validation process in order to select the elastic net parameters 
suggested that a model with λ2=0 and s=0.18 would minimise the mean squared error, 
corresponding to a 51-transcript model (Figure 41). 
 
Figure 41: Mean Squared Prediction Error (MSE) plot and trace plot of the standardised 
coefficients for the TB vs. OD paediatric comparison (s=0.18). 
 
The disease risk score was calculated for all the patients of the test set (Figure 42), as 
well as the training set using the 51 TB/OD transcript signature identified by the elastic net 
(Figure 43). The test set included 23 culture confirmed TB cases (14 HIV uninfected and 9 
HIV infected) and 34 patients with other diseases (21 HIV uninfected and 13 HIV infected). 
AUC, sensitivity and specificity of the classifier were calculated to assess the DRS’s 
classificatory performance (Table 28). The DRS based on the 51-transcript signature 
distinguished TB from other diseases of the patients in the test set with sensitivity and 
specificity of 78% CI95%(61-96) and 74% CI95%(56-88) respectively.  
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Figure 42: Classification of the South African/Malawi paediatric test set (20%) using the 
Disease Risk Score based on the 51 TB/OD transcript signature. 
Disease risk score (left) and receiver operating characteristic curve (right) based on the 51 
TB/OD transcript signature applied to the patients of the South African/Malawi paediatric 
test set (20%). Sensitivity, specificity and AUC are reported in Table 28 below. 
 
 
Figure 43: Classification of the South African/Malawi paediatric training set (80%) using 
the Disease Risk Score based on the 51 TB/OD transcript signature. 
Disease risk score (left) and receiver operating characteristic curve (right) based on the 51 
TB/OD transcript signature applied to the patients of the South African/Malawi paediatric 
training set (80%). Sensitivity, specificity and AUC are reported in Table 28 below. 
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South Africa/Malawi cohort 
Training set Test set 
AUC 
(95% CI) 
85.9% 86.2% 
(96.3 - 99.8%) (77.1 - 94.0%) 
Sensitivity 
(95% CI) 
78.5% 78.3% 
(61.0 - 94.5%) (60.9 - 95.7%) 
Specificity 
(95% CI) 
73.5% 73.9% 
(58.8 - 88.2%) (55.9 - 88.2%) 
Table 28: Classification of the South Africa/Malawi paediatric training and test sets using 
the Disease Risk Score based on the 51 TB/OD transcript signature. 
The DRS based on the 51 TB/OD transcript signature was applied to the South 
African/Malawi training and test sets.  
 
The performance of the DRS on the HIV-infected and -uninfected patients of the test 
set separately was also assessed (Table 29). The DRS performed better among the HIV 
uninfected patients in comparison to the HIV-infected patients with sensitivity of 79% 
CI95%(57-100) and specificity of 81% CI95%(62-95). In the HIV-infected group the sensitivity 
was 78% CI95%(56-100) and the specificity 62% CI95%(31-85) respectively. This could be 
explained by the alterations in gene expression that HIV infection causes and the 
suppression of the immune system.  
 
 
South Africa/Malawi cohort (test set) 
HIV- HIV+ 
AUC 
(95% CI) 
88.4% 84.6% 
(75.9 - 97.6%) (64.0 - 96.6%) 
Sensitivity 
(95% CI) 
78.6% 77.8% 
(57.1 - 100.0%) (55.6 - 100.0%) 
Specificity 
(95% CI) 
81.0% 61.5% 
(61.9 - 95.2%) (30.8 - 84.6%) 
Table 29: Classification of the South Africa/Malawi paediatric test set by HIV status using 
the Disease Risk Score based on the 51 TB/OD transcript signature. 
The DRS based on the 51 TB/OD transcript signature was applied to the South 
African/Malawi test set, separately for the HIV-infected and -uninfected patients. 
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4.5 Benchmarking using an independent cohort 
 The performance of the disease risk score was assessed further using the samples 
from the paediatric Kenyan validation cohort. This cohort included patients that were TB 
culture positive, latently infected children, children with other diseases as well as children 
that were TB culture negative. Also, Xpert® MTB/RIF results and IGRA test results were 
available for the majority of the patients in the cohort which allowed a direct comparison of 
their results with the performance of the DRS. Additionally we explored the possibility of 
using housekeeping genes to establish cut-offs for the test. 
 
4.5.1 Performance of the DRS on the Kenyan cohort 
The Kenyan validation cohort was not included in the initial analysis and derivation 
of the signatures. The analysis of the microarrays from South Africa/Malawi was performed 
as previously described but the samples from Kenya as well as their microarrays were 
handled, pre-processed (background subtracted and normalised) and analysed separately. 
After transcript selection and signature identification using elastic net on the discovery 
cohort, we calculated the disease risk score by using the expression values of the 
preselected transcripts of the microarray samples from the Kenyan validation cohort.  
First we explored the classificatory performance of the DRS based on the TB vs. LTBI 
42 transcript signature on the culture-confirmed TB patients and the LTBI individuals (Figure 
44). The dataset included 35 culture confirmed TB samples and 14 LTBI children. The DRS 
discriminated culture proven TB cases from the latently infected individuals with a 
sensitivity of 94% CI95%(86-100) and specificity of 100% CI95%(62-95) (Table 30). The 
performance of the DRS was slightly higher in the Kenyan cohort in comparison with the 
20% test set from South Africa and Malawi.  
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Figure 44: Classification of the paediatric validation cohort from Kenya using the Disease 
Risk Score based on the 42 TB/LTBI transcript signature. 
Disease risk score (left) and receiver operating characteristic curve (right) based on the 42 
TB/LTBI transcript signature applied to the patients of the paediatric validation cohort from 
Kenya. Sensitivity, specificity and AUC are reported in Table 30 below. 
 
 
Kenyan Validation Cohort 
TB vs. LTBI TB vs. OD 
AUC 
(95% CI) 
100.0% 89.0% 
(100.0 - 100.0%) (82.3 - 94.9%) 
Sensitivity 
(95% CI) 
94.3% 82.9% 
(85.7 - 100.0%) (68.6 - 94.3%) 
Specificity 
(95% CI) 
100.0% 83.6% 
(100.0 - 100.0%) (74.6 - 92.7%) 
Table 30: Classification of the Kenyan validation cohort using the Disease Risk Score based 
on the 42 TB/LTBI and 51 TB/OD transcript signatures. 
The DRS based on the 42 TB/LTBI and 51 TB/OD transcript signature was applied to the 
validation cohort from Kenya.  
 
Subsequently we assessed the classificatory performance of the DRS based on the 
TB/OD 51 transcript signature on the culture-confirmed TB patients and the patients with 
other diseases (Figure 45). The dataset included 35 culture confirmed TB samples and 55 
children with a definite diagnosis other than TB that had a negative IGRA result. The DRS 
distinguished culture proven TB cases from patients with other diseases with a sensitivity of 
83% CI95%(67-94) and specificity of 84% CI95%(75-93) (Table 30). The performance of the DRS 
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for the TB vs. OD comparison was slightly higher in the Kenyan cohort compared to the 20% 
test set from South Africa and Malawi.  
 
Figure 45: Classification of the paediatric validation cohort from Kenya using the Disease 
Risk Score based on the 51 TB/OD transcript signature. 
Disease risk score (left) and receiver operating characteristic curve (right) based on the 51 
TB/OD transcript signature applied to the patients of the paediatric validation cohort from 
Kenya. Sensitivity, specificity and AUC are reported in Table 27 above. 
 
We further evaluated the classificatory performance of the DRS on the HIV-infected 
and -uninfected children separately (Figure 46, Table 31). The HIV-uninfected dataset 
consists of 25 culture positive TB cases and 29 OD patients. The HIV-infected dataset 
comprises 10 patients with culture confirmed TB and 29 patients with other diseases. In HIV 
uninfected group DRS distinguished TB cases from patients with other diseases with a 
sensitivity of 80% CI95%(64-92) and specificity of 81% CI95%(65-93). The performance of DRS 
for the HIV-infected children was slightly higher, with sensitivity of 90% CI95%(70-100) and 
specificity of 92% CI95%(81-100). 
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Figure 46: Classification of the paediatric validation cohort from Kenya by HIV status using 
the Disease Risk Score based on the 51 TB/OD transcript signature. 
Disease risk score (top panels) & receiver operating characteristic curves (bottom panels) 
based on the 51 TB/OD transcript signature applied to the validation cohort from Kenya, 
calculated for the HIV-infected and -uninfected patients separately. Sensitivity, specificity 
and AUC are reported in Table 31 below. 
 
 
Kenyan Validation Cohort 
HIV- HIV+ 
AUC 
(95% CI) 
85.7% 93.9% 
(75.0 - 94.4%) (83.9 - 100.0%) 
Sensitivity 
(95% CI) 
80.0% 90.0% 
(64.0 - 92.0%) (70.0 - 100.0%) 
Specificity 
(95% CI) 
81.0% 92.3% 
(65.4 - 93.1%) (80.8 - 100.0%) 
Table 31: Classification of the Kenyan validation cohort using the Disease Risk Score based 
on the 51 TB/OD transcript signature by HIV status. 
The DRS based on the 51 TB/OD transcript signature was applied to the validation cohort 
from Kenya for the HIV-infected and -uninfected patients separately.   
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4.5.2 Comparison with Xpert® MTB/RIF 
The Xpert® MTB/RIF assay was performed on respiratory samples from the patients 
included for gene expression analysis in the Kenyan cohort. Therefore we compared the 
performance of the DRS with that of the Xpert® MTB/RIF in the culture-confirmed TB group, 
while the OD group was used to calculate test specificity. The Xpert® MTB/RIF test had a 
positive result for 19 out of 35 culture-confirmed TB cases and none out of 55 other 
diseases cases. Overall, 25 culture positive TB and 29 OD patients were HIV negative while 
the rest were HIV positive. 
 
Kenyan Validation Cohort 
HIV-/+ HIV- HIV+ 
AUC 
(95% CI) 
77.1% 74.0% 85.0 
(69.9 - 85.7%) (64.0 - 84.0%) (70.0 - 95.1) 
Sensitivity 
(95% CI) 
54.3% 48.0% 70.0 
(37.1 - 68.6%) (28.0 - 64.1%) (40.0 - 100.0) 
Specificity 
(95% CI) 
100.0% 100.0% 100.0% 
(100.0 - 100.0%) (100.0 - 100.0%) (100.0 - 100.0%) 
Table 32: Diagnostic performance of the Xpert® MTB/RIF in the Kenyan validation cohort. 
The Xpert® MTB/RIF test assay was used for classification of the patients in the validation 
cohort from Kenya. Results are presented for the HIV-infected and -uninfected patients 
combined as well as separately.  
 
Xpert® MTB/RIF is highly specific (specificity of 100%) but its sensitivity is limited 
(sensitivity of 54.3 CI95%(37.1-68.6)) (Table 32). These results agree with previously 
published data on the performance of Xpert® MTB/RIF in children showing that it detects 
only a portion of the culture confirmed TB cases, even when two tests are undertaken but it 
is highly specific [171]. Comparison with the results acquired using DRS from Table 30 
showed that the DRS identified a higher proportion of culture-confirmed TB cases but was 
less specific than Xpert® MTB/RIF. 
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4.5.3 Culture negative TB cases 
Many children are commenced on TB treatment without any bacteriological 
confirmation and it is widely accepted that clinical diagnostic scores over-diagnose TB but 
the extent of over-diagnosis is unknown [172]. As culture negative TB represents the 
majority of paediatric TB cases worldwide, we further explored the performance of the DRS 
in this group, for which no ‘gold standard’ is available. The DRS was calculated for the 44 
patients with culture-negative tuberculosis (8 patients in whom tuberculosis was highly 
probable, 19 in whom it was probable, and 17 in whom it was possible) (Figure 47).  
 
Figure 47: Disease risk score based on the TB/OD 51-transcript signature applied to the 
independent Kenyan validation cohort by clinical subgroup 
Disease risk score based on the 51 TB/OD transcript signature was applied to the validation 
cohort from Kenya (culture confirmed TB, culture negative TB and other diseases), 
calculated for the HIV-infected and -uninfected patients combined.  
 
Xpert® MTB/RIF results on the culture negative group of children were also available, 
so we compared the performance of both DRS and Xpert® MTB/RIF in the culture-
confirmed, “highly probable”, “probable” and “possible” culture-negative TB groups 
separately. The Xpert® MTB/RIF test had a positive outcome for 3 out of 44 culture-negative 
TB cases and 0 out of 55 other diseases cases. In each case we used the same OD group as 
the TB-negative comparator group to calculate test specificity. Among patients with 
negative cultures who were treated for tuberculosis, the DRS identified 63% CI95%(25 - 100) 
of those in whom tuberculosis was highly probable, 42% CI95%(21 - 63) of those in whom it 
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was probable, and 35% CI95%(12 - 59) of those in whom it was possible. For the same 
patients Xpert® MTB/RIF identified 25% CI95%(25 - 50) of those in whom TB was highly 
probable, 5% CI95%(0 - 18) of those in whom it was probable, and 0% of those in whom it 
was possible. Its specificity was 100% as the same OD group was used (Figure 48).  
 
 
Figure 48: Receiver operating characteristic curves for the Kenyan cohort using the Disease 
Risk Score based on the 51 TB/OD transcript signature for the different subgroups. 
Receiver operating characteristic curves based on the 51 TB/OD transcript signature applied 
to the different subgroups of the validation cohort from Kenya. Sensitivity, specificity and 
AUC are reported in Table 33. 
 
However, each category of the culture negative TB group is a mixture of “actual” TB 
cases and OD cases clinically confused with TB. Therefore, and in order to obtain more 
realistic estimates of the test sensitivity across the culture-negative groups, this was 
accounted for in the following way: 
The observed true-positive rate (TPR) was modelled as a function of the unknown 
actual TPR, the false-positive rate (FPR) estimated from the OD group, and the prevalence of 
TB (Equation 4.2), from which a corrected Receiver Operator Characteristic (ROC) curve and 
estimates of 'effective' sensitivity were calculated in each category. As the prevalence of TB 
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in each category is unknown, we investigated a range of prevalence of 70%-90%, 40%-60% 
and 30%-50% for “highly probable”, “probable” and “possible” TB respectively. The already 
calculated unadjusted sensitivity is equivalent to assuming a TB prevalence of 100% in each 
category. As the application of a classifier, such as DRS, to the culture-negative TB group 
results in an observed estimate of the true-positive rate (TPRobs) which is the proportion of 
all observed culture–negative TB cases (Pobs) scored as 'positive' by the classifier. However, 
these observed positives are in fact a mixture of actual true TB and false TB (i.e. OD), hence:  
          
     
    
    
                   
                
 
 
         
                                         
               
 
                    
       
               
              
       
               
 
 
                                                                 (4.1) 
 
where:  
Factual is the number of OD and Pr(TB) is the prevalence of true TB and in the group under 
consideration.  
FPReffective is the false-positive rate, estimated as the proportion of OD cases that are falsely 
called TB by the classifier. We can re-arrange equation (4.1) to obtain a formula for the 
effective TPR in terms of the group prevalence and the FPR estimated from the OD group: 
 
             
                           
      
                     
(4.2) 
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  AUC 
% (95% CI) 
Sensitivity 
% (95% CI) 
Effective Sensitivity 
% (95% CI) 
 
Highly 
Probable 
TB vs. OD 
(nTB=8 
nOD=55) 
Estimated “actual” TB 
prevalence in group 
100% 100% 70% 80% 90% 
DRS 
51 TB vs. OD 
signature 
77.5 62.5 82.3 74.1 67.6 
(58.2 - 94.3) (25.0 - 100.0) (41.9 - 100.0) (37.6 - 100.0) (35.1 - 100.0) 
Xpert® MTB/RIF  
62.5 25.0 35.7 31.3 27.8 
(50.0 - 81.3) (0.0 - 50.0) (1.1 - 65.7) (1.0 - 57.6) (1.0 - 51.3) 
 
Probable 
TB vs. OD 
(nTB=19 
nOD=55) 
Estimated “actual” TB 
prevalence in group 
100% 100% 40% 50% 60% 
DRS 
51 TB vs. OD 
signature 
72.3 42.1 80.8 67.9 59.3 
(59.6 - 84.2) (21.1 - 63.2) (36.4 - 100.0) (32.7 - 100.0) (30.2 - 90.6) 
Xpert® MTB/RIF  
52.6 5.3 13.3 10.6 8.8 
(50.0 - 57.9) (0.0 - 17.8) (0.0 - 36.5) (0.0 - 29.3) (0.0 - 24.5) 
 
Possible 
TB vs. OD 
(nTB=17 
nOD=55) 
Estimated “actual” TB 
prevalence in group 
100% 100% 30% 40% 50% 
DRS 
51 TB vs. OD 
signature 
64.5 35.3 79.6 63.8 54.3 
(48.4 - 77.7) (11.8 - 58.8) (7.2 - 100.0) (9.2 - 100.0) (10.2 - 91.0) 
Xpert® MTB/RIF  
50.0 0.0 0.0 0.0 0.0 
(50.0 - 50.0) (0.0 - 0.0) (0.0 - 0.0) (0.0 - 0.0) (0.0 - 0.0) 
Table 33: Classification of the culture-negative TB samples from the Kenyan validation 
cohort using the Disease Risk Score based on the 51 TB/OD transcript signature and the 
Xpert® MTB/RIF results using a range of prevalence for each subgroup. 
 
The effective sensitivity of the disease risk score for highly probable, probable, and 
possible cases of tuberculosis was 67.6 to 82.3%, 59.3 to 80.8%, and 54.3 to 79.6%, 
respectively (Table 33, Figure 49). The sensitivity of the disease risk score was higher than 
that of the Xpert® MTB/RIF assay in all tuberculosis categories, with the Xpert® MTB/RIF 
assay having sensitivities of 27.8 to 35.7% for the subgroup in which tuberculosis was highly 
probable, 8.8 to 13.3% for that in which it was probable, and 0% for that in which it was 
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possible. However, the Xpert® MTB/RIF assay was highly specific (100%). And the specificity 
of DRS remains the same as in Table 30. 
 
Figure 49: Receiver operating characteristic curves for the Kenyan cohort based on the 
Disease Risk Score based on the 51 TB/OD transcript signature for the different subgroups, 
using an adjusted sensitivity of ‘actual’ TB of 80% for the highly probable, 50% for the 
probable and 40% for the possible TB cases. 
Sensitivity, specificity and AUC are reported in Table 33. 
 
To explore how the DRS for TB/OD may contribute to TB diagnosis in clinical practice, 
we evaluated its positive and negative predictive values, calculated as functions of 
specificity, sensitivity and prevalence according to the formulae (2.19 – 2.20). Calculation of 
PPV and NPV require prior knowledge of the proportion of TB cases in the population under 
investigation. However, as prevalence of TB has a strong dependence on the recruitment 
strategy, as evidenced by the different prevalence in the three cohorts, we evaluated the 
performance of the DRS using a range of estimates representative of the three populations 
undergoing screening (10%, 30% and 50%), and probably representative of the prevalence 
among a future populations undergoing TB screening.  
 10%: reflects the prevalence of TB in the Kenyan cohort  
 30%: reflects the prevalence of TB in the South Africa and Malawi recruitment 
 50%: reflects prior filtering of the patients or combination with another test 
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Also, given the dependency of NPV and PPV on test sensitivity and specificity, we 
calculated estimates for these values reflective of the different scenarios in which a 
diagnostic test for TB would be applied. We employed the specificity of the DRS for the HIV-
infected and -uninfected other disease group from the Kenyan validation set. Regarding the 
sensitivity, we used an estimate derived from the combined culture-positive and culture-
negative TB groups: a weighted average of the 'effective' sensitivity in the culture-
confirmed, “highly probable” (HP), “probable” (Pr) and “possible” (Pos) TB. The weights are 
given by the proportion of samples in the Kenyan prospective study which were assigned to 
each of these groups. We considered three scenarios, with proportions listed below:  
 A: TB prevalence in: culture confirmed = 100%; HP TB = 70%; Pr TB =40%; Pos TB = 30% 
 B: TB prevalence in: culture confirmed = 100%; HP TB = 80%; Pr TB =50%; Pos TB = 40% 
 C: TB prevalence in: culture confirmed = 100%; HP TB = 90%; Pr TB =60%; Pos TB = 50% 
 
These scenarios allowed us to calculate a combined sensitivity: the average 
sensitivity across all culture-negative and -positive TB groups. 
Combined 
sensitivity 
Measure 
Prevalence 
10% 30% 50% 
A: 70% 
PPV % 
(95% CI) 
38.3 70.5 84.8 
(23.4 - 53.3) (57.4 - 83.7) (76.6 - 943.0) 
NPV % 
(95% CI) 
93.6 87.1 74.4 
(94.9 - 97.7) (82.8 - 91.5) (67.0 - 81.8) 
B: 75% 
PPV % 
(95% CI) 
41.0 72.9 86.2 
(25.8 - 56.3) (60.4 - 85.3) (78.7 - 93.7) 
NPV % 
(95% CI) 
96.9 89 77.6 
(95.5 - 98.2) (84.6 - 93.4) (69.8 - 85.4) 
C: 82% 
PPV % 
(95% CI) 
44.3 75.4 87.8 
(28.8 - 59.8) (63.8 - 87.1) (81.0 - 94.5) 
NPV % 
(95% CI) 
97.8 91.9 82.9 
(96.5 - 99.0) (87.6 - 96.1) (74.9 - 90.9) 
Table 34: PPV and NPV for the Kenyan validation cohort in different prevalence scenarios 
& based on the sensitivity in both culture-negative and culture-positive TB groups. 
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PPV was highest when the prevalence of TB in the screened population was high, 
and decreased as prevalence decreased, whereas NPV increased with the decreasing 
prevalence (Table 34). 
 
4.5.4 Comparison with IGRA and CRP 
To assess further the potential diagnostic role of transcriptional signatures and the 
DRS, we compared it against measurements of the levels of C-reactive protein (CRP) and the 
IGRA. In the Kenyan cohort 35 culture-confirmed TB patients and 54 patients from the OD 
group were IGRA tested. IGRA distinguished culture confirmed TB cases from other diseases 
with a sensitivity of 60% CI95%(33-87) and a specificity of 83% CI95%(72-93). The disease score 
was more sensitive than the IGRA while its specificity was the same.  
Previous studies have suggested that C-reactive protein levels may be useful for TB 
diagnosis in adult smear negative patients [173]. Therefore CRP was measured in patients’ 
serum collected at the same time as blood for RNA expression by ELISA. No significant 
differences were identified between the 44 culture negative TB, 52 other diseases and 34 
culture confirmed TB patients that were tested (Figure 45).  
 
Figure 50: Serum CRP measurements from Kenyan validation cohort patients. 
 Each dot represents one patient. Bars indicate median value.   
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4.5.5 Including IGRA+ patients in the OD group  
We have deliberately excluded from the OD category children with a positive IGRA to 
minimise this potentially important source of misclassification bias. However, in order to 
evaluate the OD patients that had a positive IGRA result, we performed the TB vs. OD 
comparison with inclusion of the IGRA positive patients. The IGRA positive patients in the 
OD group may have either self-resolving primary TB or latent TB infection. There were 9 
IGRA+ patients in the OD group randomly selected for array. The sensitivity of DRS for TB vs. 
OD remained unchanged with or without the IGRA+ patients, while specificity was 1% lower 
for when the IGRA+ patients were included (Figure 51, Table 35).  
 
                                
Figure 51: Classification of the Kenyan paediatric dataset using the Disease Risk Score 
based on the 51 TB/OD transcript signature, including the IGRA+ OD patients.  
Sensitivity, specificity and AUC are reported in Table 35 below. 
  
 
Kenya Validation Cohort 
TB vs. OD (including IGRA+) 
AUC 
(95% CI) 
89.0% 
(81.9 - 95.3%) 
Sensitivity 
(95% CI) 
82.9% 
(68.6 - 94.3%) 
Specificity 
(95% CI) 
82.8% 
(73.4 - 92.2%) 
Table 35: Classification of the Kenyan validation cohort using the Disease Risk Score based 
on the 51 TB/OD transcript signature, including the IGRA+ OD patients. 
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Disease risk score based on the 51 TB/OD transcript signature was applied to the TB/OD 
validation cohort from Kenya. The OD control group included the IGRA+ patients.  
Seven out of the nine patients of the other disease group that were IGRA positive 
were classified as “not TB” by the DRS. The two misclassified OD IGRA+ patients are 
indicated by red arrows in Figure 51. As sensitivity of the DRS was unchanged when IGRA 
positive patients were included or excluded, and to exclude possibility of including self-
resolving primary TB in the OD group, we used only IGRA negative OD cases for calculation 
of performance of DRS in the culture negative group. 
 
4.5.4 Threshold computation by housekeeping genes  
As the threshold values for the DRS are acquired from the population samples and 
are slightly different between training, test and validation cohorts, we explored the 
possibility of having a global DRS threshold based on information extrapolated from 
housekeeping genes. The housekeeping genes are genes that are crucial for fundamental 
functions in the cells and are expressed under all conditions.  
First, we identified the housekeeping transcripts within the training cohort. As a 
measure for variability for every transcript we employed the coefficient of variation in the 
training cohort calculated by dividing the standard deviation by the mean. Low values of the 
coefficient of variation indicate more homogeneity across samples regardless of location, 
HIV status and different disease group (Figure 52). We identified the 20 transcripts with 
lowest coefficient of variation values for use as housekeeping transcripts.  
Currently the thresholds for the training, test and Kenyan validation cohort are: 
135.6, 133.8 and 127.6 respectively and their ratios relative to the training set are 1, 0.99 
and 0.94. These ratios are very similar to the ratios of the medians of all the medians of the 
housekeeping transcripts which calculated in relation to the training set are: 1, 0.99 and 
0.95. The ratios of the housekeeping transcripts seem to reflect the scaling of the 
thresholds. This scaling could be attributed to the different array intensities, RNA handling 
bias or other batch effects.  
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Figure 52: Coefficient of variation calculated for every transcript across samples of the 
training cohort.  
 
Using the medians of the housekeeping genes and the threshold of the training set, 
we calculated the thresholds in the testing and validation cohorts for TB vs. OD comparison, 
which were 134.9 and 128.1 respectively. In the validation cohort from Kenya specificity 
improves from 83.6% to 87.2% while sensitivity decreases from 82.8% to 77.1%. Further 
work needs to be undertaken to finalise this analysis.  
 
4.6 Application of the TB vs. LTBI signature to the culture negative TB cases  
The culture negative TB cases presented with TB symptoms and were categorised as 
having highly probable, probable and possible TB according to the algorithm presented in 
Figure 30. The inclusion criteria in the study were any of: cough, fever or weight loss for 
more than 2 weeks, pneumonia not responding to antibiotics, history of close TB contact or 
clinician’s clinical suspicion of TB for any other reason. Although M. Tuberculosis was not 
isolated from clinical specimens, the majority of the patients - particularly in the highly 
probable and the probable group - were smear positive or had a reactive Mantoux. We 
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further explored the performance of the TB vs. LTBI 42-transcript signature in the highly 
probable, probable and possible groups (Figure 53).  
 
Figure 53: Disease risk score based on the TB/LTBI 42-transcript signature applied to the 
independent Kenyan validation cohort by clinical subgroup 
Disease risk score based on the 42 TB/LTBI transcript signature was applied to the validation 
cohort from Kenya (culture confirmed TB, culture negative TB and LTBI). 
 
The majority of culture negative TB cases were classified as TB. Only one case in the 
highly probably TB group, three cases in the probable TB group and four in the possible TB 
group were classified as LTBIs. However, as all these patients show symptoms of disease 
they may be classified as TB, because the TB vs. LTBI signature is also capturing a “disease 
vs. healthy” signature. It also is expected that clinical diagnosis would over estimate true TB 
prevalence in the “highly probable”, “probable” and “possible” TB groups. 
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4.7  Signatures 
In this section we present the transcripts that are included in the paediatric 
transcriptomic signatures, as well as their direction of regulation (Table 36, Table 37). Eight 
transcripts of the TB/LTBI signature were also present in the previously published 393-
transcript signature [60], while three were also included in the TB/OD adult signature. The 
overlap with the adult TB/LTBI signature was with only one transcript corresponding to 
GBP6. 
Array ID Gene Symbol Probe ID Direction* 
Overlap with 
393-transcript 
signature 
6480059 ACTA2 ILMN_6588 up √ 
3310324 ALKBH7 ILMN_7229 down  
5550397 APOL6 ILMN_38312 up √ 
7400341 C11ORF2 ILMN_10940 down  
1500546 C20ORF201 ILMN_25727 down  
6380187 C21ORF57 ILMN_21121 down  
1470706 C8ORF55 ILMN_25304 down  
2030170 CARD16 ILMN_21555 up √ 
6110427 CLIP1 ILMN_15054 up  
5340246 CRIP2 ILMN_29728 down  
4540239 DEFA1 ILMN_29692 up  
4860128 DEFA1B ILMN_176067 up  
2970747 DEFA3 ILMN_11220 up  
7200274 DGCR6 ILMN_138781 down  
3440647 DNAJC30 ILMN_30295 down  
3390068 E4F1 ILMN_23848 down  
4670441 FBLN5 ILMN_29187 down  
1510364 GBP5 ILMN_24462 up √ 
3780047 GBP6 ILMN_1956 up √ 
450632 GNG3 ILMN_7558 down  
1500575 HS.538100 ILMN_103699 down  
4590026 IMPDH2 ILMN_3439 down  
7330575 KLHL28 ILMN_22112 down  
2810669 LCMT1 ILMN_16696 down  
5340414 LGTN ILMN_4831 down  
2140541 LOC389816 ILMN_182870 down  
620403 LOC400759 ILMN_181219 up  
2230538 LRRN3 ILMN_306943 down  
5560075 MFGE8 ILMN_11368 down  
4210411 NDRG2 ILMN_19545 down √ 
6450424 NME3 ILMN_23571 down  
6770603 NOG ILMN_7080 down  
4150017 PAQR7 ILMN_3765 down  
2140382 PASK ILMN_19873 down √ 
4150100 PASK ILMN_19873 down √ 
7150189 PHF17 ILMN_1535 down  
3400468 RAP1A ILMN_20446 up  
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4670487 SIVA ILMN_6846 down  
6280433 SNHG7 ILMN_371358 down  
4260189 TGIF1 ILMN_162784 down  
4050059 U2AF1L4 ILMN_8757 down  
6550358 UBA52 ILMN_27795 down  
Table 36: The 42 transcript signature for distinguishing TB from LTBI in children 
* in TB patients in relation to patients with LTBI. 3 transcripts were also in the TB/OD 
signature (in bold). 
 
In the TB/OD paediatric signature, no overlap was found with the previously 
published TB/OD 86 transcript signature [60]. However, seven transcripts were common 
between the TB/OD adult and paediatric signatures corresponding to five genes ALDH1A1, 
CYB561 (2), LOC389386 (2), MIR1974.  
Array ID Gene Symbol Probe ID Direction* 
Overlap with 86-
transcript 
signature 
4180768 ALAS2 ILMN_13644 up  
1070477 ALDH1A1 ILMN_177898 up  
5910019 C1QB ILMN_36274 up  
4290026 C20ORF103 ILMN_165304 down  
2600634 C3HC4 ILMN_6980 down  
1580048 CAST ILMN_163108 up  
3390564 CCDC52 ILMN_23129 up  
3940754 CD226 ILMN_3877 up  
1780440 CD79A ILMN_37614 up  
5890653 CDKN1C ILMN_20689 down  
5340767 CEACAM1 ILMN_21651 down  
130086 CYB561 ILMN_8373 up  
840446 CYB561 ILMN_20474 up  
4540239 DEFA1 ILMN_29692 up  
1050068 F2RL1 ILMN_176188 up  
6510707 FER1L3 ILMN_18562 up  
6840767 FRMD3 ILMN_11826 down  
2350189 GBP3 ILMN_3653 up  
1510364 GBP5 ILMN_24462 up  
3780047 GBP6 ILMN_1956 up  
6220739 GRAMD1B ILMN_308544 down  
5260484 HLA-DRB1 ILMN_20550 up  
6370315 HLA-DRB5 ILMN_3178 up  
620544 HLA-DRB6 ILMN_5312 up  
630619 HPSE ILMN_165418 down  
5340762 HS.106234 ILMN_74965 up  
7320678 HS.171481 ILMN_80341 up  
4880370 JUP ILMN_3789 down  
1050215 KCNJ15 ILMN_164363 down  
2570438 KIFC3 ILMN_4695 up  
7560114 KLHDC8B ILMN_6513 up  
5310445 KREMEN1 ILMN_41914 down  
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4570164 LOC389386 ILMN_165610 up  
4780044 LOC389386 ILMN_352098 up  
2350121 LOC642678 ILMN_38908 up  
6480364 LOC647460 ILMN_38026 down  
6900291 LOC649210 ILMN_33006 down  
830639 LOC653778 ILMN_32201 down  
2260349 MIR1974 ILMN_388657 down  
830750 NCF1B ILMN_168368 up  
6760593 OSBPL10 ILMN_11112 up  
3170246 PDCD1LG2 ILMN_3561 up  
2000292 SCGB3A1 ILMN_23096 down  
160368 SEMA6B ILMN_21277 down  
1400593 SIGLEC14 ILMN_309673 up  
460463 SMARCD3 ILMN_19301 up  
540520 SNORD8 ILMN_366693 up  
1240554 TNFRSF17 ILMN_17574 up  
4760747 TPST1 ILMN_174128 up  
2630195 VAMP5 ILMN_20179 down  
3940088 ZBED2 ILMN_4927 down  
Table 37: The 51 transcript signature for distinguishing TB from OD in children 
* in TB patients in relation to patients with OD. 3 transcripts were also in the TB/LTBI 
signature (in bold). 
 
The 42 transcripts for distinguishing active TB from latent TB infection in children 
correspond to 34 unique genes (10 up-regulated and 24 down-regulated in TB disease).  
When IPA was used to map the transcripts to diseases and functions, inflammatory disease 
and antimicrobial response were the top two. Due to the nature of the disease in children 
and the recruitment process, the LTBI group includes only HIV uninfected children, while the 
active TB group includes both HIV infected and uninfected children. Although, the effect of 
HIV infection was accounted for the derivation of the signature, a more rigorous biological 
approach that would take into account all the differentially expressed genes in patients 
without HIV infection is needed, to gain biological insight into the tuberculosis disease 
pathogenesis.  
The 51 transcripts for distinguishing active TB from other diseases in children 
correspond to 41 unique genes (28 up-regulated and 13 down-regulated in TB disease). 
Some of the transcripts overlap with the adult signatures and have been discussed in 
Chapter 3. Another gene encoding for the HLA class II beta chain (HLA-DRB1) is included in 
the TB vs. OD signature paediatric signature (HLA-DPB1 is included in the adult signature), 
being up-regulated in the active TB patients. A paralogue (HLA-DRB5) and a related 
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pseudogene (HLA-DRB6) are also included [144]. A recent meta-analysis showed that HLA-
DRB1 polymorphisms were associated with susceptibility to pulmonary tuberculosis 
especially in Asian populations [174]. Additionally, CD226 (Cluster of Differentiation 226) 
that is also up-regulated is a protein coding gene, encoding for a glycoprotein expressed on 
the surface of NK cells, platelets, monocytes and a subset of T cells that is a member of the 
Ig-superfamily [144]. F2RL1 (coagulation factor II (thrombin) receptor-like 1) is involved in 
regulation of innate and adaptive immunity, and promotes inflammation [144]. KCNJ15 
(potassium inwardly-rectifying channel, subfamily J, member 15) has been found 
significantly differentially expressed in a recent whole blood TB biomarker study [175].  
The top canonical pathways in IPA included  B cell development, altered T-cell and B-
cell signalling, communication between innate and adaptive immune cells, crosstalk 
between dendritic cells and natural killer cells and the antigen presentation pathway. The 
top diseases and disorders are immunological disease, inflammatory disease and 
inflammatory response. The top upstream regulator is IRF1 that encodes interferon 
regulatory factor 1, a member of the interferon regulatory transcription factor (IRF) family. 
Out of the 41 unique genes, 15 were reported as being IFN-inducible (either type I or type II) 
in the Interferome database [148]. 
In order to explore the overlap of the transcriptomic signatures between adults and 
children, a 4-way Venn diagram of the genes corresponding to the transcripts of the TB 
signatures was created (Figure 54). Although this is not a systematic manner to deduce 
findings about the underlying biology of TB disease, we observe that the majority of genes 
are unique to each signature. There are a few genes in common between pairs of 
signatures, while only one gene, GBP6 (guanylate-binding protein 6), is common to all 4 
signatures. Its biological role is described in Chapter 3.  
A more rigorous biological approach that would take into account all the 
differentially expressed genes, and not only the members of the signatures, is needed for 
the exploration of the human host response to TB disease and infection in terms of 
pathways.  
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Figure 54: Venn diagram of the corresponding genes for the TB/LTBI and TB/OD adult and 
paediatric transcriptomic signatures.  
 
4.8  Summary 
In Chapter 4 I describe the results obtained from the analysis of a paediatric whole 
blood gene expression study including patients recruited in three African sites, to detect TB 
biomarkers. Microarrays from South Africa and Malawi were used as the discovery set for 
the biomarkers, while microarrays from patients recruited in a prospective independent 
study in Kenya were used for validation and benchmarking.  
The bioinformatics pipeline described in Chapter 2 was applied to the samples of the 
discovery cohort to identify minimal transcriptomics signatures. The signatures in the form 
of the DRS were subsequently used to classify patients in the validation cohort. The 
particular challenges of this analysis were posed by the TB culture negative group: children 
that receive TB treatment without bacteriological confirmation, so the actual burden of TB 
within this category is unknown. 
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The results showed that a small number of RNA transcripts detected in whole blood 
were able to distinguish TB from latent TB infection and from other diseases with clinical 
features similar to TB disease, regardless of HIV status. These findings extend the results 
acquired by the analysis of the adult study in Chapter 3, despite the profound differences in 
pathophysiology and clinical presentation of the disease between adults and children. 
The signatures in the form of the DRS identified the majority of TB culture confirmed 
cases and were found to be more sensitive than Xpert® MTB/RIF in both the culture 
confirmed and culture negative TB groups. The DRS identified correctly the majority of other 
disease cases regardless of their HIV and IGRA status. The high accuracy of the test provides 
evidence that diagnosis based on a host transcriptomic signature for paediatric TB is 
feasible. The transformation of multi-transcript signatures into a single value risk score will 
aid towards translation into clinical practise. 
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Chapter 5 
 
Conclusions - Discussion 
 
 
 
 
 
 
 
In Chapter 5, I present briefly the achievements and conclusions of my thesis as a whole, by 
bringing together the results and conclusions from the previous chapters. I also discuss 
some future research routes along with limitations and lessons that were learnt in this PhD 
thesis. Potential implications in the field and a personal perspective are also described. 
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5.1 What this thesis has achieved 
During this PhD I reviewed the literature on identification of host biomarkers for 
infectious diseases and particularly TB disease, using whole blood gene expression data 
(Chapter 1). The need of deriving gene expression signatures from microarray data in a 
systematic way was identified, while addressing the particular challenges that underlying co-
infections, and multiple-site studies pose. Previous studies have not been focusing on the 
diagnostic potential that small transcriptomic signatures of disease derived from 
representative populations may hold. Therefore, I reviewed methods for the statistical 
analysis of microarray data as well as methods for variable selection (Chapter 2). Then, a 
pipeline in R was implemented with the capacity to analyse gene expression microarray data 
and identify small sets of gene expression biomarkers regardless of country of origin and 
HIV infection, based on elastic net. The models defined by elastic net were subsequently 
incorporated into a single value disease risk score for every patient, without substantial loss 
of classificatory performance. 
The pipeline was first applied on a whole blood gene expression adult case-control 
study including patients with TB, LTBI and diseases phenotypically similar to TB and a 
paediatric cohort study with a similar set-up (Chapters 3, 4). After refining the pipeline to 
match the different needs for analysis of the two datasets, we found that patients with TB 
can be distinguished from LTBI individuals by measuring the expression values of 27 
transcripts in adults and 42 transcripts in children. Most importantly, the expression values 
of 44 transcripts in adults and 54 in children were able to discriminate TB from the range of 
conditions that present with similar clinical features. The signatures were validated using 
independent datasets and benchmarked against tests that are currently being used in 
clinical practice. The good classificatory performance of signatures, which was reproducible 
in both HIV-infected and -uninfected cohorts, in different geographic locations and in 
independent TB patient datasets suggests that these transcript sets are promising 
biomarkers of TB. In addition, the small number of transcripts in the signatures and the 
summarisation of the elastic net model into a single value disease risk score may increase 
the potential for using transcriptional profiling as a clinical diagnostic tool from a single 
peripheral blood sample. 
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To my knowledge, this was the first analysis of host gene expression data to identify 
small sets of TB biomarkers in adults and children from different locations, while including 
HIV-infected individuals and controls representing the ‘real world’ disease spectra from 
which TB should be clinically differentiated. 
 
5.2 Future Directions 
The field of diagnosis of infectious diseases has recently started moving from 
detecting the infectious agent to discovery of unique pathogen specific identifying host gene 
expression signatures. This analysis provides proof of principle of the feasibility of 
developing TB diagnostics based on host gene expression data, using a pipeline for both 
adult and  paediatric populations [176]. In clinical practice, the application of the TB 
signatures may be distinct as the TB/LTBI signature would be of value in contact screening, 
where the task is distinguishing active disease from previous exposure in minimally 
symptomatic individuals. The TB/OD signature would be of most value in evaluating 
symptomatic patients presenting to medical services with symptoms of TB. The use of these 
biomarkers in a clinical decision process either as an initial screening tool, or in conjunction 
with other diagnostic tools should be refined. Studies on prospective populations would be 
required in which the decisions about whether and when to initiate TB treatment are 
evaluated against the new biomarkers.  
Although a major concern in using transcriptional signatures as a clinical diagnostic 
tool in resource poor settings is the complexity and cost of the current methodologies, the 
concept of the DRS could address this. Binding of RNA from a patient’s blood to probes 
complementary to the signatures’ transcripts could be detected as a signal from all the up- 
or down- regulated transcripts combined. Expression of up- or down-regulated transcripts in 
an individual patient could be compared with that of housekeeping genes which have 
minimal variation, to allow for normalisation. There are methods that may be suitable for 
direct analysis of multiple transcript signatures in blood and at a relatively low cost, 
including lateral flow RT-PCR based systems, nano-pore technology [177], nano-particle 
enzyme linked detection and detection using nano-wires [178, 179] and electrical 
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impedance [180]. If signatures are to be translated into simple cheap assays, further 
evaluation of cost effectiveness and how a test based on host gene expression might be 
used operationally is needed. 
However, the first step is to examine whether the classification is reproducible using 
RT-PCR analysis. Some improvement in sensitivity and specificity of our DRS may also be 
achieved by weighting the signal from the most discriminatory transcripts, and this could be 
explored in subsequent refinements of the model. In terms of diagnostics it would be 
advantageous if the number of transcripts in the signatures could be reduced further, even 
with some small loss of sensitivity. Currently, in our group we are testing in-house methods 
for detecting biomarkers and they may be of use in this dataset.  
In addition to the diagnostics perspective, the two gene expression studies can act as 
an unprecedented resource to explore the biological processes of the response to the 
infection with M. tuberculosis that will enhance our understating about TB disease. They 
also offer the opportunity to study, compare and contrast paediatric and adult specific 
responses as well as the differences in the response between HIV-infected and -uninfected 
individuals. 
 
5.3 Limitations 
While this analysis provides proof of principle that relatively small numbers of RNA 
transcripts can be used to discriminate active TB from latent TB infection and other diseases 
in Africa, some limitations remain. The blood cell count for the patients was not available 
and therefore not incorporated in the analysis. This may contain additional complexity for 
the biological interpretation of the signatures and particularly for the HIV-infected 
individuals.  
Although microarrays have been successfully addressing the identification of 
differentially expressed genes, they measure gene expression in a targeted way. NGS 
technologies could have probably allowed for detection of novel sequences and alternative 
splicing events associated with TB disease and infection. In addition, regardless of the 
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overlap between the adult and paediatric signatures that has been observed, the gene 
expression TB signatures are quite different between children and adults. However, a 
combined analysis of the two datasets and identification of one TB signature independent of 
age would make the translation of the signatures into a more feasible test.  
Apart from the analysis of the microarray data and the required laboratory work, 
these studies involved large clinical endeavours over several years. The scale of the studies 
and the differences between the cohorts necessitate a rigorous “gold standard” 
classification from the clinical teams. A small proportion of false assignment by the current 
“gold standard” tests is to be expected as noted by post-mortem studies at which 
undiagnosed TB cases are confirmed [181, 182].  
 
5.4 Closing Remark 
Host gene expression signatures hold great potential for diagnosis of infectious 
diseases and the field is currently moving towards their use as clinical diagnostic tools. 
Further minimisation of the numbers of the transcripts in the diagnostic signatures and 
validation using other gene expression measuring techniques will prepare the grounds for 
diagnostic devices that can transfer the research findings from the bench to the bedside. 
What also constitutes a real challenge is the identification of systematic ways that can allow 
us to further our understanding about disease pathogenesis and progression in the host by 
extrapolating information from the multi-dimensional whole blood gene expression 
datasets. The approach presented in this thesis, can be extended and applied to other 
infections, diseases or conditions, which are currently seeking for new diagnostic and tests.   
In clinical management of TB patients, a simple transcriptome-based test which 
reliably diagnoses or excludes TB in the majority of patients undergoing investigation for 
suspected TB, using a single blood sample, would be of great value. Host gene expression 
signatures in conjunction with reliable results of existing tests, new vaccines and new drugs 
will hopefully revolutionise patient management and control of TB disease in high burden 
countries and worldwide. The challenge for the academic research community and for 
industry is to develop innovative methods to translate minimal transcript signatures with 
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maximal diagnostic performance into simple, cheap test suitable for use in African health 
facilities. 
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Appendix 
 
Quality Control of the gene expression microarrays 
Using Genome Studio software the microarray images were inspected for artefacts 
and QC parameters were assessed. Different metrics were used for ascertaining data 
quality. Illumina BeadChips have internal control probes to monitor data quality at different 
stages of the experimental process, which are either sample-dependent or sample-
independent. Data from the sample-dependent probes are based on metrics from each 
sample, while the sample-independent probes employ oligonucleotides spiked into the 
hybridisation buffer that bind to the array during the hybridisation process and allow for a 
quality overview of this experimental stage. I present here the control summary plots for 
both the adult and the paediatric study, along with their descriptions.  
Housekeeping genes  
‘Housekeeping genes’ expression is a sample-dependent measure, and this will vary 
from sample to sample due to biological variation. The fluctuation in signal intensity 
observed between the samples in our TB study showed no extreme outliers; however a few 
arrays had lower intensity values for the HK probes (i.e. <10,000) which indicates there may 
be a problem with the sample or labelling, so these were further assessed in the PCA data 
analysis to see if they were also outliers for subsequent removal from the analysis. 
Adult study*: 
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Paediatric study*: 
 
*: samples highlighted in red are the ones excluded in the PCA. 
 
Hybridisation Controls  
Hybridisation controls are a sample-independent measure based on spiked 
oligonucleotides in the hybridisation buffer. These spiked probes are designed to give a 
range of signal intensities once bound to the array surface and are expected to follow a 
“low” < “medium” < “high” signal intensity. This was seen in both sets of samples indicating 
that the hybridisation of the sample cRNA to the probes worked well.  
Adult study: 
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Paediatric study: 
 
 
Low Stringency  
Low Stringency is a sample-independent measure based on spiked oligonucleotides in the 
hybridisation buffer. Pairs of probes on the array are present so that one of the pairs will 
bind to the oligonucleotides in the hybridisation buffer perfectly and the other contains two 
mis-match bases. During hybridisation, the oligonucleotides will anneal to both the MM2 
and PM probes. The oligonucleotides that have not bound as well to the MM2 probe should 
be washed off during the experiment and this will be reflected in the intensity signal. The 
Perfect Match (PM) probe signal is expected to be higher than the Mismatch (MM2) probe 
signal. This was observed indicating that the High Temp wash buffer stage was successful. 
 
Adult study: 
 
 
 163 
Paediatric study: 
 
 
Biotin  
An amplified pool of biotin-labelled cRNA is generated from mRNA during the amplification 
stage of the microarray experimental process. During the hybridisation stage, the 
incorporated biotin in this cRNA is subsequently bound by streptavidin which is labelled with 
a fluorescent dye (Cy3). The biotin metric assess how well the biotin-streptavidin/Cy3 
binding has worked using control probes that have been labelled with biotin. For both 
studies, the signal intensity was high, indicating successful labelling during the hybridization 
stage. 
   Adult study:                Paediatric study: 
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Negative controls 
These are probes of random sequence selected to have no corresponding targets in the 
genome. The mean of these signals defines the system background and are expected to 
have very low signal intensity values. This was seen in both studies. 
         Adult study:             Paediatric study: 
 
